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A b stract
Clinical islet transplantation is an accepted treatment for the severe secondary 
complications of type 1 diabetes but is limited by the number of donors needed to 
achieve insulin independence. The requirement for multiple donors is probably due to 
the loss of up to 60% of islet mass after transplantation from hypoxia, caused by a lack 
of functional vasculature. Revascularisation of the transplanted islet does occur but takes 
up to 14 days.
The aim of this project was to investigate the revascularisation process and 
devise a method of manipulating islets in order to improve islet engraftment. The 
scientific research was supplemented by the establishment of clinical transplantation.
A sygeneic intraportal model of islet transplantation was used to explore the 
revascularisation of islets and develop a novel dual endothelial/insulin staining 
technique. The experiments show clear observation of revascularisation with 
quantifiable changes in vascular density and islet composition. Interestingly, the 
vascular density of transplanted islets was greater than native islets.
Pre treatment of isolated islets with was desferrioxamine explored as a method 
for up regulating angiogenic growth factors. This method produced a sustained increase 
in VEGF expression that did not adversely affect islet viability or secretory function but 
did not improve clinical outcome post transplant.
Three diabetic patients were transplanted with human islets and the outcome, 
clinical course and issues related to organ donation and processing are and also 
discussed.
Islet revascularisation is quantifiable and can be explored to examine the effect 
of manipulating engraftment. Iron depletion offers a simple method for manipulating 
islets prior to transplantation but further work is necessary to establish if there is any 
improvement in islet engraftment with this technique. Clinical islet transplantation 
programmes within the UK are achievable but further progress, collaboration and 
funding are required to establish islet transplantation as a routine treatment.
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Chapter 1 - Introduction
1.1 Impact of diabetes
Diabetes mellitus is an epidemic of global proportions. The incidence and prevalence of 
this common disease is increasing and diabetes will become a major global health care 
issue over the next century. In 1995, diabetes mellitus affected 135 million people world 
wide and is due to double in prevalence by 2025 (King, Aubert et al. 1998). Although 
the major increase in prevalence will be due to type 2 diabetes, the global incidence of 
type 1 diabetes is also increasing by 3% per year (Onkamo, Vaananen et al. 1999). In the 
United Kingdom, diabetes affects 2.1 million people of which about 200,000 have type 1 
diabetes. The incidence of type 1 diabetes in the United Kingdom is increasing by 1.9 to
9.5 % every year and by 2010 the incidence will have almost doubled (Onkamo, 
Vaananen et al. 1999).
The increasing incidence and prevalence will have major financial implications as health 
care services face the cost of treating diabetes and its associated complications. In 2002, 
the American Diabetes Association (ADA) estimated the total annual cost of diabetes in 
the US to be $132 billion (see figure 1.1), of which $92 billion was spent on direct 
healthcare costs and $40 billion was lost due to disability (ADA 2003). The direct 
medical costs of diabetes in the United States represent 19% of total personal health care 
expenditures while diabetics only account for 4.2% of the US population (ADA 2003).
In the United Kingdom, the overall healthcare cost of diabetes is unclear, although 
Evans and colleagues estimated that within their local population of Dundee, diabetic 
patients consumed 8% of the overall NHS drug budget while only accounting for 1.9% 
of the local population (Evans, MacDonald et al. 2000). A further study within the same 
population also estimated the rate of severe hypoglycaemia (requiring outside help) to be 
12 per 100 patient years, at a local cost of over £92,000 per annum and estimated 
national cost of over £13 million (Leese, Wang et al. 2003).
As well as the impact on health expenditure, diabetes also reduces health-related quality 
of life (Hart, Bilo et al. 2003). The reduction in quality of life is not only associated with
16
complications of the disease, most particularly macrovascular complications (Hart, Bilo 
et al. 2003), but further decreases with increasing intensity of treatment (Maddigan, 
Majumdar et al. 2003). In order to improve the treatments for diabetes, a therapy would 
therefore have to reduce the secondary complications whilst improving quality of life 
and be cost effective.
Figure 1.1: Cost of diabetes in the United States (in billions of US dollars). Solid 
slices represent direct medical costs and crosshatched represent indirect costs. 
Statistics are from the American Diabetes Association, 2002.
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1.2 Treatment options for diabetes
The current treatment for most patients with type 1 diabetes is insulin, with the aim of 
providing near normal glycaemic control. However, despite treatment with insulin, most 
patients do not achieve normal metabolic control of their diabetes and will still acquire 
secondary complications. Clinical trials indicate that improved control of blood glucose 
with intensive insulin regimes can reduce the incidence of secondary diabetic 
complications but dramatically increases the risk of potentially dangerous episodes of 
hypoglycaemia (DCCT 1993). Transplantation of the whole pancreas achieves optimal 
metabolic control without an increased risk of hypoglycaemia (Robertson, Sutherland et 
al. 1996) but requires major surgery with significant morbidity and mortality (Manske 
1999). Transplantation of the insulin-producing cells alone (Islets of Langerhans) offers 
an effective method of obviating these drawbacks and studies from Canada have shown 
that clinical islet transplantation can be successful, with early insulin independence rates 
similar to those of whole pancreas transplantation (Shapiro, Lakey et al. 2000; Ryan, 
Lakey et al. 2002). Clinical islet transplantation now offers an alternative treatment 
strategy for type 1 diabetic patients by providing an improvement in glycaemic control 
without the risk of life threatening episodes of hypoglycaemia or the morbidity and 
mortality associated with major surgery.
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1.3 Clinical islet transplantation
The first reported non vascularised pancreas transplant was performed in Bristol (UK) in 
1894 by P. Watson Williams, who implanted sheep pancreatic tissue under the skin of a 
15 year old diabetic boy. Unfortunately, the boy died 3 days later and only one further 
attempt was recorded, in 1924, until the successes of Najarian who introduced islets into 
the peritoneal cavity of a diabetic patient (Najarian, Sutherland et al. 1977).
Long term function of allografted islets was first reported in 1980 (Largiader, Kolb et al. 
1980) but reproducible insulin independence was only achieved in the 1990s. At this 
time intra-portal islet transplantation, embolisation of islets into the liver via the portal 
vein, had become the recognised route for administering islets. Despite advances in 
isolation, purification and transplantation techniques, insulin independence rates were 
still poor with only 8-14% of patients free from insulin after one year (Islet Transplant 
Registry, Giessen). The Edmonton protocol (Shapiro, Lakey et al. 2000) improved the 1 
year insulin independence rates to a more respectable level of 80% (Ryan, Lakey et al.
2002) and transformed islet transplantation from a research technique to a clinical tool 
for the treatment of diabetes.
Since the publication of the Edmonton paper (Shapiro, Lakey et al. 2000), a number of 
centres worldwide have set out to use this protocol and repeat the success of this original 
investigation. The best indicator o f the reproducibility of the Edmonton protocol will 
probably be the Immune Tolerance Network trial. This trial has set out to examine the 
outcomes of patients receiving islet transplants under the Edmonton protocol within 9 
centres throughout North America and Europe. Although the trial has not yet reported, 
interim data presented at the American Transplant Congress in 2004 suggests that the 
technique is transferable with 53% of patients becoming independent of insulin and a 
further 19% who are C peptide positive on reduced doses of insulin, after at least one 
year follow up (Shapiro, Ricordi et al. 2004). Unfortunately, a further 17% of patients 
had primary non function of their grafts and 11% withdrew due to complications. These 
results were disappointing when compared to the original Shapiro data and have been 
further compounded by poor long term graft survival which suggests that insulin
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independence only lasts for a median of 15 months and less than 10% remain insulin 
independent after 5 years (Ryan, Paty et al. 2005). Despite the poor long term insulin 
independence rate, patients with a functioning graft (C peptide positive) had an 
improved hypoglycaemic score and metabolic function compared to patients with a 
failed graft; HbAlc of 6.7% in C peptide positive, insulin requiring patients compared 
with an HbAlc of 9.0% in C peptide negative recipients.
Islet transplantation has advanced a long way since the first xenogenic transplant in the 
late 19th century but progress has been slow. The early success of the Edmonton protocol 
has been tempered with poor long term graft survival but islet transplantation still 
remains a useful clinical tool and the number islet transplant centers around the world 
are still increasing.
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1.4 Clinical islet transplantation in the United Kingdom
1.4.1 History and current situation of UK clinical islet transplantation
The first human allogenic non vascularised pancreas transplant in the UK was performed 
in 1916 at Newcastle-upon-Tyne by F.C. Pybus (Pybus 1924). In this case, human 
allogenic tissue was transplanted underneath the skin of the abdominal wall without 
immunosuppression and was rapidly destroyed. Despite a slight and temporary reduction 
of glucose concentrations in one recipient, the grafts “failed to relieve the diabetes”.
Intra portal allogenic islet transplantation, as we know it today, was not performed for 
another 66 years until Prof Nick London’s team in Leicester transplanted a patient on the 
2nd of August 1991. This was followed by Prof Derek Gray and colleges in Oxford who 
performed another transplant on the 3 1st August 1991. This initial success was then 
followed by a further 10 allogenic islet transplants, 8 at Oxford and 2 at Leicester. The 
initial results from these patients were disappointing with C peptide becoming positive 
in only a few patients and no insulin independence achieved. With the improved results 
and safety of whole pancreas transplantation, the interest in islet transplantation in the 
UK diminished and the last transplant, under the original protocol, was performed at 
Oxford in 1998.
It was not until the excitement of the data from Edmonton that interest in human islet 
transplantation was rekindled and a number of centres started to re-establish islet 
transplant units within the UK. Since then, and as of January 2006, eight further patients 
have been transplanted in the UK using the Edmonton protocol (4 patients at Kings 
College hospital, 3 at the Royal Free hospital and 1 at the Churchill hospital in Oxford). 
In addition, three further centres (Bristol, Leicester and Edinburgh) are establishing islet 
isolation programmes with a view to allogenic islet transplantation.
1.4.2 Funding and staffing of UK islet transplant centres
Despite the renewed interest in clinical islet transplantation within the UK, the 
establishment of clinical programmes remains difficult and centralised public healthcare
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funding is not forthcoming. The reason for the reluctance to acknowledge clinical islet 
transplantation as a treatment option in the UK is probably related to the high cost to 
benefit ratio and perceived lack of efficacy of islet transplantation within the UK. This 
view point has been reinforced by the latest National Institute of Clinical Evidence 
(NICE) guidelines for Pancreatic Islet Cell Transplantation (Appendix 2), which have 
not endorsed the technique as an accepted treatment within the UK.
“Current evidence on the safety and efficacy of pancreatic islet cell transplantation does not 
appear adequate to support the use of this procedure without special arrangements for consent 
and for audit or research.”
NICE guidance issued October 2003.
This difficult funding situation has been further compounded by the issue of whether 
islet transplantation should be considered as research or an accepted clinical treatment. 
Therefore, public healthcare funding is not available because national recommendations 
suggest the technique is still a research tool and research funding bodies have accepted 
the published data from international centres and classify islet transplantation as an 
established clinical treatment. The poor level of funding available is further added to by 
the high standards of manufacturing (set by the Medicines and Health Related Agency) 
required of an islet isolating facility and the number of staff required to run an isolation 
unit on a continuous basis and comply with European Working Time Directive.
The current situation in the United Kingdom has meant that islet isolation facilities are 
funded by charities which support the treatment of diabetic patients and staff are funded 
by research grants in areas allied to islet transplantation. The cost of transplanting 
patients with islets is currently funded by Diabetes UK but this will only stretch to the 
first 15 transplants and it is unclear where funding will come from in the future.
1.4.3 Isolation and purification of human islets for transplantation 
After funding and staffing issues have been addressed, the process of islet isolation has 
to be considered. Human islet isolation is a complicated and lengthy procedure which 
starts with the provision of a healthy and suitably retrieved pancreas. Islets are then
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digested from the exocrine pancreas using a blend of collagenase and neutral protease 
enzyme and mechanical dissociation. The resultant islet/exocrine mixture is 
subsequently purified using a Ficol based gradient loaded onto a Cobe 2991 cell 
separator (Gambro BCT, Germany). Semi-pure islet preparations are either cultured for 
up to 3 days in CMRL (Connaugh Medical Research Laboratories, cell culture medium) 
based medium or transplanted fresh into the portal vein via a radiological approach.
Although the procedure of islet isolation is based on the semi-automated technique 
originally described by Ricordi (Ricordi, Lacy et al. 1988), the technique is by no means 
standardized and there are multiple factors which influence the outcome of the 
procedure. The complicated and variable isolation technique gives rise to a steep 
learning curve for centres setting up an islet isolation facility which only compounds the 
cost and staffing issues. Once consistent islet isolation is established, there are further 
hurdles to overcome, such as sterile handling, product release, infusion, patient listing 
and patient management.
1.4.4 Donor pancreases for islet isolation
The isolation of islets for transplantation is dependent on a supply of donor pancreases, 
with well procured organs leading to improved islet isolation (Nano, Clissi et al. 2005) 
and transplant outcome (Goto, Rahman et al. 2005).The general shortage of organ 
donors means that there are few donor pancreases available for transplantation and 
current practice in the UK gives priority of organ placement to whole organ 
transplantation. In addition, only 27% of potentially suitable donors have the pancreas 
retrieved, in spite of a further 12% being offered but not retrieved (Ridgway, White et al. 
2005). The small quantity of donor pancreases received at islet isolation centres 
prohibits the necessary number of processes required to maintain the basic skills for islet 
isolation and a better supply of quality organs will be essential to the maintenance of 
clinical islet transplant programmes in the UK.
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1.4.5 Patient selection and management
The current indications for islet transplantation in type 1 patients are hypoglycaemic 
unawareness, severe progressive secondary complications, despite best intensive insulin 
treatment, and patients who are already immunosuppressed for another transplant 
(Federlin and Pozza 1999; Bertuzzi, Secchi et al. 2004). Despite these broad categories, 
there are surprisingly few patients who are truly suitable for islet transplantation and 
French studies would suggest that only 27% of islet alone patients referred by their 
diabetologists to a transplant centre are suitable for assessment (Vantyghem, Hazzan et 
al. 2004). This situation is further compounded by the lack of data for the risk benefit 
ratio of islet transplantation.
Although improved glycaemic control in type 1 diabetics has been shown to reduce 
secondary diabetic complications (DCCT 1993), a reduction in mortality from 
improving diabetic control is less clear. Extrapolations can be made from reducing 
known mortality risk factors, such as nephropathy (Go, Chertow et al. 2004), or 
observational studies of lower mortality associated with lower baseline glycated 
haemoglobins in type 1 (Klein 1995) and type 2 diabetics (Stratton, Adler et al. 2000). It 
is also possible that the abolition of hypoglycaemic unawareness by transplanting 
patients with islets may reduce mortality but only a small number of patients have been 
transplanted so far and there is no comparative data to prove any benefit. The situation 
where the argument for reduced mortality from better glycaemic control is probably 
stronger is in patients who receive renal transplants. In this situation, beta cell 
replacement in the form of a whole pancreas at the time of renal transplantation has been 
shown to reduce mortality when compared to kidney transplant alone (La Rocca, Fiorina 
et al. 2000; Reddy, Stablein et al. 2003). The further benefit of islet transplantation over 
pancreas transplantation is the reduced morbidity and mortality. Although no formal 
assessment of risk of death from islet transplantation has been performed, there has not 
been a single death directly related islet transplantation so far. This compares favourably 
to whole organ transplantation, where the relative risk of death is increased between 2.4 
to 6.1 times within the first 90 days post transplantation, depending on whether the
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pancreas is transplanted with or without a kidney respectively (Venstrom, McBride et al. 
2003; Gruessner, Sutherland et al. 2004).
Any benefit of islet transplantation, either perceived or proven, has to be balanced 
against the risks of transplantation. Although there are some peri-procedural risks from 
islet transplantation (such as a 4% risk of reversible portal vein thrombosis and roughly 
10% risk of hepatic bleeding), the main risks are associated with immunosuppression. 
Once again, there is little islet specific literature but if an extrapolation is drawn from 
solid organ transplantation, the main risk comes from infection, malignancy and direct 
toxic effects of immunosuppressants. Infection occurs in 15-44% of renal transplant 
recipients within the first year (Soulillou and Giral 2001) and accounts for 15-20% of 
deaths following renal transplantation (Briggs 2001). In addition, the risk of malignancy 
is increased in transplant recipients and a study from the United Kingdom has estimated 
that the risk of malignancy 20 years post transplant was 40% compared with a 6% 
cumulative risk in an age matched control population (London, Farmery et al. 1995).
This increased risk is further backed up by registry data in the United States which 
estimates a 3-4 times increased relative risk for all malignancies in transplant patients, 
with a range from 2 times relative risk for colonic cancer and up to 500 times relative 
risk of Kaposi’s sarcoma (Penn 2000). Lastly, the immunosuppressants have important 
side effects which include dyslipidaemia, lymphopenia, mouth ulcers, diabetes and most 
importantly, nephrotoxicity.
All the risks and benefits have to be considered and explained to potential recipients 
before listing a patient for islet transplantation. At present, our experience with islet 
transplantation is limited and clinicians must err on the side of caution when considering 
patients for transplantation. With time, we will gain experience and a better 
understanding of where this potentially promising treatment fits into the array of 
therapies available to diabetic patients. In the meantime, we must fully inform potential 
recipients of the poor long term insulin independence rates achieved with clinical islet 
transplantation and look to ways of improving clinical outcome and reducing the number 
of donors required to induce insulin independence.
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1.5 Insulin independence and peri-transplant islet loss
The original publication by Shapiro and his colleagues (Shapiro, Lakey et al. 2000) 
showed that acceptable rates of early insulin independence were achievable. The 
impressive levels of early insulin independence achieved by the Edmonton protocol was 
probably due to a number of changes made to the isolation and transplant protocol, 
including use of non-xenogenic proteins, a new steroid free immunosuppressive regime, 
transplantation of freshly isolated islets, rapid sequence transplantations and most 
importantly, use of a large dose of fresh islets (~11,000 islet equivalents per patient) 
(Shapiro, Lakey et al. 2000). In order to achieve this high dose of islets, each recipient 
required islets from at least 2 donor pancreases.
This need for multiple donors contrasts with the single donor to recipient required for 
insulin independence after whole pancreas transplantation and emphasises that 
successful islet transplantation is dependent on the number of islets transplanted and 
perhaps, more critically, the proportion which survive. Indeed, up to 60% of donor islets 
may be lost in the immediate post transplant period due to necrosis and apoptosis 
(Biames, Montolio et al. 2002). The cause for this high rate of loss remains unclear but 
is probably related to the disruption of the normal islet microvasculature during isolation 
from the whole pancreas and the hypoxic environment of the portal vein, into which the 
islets are transplanted. In order to investigate this reasoning, the native and transplanted 
islet vasculature should be considered further.
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1.6 Native islet structure and vasculature (Figure 1.2)
Pancreatic islets are organised conglomerations of different cells which produce a 
variety of endocrine hormones. The structure of islets consist of a central core of p cells, 
which produce insulin, surrounded by an outer mantle of a, 5 and pp cells which secrete 
glucagon, somatostatin and pancreatic polypeptide, respectively. In the rat, the sizes of 
the islets are variable and range from 30 to 300pm (Lifson, Lassa et al. 1985). Each islet 
is highly vascular and although islets only account for 0.3% of the volume of the 
pancreas, they receive 6% of the arterial blood flow with smaller islets receiving 
relatively greater blood flow per volume than larger islets (Lifson, Lassa et al 1985). 
Each islet is supplied by one to three afferent arterioles which divide at the mantle of the 
islet into a glomerular-like network of capillaries and either coalesce at the edge of the 
islet to form a network of collecting venules or traverse the central beta core of the islet 
to connect with the collecting venules on the other side (Bonner-Weir and Orci 1982; 
Liu, Guth et al. 1993). The venules then either drain into the acinar (exocrine) venous 
system or directly into interlobular veins and subsequently into the portal vein (Liu, 
G uthetal. 1993).
Figure 1.2: Structure and vascular supply of native islets, modified from (Bonner- 








1.7 Transplanted islet vasculature
A number of animal models (intra-portal, kidney subcapsular and skin fold) have been 
used to investigate the revascularisation of transplanted islets and will be discussed later 
in section 1.12.
1.7.1 Structure of transplanted islet vasculature
Studies on experimental animals show that transplanted islets revascularise and reform a 
glomerular-like network of blood vessels (Vajkoczy and Menger 1995). The process of 
revascularisation can take up to 14 days (Vajkoczy, Menger et al. 1995) and further 
dynamic reorganization of blood vessels may continue after a month post transplant 
(Rooth, Dawidson et al. 1989). During this period of time the islets remain hypoxic and, 
even after the formation of new vessels, the partial pressure of oxygen and vascular 
density are reduced when compared to endogenous islets (Carlsson, Palm et al. 2002). 
The reduction in oxygen partial pressures and vascular density persists and can still be 
seen 6 months post transplant (Jansson and Carlsson 2002; Mattsson, Jansson et al.
2003). These observations have led to the suggestion that hypoxia and poor 
revascularisation are the main factors responsible for the failure of transplanted islets in 
the immediate post-transplant period (Carlsson, Palm et al. 2002).
Intra-portally transplanted islets revascularise from the hepatic arterial system with 
venous drainage into the portal vein (Griffith, Scharp et al. 1977; Andersson,
Korsgren et al. 1989). The revascularisation of intra-portal islets begins around day 
four post transplantation and is usually completed between days eight and eleven 
(Griffith, Scharp et al. 1977).
1.7.2 Origin of transplanted islet endothelium
The origin of the endothelium within transplanted islets is unclear but would be 
expected to have an impact on both allorecognition and immune destruction of a 
transplanted graft. Intravital microscopy studies of islets transplanted into the dorsal 
skin fold of nude mice have suggested that endothelium grows into the islet from the 
host arterial system (Vajkoczy, Menger et al. 1995), suggesting that transplanted
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islets gain their endothelium from a host source. The authors further substantiated 
this observation by using a xenogenic dorsal skin fold model of islet transplantation 
to track the origin of the endothelium of transplanted islets (Vajkoczy and Menger 
1995). Species-specific antibodies for endothelium (anti-PECAM-1 and anti-factor 
VIII) were used to delineate the origin of the endothelial cells and suggested that the 
new endothelium was derived entirely from the recipient. This model gives some 
insight into the origin of the endothelium but is compromised by the site to which the 
islets are transplanted, the endothelial markers chosen for the experiment and the 
cross species model used. It is possible that the antibodies may have cross reacted in 
this experiment and the endothelial markers used may not have been as robust as the 
lectin Bandeiraea Simplicifolia (Mattsson, Carlsson et al. 2002). In addition, the 
authors did not mention any complications of cross species transplantation which 
may have interfered with the results. A further study by Linn and colleagues has 
subsequently shown that free islets embedded in a fibrin matrix develop out growths 
of endothelial cords from the islet into the fibrin matrix (Linn, Schneider et al. 2003). 
When they then used a Lac-Z reporter gene in islets transplanted into wild type mice, 
donor endothelium was found around and within the transplanted islet, suggesting 
that donor endothelium may also play a role in the revascularisation of transplanted 
islets.
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1.8 Control of the revascularisation process
The factors which control the revascularisation process have yet to be fully 
elucidated, although there is some evidence from less clinically relevant models of 
islet transplantation. In-vitro studies of cultured islets have shown a 3 fold increase 
in the mRNA expression of the angiogenic polypeptide vascular endothelial growth 
factor (VEGF) after 2 days in culture (Vasir, Aiello et al. 1998). In kidney sub- 
capsular models of islet transplantation, the angiogenic factors basic fibroblast 
growth factor (bFGF), transforming growth factor beta (TGFp) and VEGF are found 
in increased concentrations during the early stages of the revascularisation process 
(Vasir, Reitz et al. 2000). These molecules are known to be increased in response to 
hypoxia and can modulate the neovascularisation process, thus making them likely 
candidates to control revascularisation. VEGF is probably a major factor in 
revascularisation but its expression is only increased for the first two to three days in 
transplanted islets and levels return to normal by day 5 post transplant (Vasir, Jonas 
et al. 2001). This pattern of expression would suggest, as in revascularisation of 
other tissues, that VEGF initiates revascularisation but other factors are needed for 
the formation of a mature network of vessels (Yancopoulos, Davis et al. 2000). In 
models of angiogenesis, over-expression of VEGF alone leads to the formation of 
large numbers of leaky vessels whereas over-expression of both VEGF and 
angiopoietin 1 (Ang-1) leads to the formation of an increased number of larger, 
leakage resistant vessels (Thurston, Suri et al. 1999; Thurston, Rudge et al. 2000).
The angiopoietin family of endothelial specific growth factors has recently been 
characterised and consists of 4 molecules (Ang 1, Ang 2, Ang 3 and Ang 4) which 
exert their action mainly through the Tie 2 receptor. Ang 1 and Ang 2 are the better 
characterised molecules and seem to work in combination with VEGF for optimal 
blood vessel formation. In contrast to VEGF, Ang 1 does not induce endothelial cell 
proliferation but seems to mediate the interaction between the endothelial cells and 
surrounding matrix and support cells (Suri, Jones et al. 1996). Ang 2 is a natural 
antagonist to Ang 1 with similar affinity for Tie 2 receptors and probably blocks the 
stabilising effects of Ang 1 on vessels, creating destabilised vessels which are prone
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to regression. Therefore, Ang 2 would have more of a role in remodelling of vessels 
by allowing vascular beds to be more flexible (Maisonpierre, Suri et al. 1997). In 
corpus luteum development, Ang 2 is expressed in the early stages together with 
VEGF and is thought to block the stabilisation of vessels allowing them to remain 
more responsive to the proliferative and sprouting effects of VEGF (Maisonpierre, 
Suri et al. 1997). In contrast, Ang 1 expression is found later in corpus luteum 
development and is associated with stabilisation of the vessels. It is therefore 
possible that Ang 2 may be expressed in the very early stages of islet 
revascularisation, when there is known to be regression of endothelium and lack of 
capillary spaces (Griffith, Scharp et al. 1977). The regression process would then be 
followed by new vessel formation, under the influence of VEGF and other factors, 
and a subsequent maturation process under the influence of Ang 1.
31
1.9 Manipulation of the revascularisation process
Our present understanding of the molecular mechanisms necessary for the 
revascularisation of transplanted islets has allowed an insight into how this process 
could be manipulated. With this knowledge, the aim would be to target the 
mechanisms responsible in order to accelerate the revascularisation of transplanted 
islets and hopefully reduce the beta cell loss. A number of authors have investigated 
methods for increasing the expression of single growth factors either by local 
delivery of the molecule (Nakano, Yasunami et al. 2000) or adenoviral-mediated 
gene delivery (Garcia-Ocana, Takane et al. 2003; Lopez-Talavera, Garcia-Ocana et 
al. 2004; Zhang, Richter et al. 2004).
Increased delivery of hepatocyte growth factor (HGF) to islets by adenoviral 
techniques has been shown to reduce beta cell death, improve graft function, 
increase the insulin content and number of islets surviving intra-portal transplant and 
hence augment the reversal of diabetes by marginal islet transplants (Garcia-Ocana, 
Takane et al. 2003; Lopez-Talavera, Garcia-Ocana et al. 2004). A further study by 
Zhang and his colleagues increased the expression of VEGF by adenoviral 
techniques and found an improvement in the reversal of diabetes and vascular 
density in treated islets transplanted under the renal capsule of mice (Zhang, Richter 
et al. 2004). Although these experiments provide a good insight into the 
manipulation of the revascularisation process, they rely on the insertion of new 
genetic material into the cells and use viral transfection systems which may increase 
the immunogenicity of transplanted cells. In addition, the percentage of cells over­
expressing the target factor can be as low as 30% (Garcia-Ocana, Takane et al. 2003) 
and over-expression of only a single target molecule is achieved, rather than 
inducing a more coordinated and physiological response involving several growth 
factors.
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1.10 Hypoxia sensing and hypoxia inducible factor
The expression of some angiogenic factors are controlled by the hypoxia sensing 
pathway (Wenger 2000) and may therefore be amenable to manipulation at a higher 
point in the hypoxia activation cascade. The benefit of this approach is to produce a 
more balanced and physiological approach to accelerating revascularisation which 
should provide all the angiogenic factors necessary for the formation of a mature and 
intact vasculature. The mechanism responsible for sensing hypoxia (figure 1.3) is 
dependent on hypoxia-inducible factor (HIF), and has recently been reviewed 
(Wenger 2000; Lando, Gorman et al. 2003). In hypoxic conditions, the heterodimeric 
HIF-1 transcription factor is formed by the combination a HIF alpha (HIF a ) sub­
unit binding to a HIF beta subunit. This transcription factor can directly bind to DNA 
in hypoxia responsive elements of oxygen-regulated genes, in order to alter the 
expression of these molecules.
In normoxic conditions, HIFa is metabolised in order to regulate the expression of 
hypoxia response genes. The first step in the metabolism of HIFa is by the iron and 
oxygen dependent group of enzymes, HIF prolyl hydroxylases (HPH) (Jaakkola, 
Mole et al. 2001; Yu, White et al. 2001). These enzymes hydroxylate proline 
residues within the oxygen-dependent degradation site (ODD) of HIF a  and allow 
binding of the von Hippel-Lindau protein to HIFa (Maxwell, Wiesener et al. 1999). 
The von Hippel-Lindau protein poly ubiquitinates HIFa, which subsequently marks 
the molecule for destruction by proteosomes (Maxwell, Wiesener et al. 1999). HIF 
expression can also be regulated by the oxygen dependent hydroxylation of an 
asparginyl residue in the COOH-terminal transactivation domain (CAD) of HIFa 
(Lando, Peet et al. 2002; Maxwell 2003). This hydroxylation limits the binding of 
the CAD with the p300 co-activator necessary for transcriptional activation, 
therefore regulating the activity of HIF-1. The hydroxylation of asparginine within 
the CAD is performed by the iron containing enzyme FIH-1 (factor-inhibiting HIF) 
which can be inhibited by iron chelators (Lando, Peet et al. 2002) and thus provides 
a further mechanism for the increased expression of HIF by agents such as DFO.
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Figure 1.3: The metabolism of Hypoxia Inducible Factor alpha (HIF a) during 
normoxia, hypoxia and iron depletion.
Desferrioxamine (DFO) inhibits the iron dependent HIF prolyl hydroxylases 
(HPH) to reduce to destruction of HIF la  and inhibits factor-inhibiting HIF 
(FIH-1) to reduce the blocking HIF transactivation. Abbreviations: HIF b = 
Hypoxia Inducible Factor beta, OH = hydroxyl group, VHL = Von Hippel 
Lindau protein, Ub = Ubiquitin residue, ODD = oxygen-dependent degradation 
site, CAD = COOH-terminal transactivation domain, P300 = CBP/P300 
transcription adapter.
Modified from (George and Kaelin 2003) and (Maxwell 2003).
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Hypoxia-inducible factor is known to positively regulate the expression of VEGF, 
VEGF receptor, Ang 2, Ang 4, Tie 2 and bFGF (Grimm, Wenzel et al. 2002; 
Yamakawa, Liu et al. 2003). Therefore, increasing the expression of HIF should 
subsequently up regulate these important angiogenic factors and provide a more 
coordinated signal to stimulate angiogenesis. Studies of transgenic mice over 
expressing HIF-la in the epidermis show an up regulation of VEGF mRNA by 8 to 
13 times when compared to non transgenic animals (Elson, Thurston et al. 2001). In 
addition, the dermal blood vessels were increased by 30% but did not have increased 
vascular permeability and were of normal morphology, when compared to non 
transgenic animals (Elson, Thurston et al. 2001). This observation contrasts with the 
increased vascular permeability induced in animals over-expressing VEGF alone 
(Thurston, Suri et al. 1999) and adds to the argument that angiogenesis should be 
stimulated in a more physiological and coordinated way than the isolated over­
expression of a single factor. The question still remains as to which other factors are 
over expressed to reduce vascular permeability, as although initial experiments 
suggested this may be due to angiopoietins (Thurston, Suri et al. 1999), Ang 1 and 
Ang 2 are not found at increased levels in transgenic mice over expressing HIF 1 a 
(Elson, Thurston et al. 2001).
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1.11 Hypoxia sensing and desferrioxamine
The first step in the metabolism of H IF-la requires the iron dependent enzyme HPH 
(Jaakkola, Mole et al. 2001). Iron chelating agents, such as desferrioxamine (DFO), 
have been used to inhibit HPH with the effect of increasing the expression of HIF 
and the hypoxia regulated molecules VEGF, Tie 2 and angiopoietins (Yamakawa,
Liu et al. 2003). Treating islets with desferrioxamine may provide a theoretically 
attractive technique for pre-treating islets before transplantation that does not require 
the insertion of new genetic material into the islets and should affect all transplanted 
cells. This method should enable the increased expression of a number of angiogenic 
factors post islet transplantation in a more physiological and coordinated fashion and 
hopefully improve islet engraftment.
Desferrioxamine and its subsequent up regulation of HIF-1 and erythropoietin have 
also been explored in other models of hypoxia, in order to precondition or salvage 
tissue from hypoxic damage. In a rodent model of cerebral infarction, 
desferrioxamine pre-treatment in-vivo was shown to reduce cerebral infarct volumes 
by up to 35% when compared to non desferrioxamine treated animals (Prass,
Ruscher et al. 2002). Subsequent experiments on rat primary cortical neurons 
exposed to hypoxia and glucose deprivation also showed that pre-treatment with 
desferrioxamine in-vitro reduced cell death when compared to controls, with 
significant reduction occurring at 150|JM desferrioxamine (Prass, Ruscher et al. 
2002). A further study in an in-vivo rodent model of cerebral ischaemia looked at 
whether desferrioxamine treatment after a hypoxic insult could ameliorate cell 
damage. Desferrioxamine injected intra-peritoneally after a 1.5 hour ischaemic insult 
resulted in a significant reduction of cerebral volume loss and caused a significant up 
regulation of HIF-1 compared to control which extended after 24 hours post dose 
(Mu, Chang et al. 2005).
The mechanism by which DFO protects against ischaemic injury has not been fully 
elucidated. Some authors have suggested that protection in a neuronal ischaemic 
model may be due to the up regulation HIF-1 and subsequent increase of down
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steam hypoxic response elements, such as erythropoietin (Prass, Ruscher et al. 2002; 
Mu, Chang et al. 2005). This theory has been substantiated by a reduction of 
desferrioxamine induced neuroprotection by H IF-la specific antisense 
oligonucleotides (Hamrick, McQuillen et al. 2005), although the neuroprotective 
effect of DFO was not fully abrogated. The incomplete blockade of neuroprotection 
by impeding the HIF pathway suggests that there may be another mechanism by 
which DFO affords protection against hypoxia. Iron chelators are known to interfere 
with Fenton chemistry (Merkofer, Kissner et al. 2006), the process by which oxygen 
radicals are formed, and DFO has been shown to reduce the formation of oxygen 
radicals (Kozlov, Ostrachovitch et al. 1994; Urbanski and Beresewicz 2000). 
Desferrioxamine is able to reduce the damaged to cells caused by free radical 
formation (Horackova, Ponka et al. 2000; Yun, Takagi et al. 2003; Kurz, Gustafsson 
et al. 2006) and experiments in a hepatic ischaemia reperfusion model have shown 
that pre-treatment with DFO reduces secondary oxidative stress in the kidney (Polat, 
Tokyol et al. 2006). These experiments propose that DFO may reduce the cellular 
damage associated with oxidative stress and provide another mechanism by which 
DFO might protect islets from the insult of transplantation.
These experiments suggest that desferrioxamine may, in addition to up regulating 
VEGF, be able to “precondition” islets prior to transplantation with a view to 
reducing p-cell death after transplantation, thereby improving transplant outcome.
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1.12 Experimental models of islet transplantation
The models of islet transplantation from which most results have been derived 
(kidney subcapsular or dorsal skin fold transplantation sites) were developed to 
permit visualisation of grafts and allow easy retrieval of the transplanted islets. The 
problem with these models is that the tissue into which the islets are transplanted 
may have different characteristics and responses to vascular growth factors than the 
more clinically relevant hepatic portal system. In addition, the process of injecting 
islets under the renal capsule or dorsal skin fold does not allow the assessment of an 
islet surrounded by host tissue as islets are often clumped in close association with 
each other. The clumping of islets and surrounding fluid may increase the diffusion 
distance for molecules, such as oxygen, increasing hypoxia and therefore altering 
revascularisation and expression of angiogenic factors. The drawback to intra- 
hepatic models has been the poor retrieval of islets which are widely dispersed 
throughout the liver. In order to combat this problem, our laboratory has validated an 
intra-portal transplant model for the localisation of islets to only 2 out of 7 lobes of 
the rat liver (20% of the liver volume, see figure 1.4). This method allows much 
better visualisation of islets and a greater number of islets per tissue slice (Juszczak 
M 2003).
Figure 1.4: Caudal view of rat 
liver showing the 2 lobes of the 
liver (arrowed) supplied by the 
right branch of the portal vein.
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1.13 Purpose of research
Diabetes is a chronic disease with a major impact on both patient quality of life and 
health care costs. The current therapies for patients with type 1 diabetes do not provide 
the immaculate metabolic control necessary to stop or reverse the secondary 
complications of diabetes. Whole organ pancreatic transplantation can provide this level 
of metabolic control but requires a major abdominal operation which is associated with 
significant morbidity and mortality (Manske 1999) and is usually reserved for patients 
who are receiving a concomitant renal transplant. Islet transplantation offers an 
alternative therapeutic option to whole organ transplantation that is not associated with a 
high morbidity and mortality and is open to a wider range of patients (Federlin and 
Pozza 1999). The current limitation of islet transplantation is the need for two or more 
transplants per recipient in order to achieve insulin independence. The requirement for 
two or more transplanted organs is further compounded by the fact that only 50% of 
processed pancreases yield sufficient islets for transplantation so that each recipient may 
require four or more donor organs to achieve insulin independence. If a comparison is 
drawn from the Swiss-French experience, an average of 5.6 pancreas processes were 
required for each recipient at a cost of €5902 per process (including transport and 
procurement) (Guignard, Oberholzer et al. 2004). The overall cost for a single recipient 
was €77,745, of which pancreas procurement, transportation and isolation accounted for 
43% of the total cost. If patients required fewer islets to achieve insulin independence, a 
smaller number of pancreas processes would be required and islet transplantation would 
become more cost effective.
The research described in this thesis is focused on the revascularisation of islets in order 
to elucidate the mechanisms responsible for this complex process and establish a method 
for manipulating revascularisation with a view to increasing the number of islets which 
survive after transplantation. If successful, the number of transplanted islets and donor 
organs required to achieve insulin independence could be reduced and more patients 
would be able to be transplanted from the limited resources and donor organs available.
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Despite the current limitations, clinical islet transplantation has been accepted as a 
possible alternative to whole pancreas transplantation in patients who do not require 
renal replacement. The United Kingdom has been slow to initiate clinical islet transplant 
programmes and this thesis will explore the establishment of a clinical transplant 
programme and the methods required for optimising islet isolation and transplantation.
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1.14 Hypothesis
1. Intra-portally transplanted islets revascularise in a coordinated and quantifiable 
fashion
2. Transplanted islet endothelium is derived from both donor and recipient.
3. Desferrioxamine treatment increases the expression of a number of key 
angiogenic factors required for the revascularisation of islets.
4. Increasing the expression of these key angiogenic factors early in the post 
transplant period will accelerate revascularisation of the islet, therefore reducing 
beta cell loss and improving post transplant outcomes.
5. Human clinical islet transplantation can be established in the United Kingdom
1.15 Aims of the research described in this thesis
1. Devise a robust methodology which will allow the clear examination and 
quantification of the revascularisation of intra-portally transplanted islets
2. Delineate the origin of transplanted islet endothelium.
3. Explore whether desferrioxamine treatment of islets improves revascularisation 
and post transplant outcomes.
4. Establish human islet isolation and transplantation at a centre within the United 
Kingdom.
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Chapter 2 - Materials and methods
2.1 Commonly used solutions
Shown in Appendix 1
2.2 Common in-vivo techniques
The exploration of islet transplantation requires an in-vivo islet transplant model. We 
used a syngeneic transplant model between inbred Lewis rats. The in-vitro islet 
experiments were performed on islets isolated from locally bred Sprague Dawley rats.
2.2.1 Experimental subjects
Adult rats were used as donors of islets and recipients of islet transplants. Adult male 
Sprague Dawley rats (local source) of 250-300g were used as donors for in-vitro islet 
experiments. Inbred adult male Lewis rats (Harlan, Indiana, USA) of 250-300g were 
used as islet donors for in-vivo transplant experiments. Inbred adult male Lewis rats 
(Harlan) of 250-300g or inbred adult female Lewis (Harlan) rats 180-220g were used for 
syngeneic in-vivo transplant experiments. All animals were kept in accordance with 
Home Office regulations with free access to standard rat chow and water and 12 hour 
light/dark cycles.
2.2.2 Isolation of rat islets
Rats were anaesthetised with 24mg (0.4ml) of pentobarbitone (Rhone Merieux, France) 
intra-peritoneal (ip). After deep anaesthesia was achieved, a midline abdominal skin 
incision was made from xiphistemum to the pubic region. The abdominal cavity was 
opened and bowel retracted to expose the pancreas and duodenum. The proximal end of 
the common bile duct was isolated and a loose ligature passed around the duct. The 
distal end of the common bile duct, just before the insertion into the duodenum, was 
dissected free from the surrounding pancreas and a loose ligature passed around the duct. 
The duct was incised and a 2F cannula inserted into the duct toward the liver. Correct
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positioning of the cannula was identified by the ante grade flow of bile down the cannula. 
The cannula was held in place by tightening the ligature around the distal end of the bile 
duct and the ligature at the proximal end was tightened to avoid retrograde flow of 
collagenase solution into the liver. The animal was exsanguinated through a jugular 
incision, the blood centrifuged and serum saved for future use in transplant solution. 
3.3ml of ice-cold collagenase solution was injected down the cannula into the pancreas 
while the pancreas was directly observed to confirm uniform distension. The cannula 
was then removed and the pancreas completely excised.
The excised pancreas was briefly bench dissected to remove the spleen and associated 
fat and subsequently placed in a 30ml universal tube containing 10ml of HBSS at 37°C. 
The pancreas was incubated in the universal tube for 15-17 minutes (depending on 
activity of enzyme lot) at 37°C, aspirated twice through a 10G hollow needle and 
washed three times at 400 x g for 2 minutes room temperature (RT) in ice-cold HBSS 
supplemented with 0.5% BSA (HBSS/BSA). After the final wash, the pancreatic tissue 
was resuspended in HBSS/BSA and separated from any undigested lumps of pancreas. 
The digest was re-pelleted and bottom loaded onto Ficoll of density 1.084 (Histopaque, 
Sigma Chemicals, UK). Ice cold HBSS/BSA was layered on top of the Ficoll and the 
tube was centrifuged for 18 minutes at 600 x g at 4°C. After centrifugation, the 
pancreatic islets were harvested from the interface, resuspended in ice cold HBSS/BSA 
and washed a further 3 times before being transferred to a petri dish containing 
HBSS/BSA. Islets were then hand picked under an inverted stereo microscope and 
transferred to a 15ml polypropylene test tube.
2.2.3 Measurement of blood glucose
Capillary blood glucose was measured from the tails of rats, in order to reduce the stress 
and trauma of repeated tail tipping. The tails of rats were pricked with a 25G needle and 
massaged to express capillary blood. Blood glucose concentrations were measured with 
an Accu-Check Advantage II glucometer (Roche Diagnostics, Germany).
43
2.2.4 Induction of diabetes
Streptozotocin (STZ) was reconstituted in normal saline immediately before use at a 
concentration of 50 or 55mg/ml. Healthy adult male Lewis rats were weighed and 
injected i.p. with 55mg/Kg streptozotocin. Females received a dose of 50mg/Kg of 
streptozotocin, as higher doses had proved to induce fatal diabetic coma; probably due to 
a higher fat to lean body mass ratio in females. Animals were fed normal rat chow with 
free access to water. After 3 days, the animals were reweighed and blood glucose was 
estimated to confirm diabetes. Animals were considered to be diabetic and suitable for 
transplantation if blood glucose concentrations were over 20 mmol/1 and animals had 
lost over 5% of body mass when compared to pre-streptozotocin levels.
2.2.5 Transplantation of islets
Transplant recipients were weighed and blood glucose was estimated, as above. 
Anaesthesia was induced with a 4% halothane in oxygen mixture in a small animal 
anaesthetic box. When anaesthetised, the abdominal area was shaved and the rat 
transferred to a warming board. Anaesthesia was maintained with a 1 -  1.5% halothane 
in oxygen mixture and the rats checked for level of anaesthesia by the hind paw 
withdrawal method. Rats were continuously checked throughout the operation for 
respiratory rate and depth of anaesthesia, with appropriate adjustment of halothane dose. 
Neuromuscular blocking agents were not used during the procedure.
When the animal was fully anaesthetised, the abdominal skin was washed with betadine 
solution and incised from xiphistemum to pelvic region. The abdominal cavity was 
opened, the rib cage gently retracted supero-laterally on either side and the bowel 
presented outside of the abdominal cavity onto gauze moistened with normal saline. The 
bowel was gently moved laterally to the left of the rat, in order to expose the porta 
hepatis, and covered with further saline moistened gauze. A dissecting microscope was 
employed to visualise the porta hepatis and assist transplantation (figure 2.1). The left 
aspect of the portal vein was dissected free just inferior to the bifurcation of the portal 
vein (area a, figure 2.1) and a dissecting forceps passed underneath the portal vein to an 
area just inferior to the bifurcation of the portal vein on the right side of the rat (area c,
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figure 2.1). The posterior aspect of the portal vein was then dissected free from the 
surrounding fascia. Next, an area in between the two branches of the portal vein was 
dissected (area b, figure 2.1), taking care not to handle the hepatic artery. A loose 
temporary ligature was placed around the left branch of the portal vein from area a to 
area b. It was not always possible to perform this in a single manoeuvre without damage 
to the hepatic artery and local structures, so the ligature was passed from area b to area c 
and then passed under the portal vein to area a.
At this point, the hand picked islets were resuspended in 0.1 ml of HBSS containing 
10% rat serum and aspirated through a 21G needle into a sterile 1ml syringe. The test 
tube was washed twice with 0.1ml of HBSS containing 10% rat serum, in order to 
transfer all islets from the test tube to the syringe. The needle on the syringe was 
changed to a 25G needle and the tip bent through 45°, in order to be more ergonomic for 
transplantation. The syringe was inverted and gently agitated, in order to collect the 
purified islets as close to the needle as possible. The temporary ligature around the left 
branch of the portal vein was tightened, diverting all blood flow into the right branch, 
and the 25G needle was inserted into the portal vein well below the bifurcation. The 
islets were slowly injected into the portal vein and blood was aspirated and re-injected 
three times to wash the syringe of any remaining islets. The temporary ligature was 
removed, restoring portal blood flow to both branches of the portal vein, and the needle 
removed. The portal vein was tamponaded with a cotton wool bud for at least 3 minutes 
or until haemostasis was achieved. The bowel was returned to the abdomen and the 
wound closed in layers with 4/0 vicryl. Five millilitres of normal saline was left in the 
peritoneal cavity for fluid replacement and sub-cutaneous Temgesic was administered as 
pain relief. The rats were transferred to a clean cage and placed in a warmed recovery 
suite for 48 hours postoperatively. Rats were allowed free access to standard rat chow 
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Main branch portal vein transplants (used for initial validation of the transplant 
technique) were performed in a similar manner to above description but xiphistemum 
removal, micro-dissection and use of a ligature around the portal vein was not performed.
2.2.6 Intra-peritoneal glucose tolerance test
Rats were anaesthetised with 24mg (0.4ml) of pentobarbitone (Rhone Merieux) ip. After 
deep anaesthesia was achieved, the tip of the rat’s tail was amputated and blood 
expressed. One drop of blood was used for measurement of blood glucose, as above, and 
a further 6-7 drops were collected in a 500pl eppendorf, spun at 15,000 x g in a 
microcentrifuge RT and the plasma stored at -20°C. The rat received 2g/Kg of dextrose 
intra-peritoneally and further samples were taken at 15, 30, 60, 90 and 120 minutes.
After 120minutes, the animals were humanely killed by rising inspired carbon dioxide 
concentration. Death was confirmed by cervical dislocation.
2.2.7 Retrieval of liver and pancreas
After death was confirmed, as above, the liver and pancreas were retrieved from the 
cadavers. A midline skin incision was made from xiphistemum to pelvic region and the 
abdominal cavity was opened. The liver was gently retracted inferiorly with two fingers 
and the liver was carefully dissected out of the rat.
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2.2.8 Fixation and embedding of livers
The livers of transplanted rats were examined histologically for morphology or the 
expression of angiogenic factors by in situ hybridisation. Both techniques require 
different methods for the processing of the tissue.
2.2.8a Paraffin-embedded sections
Livers were retrieved as above and were divided into lobes supplied by the right 
branch of the portal vein (RB) and those supplied by the left branch (LB). The 
LB tissue was then divided into equal sections of 4mm thickness and placed into 
6 separate cassettes. The RB tissue was also divided into sections of roughly 
4mm thickness and placed into 3 separate cassettes. The right anterior lobe was 
placed in a single cassette and the right posterior lobe was divided antero- 
posteriorly before placing each section in a separate cassette. The tissue sections 
were kept in 4% neutral buffered paraformaldehyde for a further 2 -  4hours until 
processed in an ASP 300 automated tissue processor (Leica). After processing, 
the tissue was embedded in paraffin and kept until sectioned. The tissue used for 
haematoxylin and eosin staining were initially incubated for an additional 24 
hours in 4% neutral buffered paraformaldehyde prior to processing.
2.2.8b Frozen livers for in situ
Livers were retrieved as above and fixed in 4% paraformaldehyde overnight. The 
livers were then freeze protected by incubating in sterile autoclaved DEPC 
treated 20% sucrose solution for six hours. The tissue was then transferred 
carefully to aluminium foil boats, covered in Tissue TEK, OCT compound 
(Sakura Finetek, Europe), frozen on carbon dioxide ice and transferred to a - 
20°C freezer until needed.
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2.3 Histological analysis of transplanted islets
2.3.1 Haematoxvlin and eosin staining
Paraffin-embedded livers were sectioned at 4 pm thickness, placed onto water at 40°C 
and floated onto plain glass slides. The slides were baked on a 65°C hot plate for 10 
minutes and processed through an automated slide staining system which incorporated 
dewaxing, rehydration, haematoxylin and eosin staining and dehydration. The slides 
were automatically cover slipped with a xylene-based compound and visualised 
immediately.
2.3.2 Immunohistochemistrv techniques
Paraffin-embedded livers were sectioned at 4pm thickness, placed onto water at 40°C 
and floated onto TissueBond (Abeam Ltd, Cambridge, UK) coated slides. The slides 
were transferred to a humidified incubation box and kept overnight at 37°C. The tissue 
was dewaxed in 2 washes of xylene, passed through graded alcohol concentrations 
(100%, 95% and 70%) to water and washed in running water. Antigen retrieval was 
carried out by heating the slides in a microwave oven whilst immersed in buffer (table 
2.1). The slides were cooled in running water, to avoid snap drying, and washed in tris- 
buffered saline (TBS). The slides were marked with a hydrophobic edging pen (Vector 
Laboratories, Peterborough, UK) and incubated with primary antibody diluted in 0.05M 
TBS, as per table 2.1. All antibodies were sourced from Vector Laboratories. After 1 
hour, the slides were washed 3 times in TBS and incubated with a biotinylated 
secondary antibody for 30 minutes. The slides were washed a further 3 times and 
incubated with streptavidin-peroxidase complex (Vector Laboratories) for 30 minutes 
before washing again in TBS and then incubating with DAB (Vector Laboratories) for 
between 5-10 minutes while watching for brown colour development. After a further 
wash with TBS, the slides were counter stained with Mayer’s Haematoxylin, incubated 
in acid-alcohol solution to wash out cytoplasmic haematoxylin and placed into blueing 
solution. After washing in water, the slides were dehydrated through graded alcohols, 
cover slipped with a xylene-based compound and imaged under a light microscope.
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Table 2.1: Antigen retrieval and dilution of antibodies for immunohistochemistry.
Antibody directed against Dilution Antigen retrieval technique
Microwave time Buffer
CD31 1/100 20 minutes Tris EDTA
Factor VIII related antigen 1/1000 10 minutes Citrate
CD34 1/50 10 minutes Citrate
Insulin 1/100 10 minutes Citrate
2.3.3 Combined endothelial and insulin staining
Paraffin-embedded livers were sectioned at 4pm thickness, placed onto water at 40°C 
and floated onto Vectabond (Vector laboratories, UK) coated slides. The tissue was air 
dried at room temperature overnight, dewaxed in 2 washes of xylene, passed through 
graded alcohol concentrations (100%, 95% and 70%) to water and washed in TBS. The 
slides were marked with a hydrophobic edging pen (Vector Laboratories) and incubated 
overnight at 37°C in O.lU/ml neuraminidase V (Sigma Aldrich, UK) diluted in acetate 
buffer (pH 5.0) supplemented with calcium chloride (see Appendix 1). Slides were 
washed in TBS x 3 and blocked by incubating for 1 hour with TBS containing 1:100 
sheep serum (Sigma Aldrich). Primary incubation was overnight at 4°C in TBS 
supplemented with 0.1% (w/v) BSA containing 20pg/ml of biotin conjugated BS-1 
(Sigma Aldrich) and 1:500 mouse anti-insulin antibody (Sigma Aldrich, UK). The slides 
were washed 3 times in TBS and then incubated with phosphate-buffered saline 
supplemented with 0.1% sodium azide containing 20pg/ml streptavidin-FITC (Sigma 
Aldrich) and 1:500 sheep anti-mouse antibody conjugated with rhodamine (Immune 
Systems Ltd, Paignton, UK). Slides were washed a further 3 times in TBS, 
counterstained for 3 minutes with methanol containing 4',6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) 5pg/ml and washed a final 3 times in TBS before cover-slipping 
with Citifluor anti-fade agent (Agar Scientific, UK).
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The slides were imaged with a Zeiss Axioskop 2 fluorescent microscope, photographed 
with a Zeiss MRm monochrome camera and processed with Zeiss Axiovision software. 
The final tricolour image was composed by overlaying the three colour images; green- 
for endothelium, red for insulin and blue for nuclei (see figure 2.2)
Figure 2.2: Formation of the tricolour image for the dual BS-1 and insulin 
technique. The final image (a) was created using Zeiss Axiovision software by 
overlaying the three consecutive images of blue- DAPI stained nuclei (b), green- 
FITC stained endothelium (c) and red- rhodamine stained insulin (d).This figure 
shows a single islet which spans between two portal triads. The labelled structures 
are: PV- portal vennule, HA- Hepatic arteriole, BD- bile ductule, HS- hepatic 
stroma, IV- islet vasculature. All further images in the thesis will be merged 
tricolour images of islets.
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2.3.4 Quantitative histological analysis
Quantitative analysis of JPG images obtained from the imaging of transplanted islets 
was performed using Image J software (freely available from the National Institutes of 
Health website, USA). Only islets with an area over 1000pm2 were used for analysis, in 
order to reduce the over/underestimation of endothelium and vascular density.
2.3.4a Scaling of images
Images were taken of a haemocytometer grid at the defined magnifications used 
for imaging islets (lOOx, 200x and 400x). The images were processed with Zeiss 
Axiovision software to obtain a scale for the number of pixels per pm, for each 
magnification. Four repeat measurements were used to reduce error in scale 
measurement. Zeiss Axiovision software was used to apply scale bars to images.
2.3.4b Measurement of engrafted islet area
JPG images of engrafted islets were imported into the Image J software. The 
scale was set within Image J (as derived from above calculations) and the outline 
of the insulin area of the islet (red) was drawn around, as shown in figure 2.3A. 
The area was calculated by the Image J software and displayed in pm2.
2.3.4c Measurement of percentage vascular area of islets 
The images from islet area analysis were further manipulated within Image J 
software to generate a percentage estimation of vasculature within the islet. The 
image with outlined islet area was converted into a JPG stack and selected for the 
green channel; which will highlight only the signal for endothelium. A threshold 
for the green image was set (as shown in figure 2.3B) and the area of 
endothelium within the measured area was calculated in pm2. The vascular area 
was then divided by the total area of the islet to produce a percentage of the islet 
which was vascular endothelium.
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2.3.4d Measurement o f vascular density
The vascular density of islets was measured by two separate methods. The 
number of vessel branches was measured manually using the cell counter plug-in 
within Image J, as shown in figure 2.3C. The generated value for the number of 
vessel branches was then divided by the total islet area, as estimated above. It is 
possible that this methodology could be open to bias because a single vessel 
branch was only counted once, no matter what the length. Therefore a further 
method was used which would take into account the contribution of length of 
vessels. A grid of 225pm2 was applied to the islet image and vessels were 
counted within the islet if they crossed the upper or left hand edge of a grid, as 
shown in figure 2.3D. The generated value was then divided by the islet area to 
generate a value for vascular density.
2.3.4e Calculation of the branching index
Two different techniques are used to estimate the vascular density of islets. The 
first method measures the number of vascular branches for a given sized islet and 
the second uses a grid technique to measure vessels within the islet. These two 
different techniques will give different information of the vascular architecture 
within an islet. If an islet has a small number of vessels with no branches, the 
first method will score the density low but, when using the grid method, the 
vessels will cross the grid at a number of points and the score will be relatively 
higher. Therefore, islets with vessels that have few branches will have a 
relatively lower score on the vessel counting method but higher score on the grid 
method. Islets with vessels that have a much higher number of branches (i.e. a 
glomerular type network of vessels) will have more comparable estimations for 
both techniques. This observation was further extrapolated to form a “branching 
index”, which would give an estimation of the number of vessel branches within 
the imaged islet. The branching index was calculated by dividing the vascular 
density using the vessel branch counting method by the vascular density 
calculated using the grid method. If the number of vessel branches within islets
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increases, the branching index will have a higher score and quantify whether the 
islets formed a new vascular network.
2.3.4f Measurement of vessel size
High magnification images (400x) only were used for the estimation of vessel 
diameter. Zeiss Axiovision software was used to analyse the image by measuring 
the diameter of vessel lumens on a pre-scaled image. The measurements were 
made perpendicular to the vessel walls and only vessels within the image with 
clear delineation of the lumen (parallel “tramline” staining of both vascular walls 
of the vessel) were measured.
Figure 2.3: Methodology for assessing islet area (A), percentage vascular area of an 
islet (B) and vascular density (C and D).
100 taw
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2.3.5 Fluorescent in-situ hybridisation of the Y chromosome
Digoxegenin was directly incorporated into the Y chromosome probe from the plasmid 
using a PCR Dig incorporation kit (Roche Applied science, Lewes, UK) and internal 
primers. The PCR product was purified using Quiaquick PCR purification columns 
(Quiagen, Crawly, UK) and aliquots were checked for size by gel electrophoresis and 
quantity using ultraviolet absorbance spectrophotometry in a Gene-Quant (Pharmacia 
Biotech, Cambridge, UK) analyser (see below). The digoxigenin incorporated probes 
were resuspended in HybMix (Sigma Aldrich, UK) at 40-60ng/pl and heated to 100°C 
for 2 minutes, in order to denature the probe. The probes were cooled on ice and used 
immediately.
Paraffin embedded liver tissue was sectioned at 7 pm, dewaxed with xylene and passed 
through graded alcohol to water before washing in PBS. The slides were marked with 
hydrophobic pen and incubated with 0.4% pepsin (Sigma Aldrich) in 0.1 M hydrochloric 
acid at 37°C for varying periods of time. The reaction was quenched with 0.2% glycine 
in 2xPBS for 2 minutes before washing in PBS and post fixing in 4% paraformaldehyde. 
Twenty microlitres of the HybMix/probe solution was applied to the tissue. The slides 
were coverslipped and sealed with heat resistant glue (Evostick, UK) and incubated on a 
hot plate for 10 minutes before transferring to a moist incubator at 50°C overnight.
The next day, the coverslips were removed and tissue washed in lxSSC at 37°C for 5 
minutes. The slides were washed in PBS and subsequently incubated with FITC labelled 
anti-digoxegenin Fab fragments at 1:100 concentration in PBS containing 0.5% BSA for 
2 hours. The slides were washed again in PBS, counterstained with 5pg/ml DAPI in 
methanol and coverslipped with Citifluor antifade reagent (Agar Scientific). The slides 
were imaged as above.
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2.4 In-vitro desferrioxamine treatment studies
Isolated islets were treated with the iron chelating agent desferrioxamine (DFO) and 
investigated for the expression of key angiogenic factors, viability, apoptosis, glucose 
stimulated insulin release and insulin content.
2.4.1 Effect of desferrioxamine treatment on expression of VEGF and bFGF protein in 
cultured islets
Islets were isolated and washed in CMRL culture media containing foetal calf serum, 
penicillin/streptomycin, HEPES buffer and L-glutamine (CMRL) (see Appendix 1). 
Aliquots of islets were hand counted under a stereoscopic microscope and transferred to 
6 well, flat-bottom culture plates. Each aliquot was covered with either 2ml of CMRL 
alone (control cultured) or 2ml of CMRL containing increasing concentrations of DFO. 
The concentrations of DFO used were lOpM (DFO 10), lOOpM (DFO 100) or lOOOpM 
(DFO 1000). The islets were cultured overnight under standard conditions in a 
humidified incubator at 37°C with 5% carbon dioxide. Hypoxic control islets were 
cultured in open plates containing CMRL within a modular incubator chamber (Billups 
Rothenberg, Del Mar, California, USA) which had been gassed for 20 minutes with a 
1% oxygen, 5% carbon dioxide and balance nitrogen gas (BOC Ltd, Surrey, UK), an 
ambient oxygen concentration which had been shown to up regulate HIF-1 alpha in 
cultured islets (Moritz, Meier et al. 2002). Hyperoxic control islets were cultured as for 
the hypoxic controls but the modular incubator was gassed with 95% oxygen and 5% 
carbon dioxide (BOC Ltd, Surrey, UK).
After 16 hours, the islet cultures were inspected for evidence of contamination and 
integrity of cultured islets. If there was no evidence of contamination and islets were 
intact, the culture medium was completely aspirated, transferred to a 5ml polypropylene 
test tube and centrifuged at 800 x g for 5 minutes RT, to sediment any aspirated cellular 
material. The supernatant was carefully harvested and frozen at -20°C until analysed.
The remaining islets on the culture plates were covered with 2ml of the iron-containing 
medium Ml 99 supplemented with foetal calf serum, penicillin/streptomycin, HEPES
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buffer and L-glutamine (M l99) (see Appendix 1). After a further 24 hours, the cultures 
were inspected and the culture supernatants were harvested and frozen as above. This 
process was repeated for a further 4 days in each culture.
2.4.2 Measurement of angiogenic growth factors bv ELISA
The quantification of different growth factors was analysed by techniques according to 
the factor assayed. All ELISA plates were read on a 3550 microplate reader (Bio Rad) 
and analysed with Microplate Manager v2.0.2 software (Bio Rad).
2.4.2a Measurement of VEGF
Fifty hand picked islets were cultured as outlined above. The stored supernatants 
were defrosted and warmed to room temperature. The samples were vortexed to 
mix and analysed by mouse-specific VEGF ELISA (R&D Systems).
2.4.2b Measurement of bFGF
Three hundred hand picked islets were cultured overnight. The supernatants from 
the cultures were harvested the next day and islets were then washed twice in 
PBS before resuspending in 250pl of lysis buffer #11. The lysing cells were 
incubated on ice for 40 minutes before repeated aspiration through a 25G needle 
to shear DNA. Cell lysates were analysed using a human specific bFGF ELISA 
(R&D Systems).
The bFGF expression from lysed islets was corrected for total protein 
concentration within lysates, in order to correct for cell loss during the washing 
steps prior to lysis, and expressed as pg of bFGF per g of total protein. Total 
protein estimation was performed using a Lowry technique, as outlined below.
2.4.2c Measurement of HIF-la
Culture conditions and sample preparation were similar to that for bFGF. The 
samples were analysed using a human/mouse H IF-la experimental ELISA kit 
(R&D Systems).
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2.4.2d Measurement of total protein concentration from cell lvsates
Twenty microlitres of cell lysate, from above, was diluted in 980pl of double 
distilled water. Standard samples of known protein concentration were prepared 
from bovine serum albumin (Roche Applied Science, UK) and made up to lml. 
The standard concentrations of protein were 0, 5, 10, 20, 40, 60, 80 and 
lOOpg/ml. The standards and samples were mixed with Lowry solution C, a 
solution made from a 100:1 mixture of Lowry solution A and Lowry solution B 
(see appendix 1). The samples and standards were incubated for 10 minutes at 
room temperature before adding 0.15ml of 2N Folin-Ciocalteu solution and 
incubating at room temperature for a further 45 minutes.
The standards and samples were read at 660nm on a Lambda 3B 
spectrophotometer (Perkin Elmer, UK). The standards were used to calibrate the 
spectrophotometer and sample concentrations were calculated by comparison to 
the standard curve.
2.4.3 Effect of desferrioxamine treatment on angiogenic factor gene expression 
Islets were isolated from adult male Sprague Dawley rats, as above. The islets from a 
single donor were washed in CMRL and cultured overnight either in CMRL, DFO 100, 
DFO 1000 or CMRL under hypoxic conditions (1% oxygen), as above. The next day, 
islets (400-500 per experiment) were hand picked under a stereoscopic microscope and 
used for the extraction of RNA, as detailed in the molecular section below. Hand picked 
fresh islets were used as controls.
2.4.4 Effect of desferrioxamine treatment on islet viability
The viability of fresh, control overnight cultured (CMRL), desferrioxamine treated 
(DFO 10, DFO 100 and DFO 1000) and hypoxic islets was assessed by direct 
visualisation of whole islets and by flow cytometry on the cells from dispersed islets. 
Fresh hand picked islets treated with 150pM hydrogen peroxide were used as positive 
controls for cell death.
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2.4.4a Flow cytometry method on dispersed islets
Fifty hand-picked islets were dispersed by incubation with acutase (Innovative 
Cell Technologies, California, USA) in a polypropylene test tube. The islets were 
initially incubated static with 1ml of Acutase at 37°C for 10 minutes, followed 
by a further 5 minutes of incubation at 37°C with gentle pipetting of the cell 
suspension using a 1ml pipette. The dispersion was visualised under a stereo 
microscope and the reaction was stopped when the islets were fully dispersed by 
adding 1ml of cold phosphate buffered saline (PBS) containing 10% new bom 
calf serum. The resultant cell suspension was pelleted by centrifugation at 800 x 
g RT for 5 minutes, the supernatant removed and the cells gently resuspended by 
tapping the end of the tube. The resuspended cells were stained by adding 2.5 pi 
of 250pg/ml solution of propidium iodide and incubating in the dark at room 
temperature for 10 minutes. The mixture was diluted with 500pi of PBS and 
analysed on an Epics XL flow cytometer (Beckman Coulter). Non-viable cells 
were stained by propidium iodide and the signal picked up on the FL3 sensor.
The percentage viability of dispersed cells was calculated as the percentage of 
non-stained cells counted compared with all cells counted. The positive control 
for cell death was islets incubated in 150pM hydrogen peroxide prior to dispersal. 
Each sample was analysed in triplicate.
2.4.4b Direct visualisation of whole islets
Ten intact islets were hand picked in 100 pi of culture medium and placed onto 
untreated glass slides (Sigma Aldrich). The cell suspension was stained with 1 pi 
of acridine orange (0.02mg/ml) and counterstained with 2.5pl of propidium 
iodide (250pg/ml). The solution was gently mixed with the tip of a pipette, 
incubated for 5 minutes in the dark, cover slipped and visualised immediately on 
an Axiophot fluorescence microscope (Carl Zeiss, Germany). Images were 
acquired with stimulation by mercury light and filters for green and red light 
fluorescence, using a TS100 digital camera (Olympus) attached to the eyepiece 
of the microscope and stored for analysis. The pictures were analysed with Image
58
J cell counting software (NCBI) to assess the number of viable cells (positive 
green fluorescence) compared with non-viable cells (propidium iodide/red 
positive fluorescent nuclei). The assessment was repeated at least four times to 
gain a representative sample of the population tested.
2.4.5 Effect of desferrioxamine treatment on apoptosis of islets .
Apoptosis was assessed by Annexin V (Roche Applied Science, UK) and 7AAD 
(Invitrogen, UK) staining of dispersed cells on a flow cytometer, modified from the 
technique suggested by Cattan et al. (Cattan, Bemey et al. 2001). Hand-picked islets 
were dispersed by incubation with acutase (as described above). The cells were 
centrifuged for 5 minutes at 800 x g RT and washed 3 times in Dulbecco’s A PBS 
(without calcium or magnesium to avoid cell clumping). The dispersed islets were 
stained with Annexin V from the apoptosis assessment kit (Roche Applied Science, UK) 
and 7AAD (Invitrogen, UK) and resuspended by vortexing. The cell suspension was 
diluted in the phosphate based buffer provided by Roche Applied sciences and assessed 
on an Epics XL flow cytometer (Beckman Coulter, UK).
Positive controls (150 pM hydrogen peroxide treated islets) and fresh islets were used 
for the set up of the flow cytometer. Single stained cells, either annexin V or propidium 
iodide, of either fresh or hydrogen peroxide treated groups were used to set the voltages 
and compensation on the flow cytometer.
2.4.5a Isolation and staining of peripheral blood mononuclear cells 
The flow cytometry method for apoptosis assessment of disrupted islets proved 
problematic. In order to assess the methodology and check the function of the 
flow cytometer in non disrupted cells, peripheral blood mononuclear cells were 
used as an easy to access cell line with known cell surface markers.
Venous blood was obtained by standard venepuncture techniques and collected 
into heparinised syringes. Blood was mixed in equal quantities with RPMI 1640 
(Life Technologies Ltd, UK) and layered onto Lymphoprep (Axis-Shield, UK) in
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30ml polystyrene tubes (Greiner Bio-one Ltd, UK). The blood/density gradient 
mixture was centrifuged for 20minutes at 2000 x g RT and the interface 
harvested and diluted further in RPMI. The resultant peripheral blood 
mononuclear cells were washed three times in PBS and stained with 
annexin/propidium iodide as above. Apoptosis was induced as above with al 
hour incubation in 150pM hydrogen peroxide, prior to staining.
A reliable positive control was required for assessment of flow cytometer 
function. The T cell marker CD4 was used for this purpose and freshly isolated 
peripheral blood mononuclear cells were stained with CD4-FITC antibody (Sero- 
Tech, UK) in PBS and washed a further three times in PBS before resuspending 
and analysing.
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2.4.6 Effect of desferrioxamine treatment on the glucose related function of islets
The glucose stimulated insulin release and islet insulin content was assessed to gain an 
indication of the effect of desferrioxamine treatment on the metabolic function of islets.
2.4.6a Glucose stimulation test
Aliquots of ten islets were hand picked under a stereo microscope and placed 
into 2ml eppendorfs. One millilitre of Krebs ringer solution supplemented with 
20mM Hepes buffer (pH 7.4) and 2% bovine serum albumin containing either 
1.67mmol/l glucose (basal) or 16.7mmol/l (stimulated) was added to the islets 
and incubated for 1 hour at 37°C. The eppendorfs were centrifuged at 1000 x g 
for 10 minutes, to sediment cellular debris, and 400pl of supernatant harvested 
and frozen at -20°C for analysis of insulin content at 1:10 dilution by a rat 
specific insulin ELISA (Mercodia AB, Uppsala, Sweden). The stimulation index 
was calculated by dividing the stimulated insulin concentration by the basal 
insulin concentration. The islet pellet was frozen in the remaining Krebs Ringer 
solution and stored at -20°C for further analysis of insulin content.
2.4.6b Assessment of insulin content of islets
The pelleted islets from static glucose stimulation tests were thawed and 
vortexed to resuspend islets. The islet suspension was sonicated twice for 
lOseconds at 18microns in a Soniprep 150 ultrasonic disintegrator (MSE 
Scientific Instruments, Crawley, UK). The resultant mixture was re-vortexed to 
mix and analysed for insulin content at 1:500 dilution by a rat specific insulin 
ELISA (Mercodia AB). The results were expressed as insulin content per islet.
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2.5 RNA molecular techniques
The expression of angiogenic growth factors was assessed at both protein and message 
level. The assessment of mRNA required a number of techniques, which will be 
described here.
2.5.1 Isolation of RNA
Hand picked islets were washed in CMRL and centrifuged at 800x g for 5minutes RT. 
The supernatant was removed and the islets recentrifuged with further total removal of 
all culture medium. The islets were lysed with 1ml of TRIzol reagent (Invitrogen, UK) 
by active pipetting with a 1ml pipette and then transferred to a clean, RNAse free 1.5ml 
eppendorf. The homogenised samples were incubated static for 5 minutes at room 
temperature and then 200pl of chloroform were added. The resultant mixture was 
vigorously agitated for 2 minutes before centrifuging at 12,000 x g for 15 minutes at 4°C. 
After centrifugation, 400pl of the upper aqueous phase of the supernatant was carefully 
removed without disturbing the interface (which contains sheared genomic DNA) and 
transferred to a clean RNAse free eppendorf. 500pl of isopropanol was added, to 
precipitate the RNA, and the solution was incubated for ten minutes at room temperature 
before centrifuging at 12,000 x g for 10 minutes at 4°C. The supernatant was carefully 
removed and the resultant RNA pellet washed in 1ml of 75% ethanol. The ethanol and 
RNA solution was recentrifuged at 7,500 x g for 5 minutes at 4°C, the supernatant 
completely removed, recentrifuged and any remaining supernatant completely removed 
before air drying the pellet. After drying, the RNA pellet was resuspended in 50pl of 
molecular biology grade water (Sigma Aldrich, UK) and the resultant solution was 
analysed spectrophotometrically for RNA concentration and purity.
2.5.2 Analysis of RNA concentration and purity
The concentration and purity of RNA was estimated by ultraviolet absorbance 
spectrophotometry, using a Gene-Quant (Pharmacia Biotech, Cambridge, UK) analyser. 
Absorption of light was quantified at 260nm and 280nm to derive concentration and 
ratio values.
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2.5.3 DNAse treatment of RNA samples
RNA samples were treated with DNAse to reduce any contamination of genomic DNA 
in the RNA samples, which might interfere with the real time PCR estimation of gene 
quantification.
One microgram of total RNA, as estimated above, was diluted in 8 pi of water for 
molecular biology (Sigma, UK) and added to 1 pi of DNAse (Invitrogen, UK) and 1 pi of 
RT buffer (Invitrogen, UK). The solution was vortexed to mix and incubated at room 
temperature for 15minutes. lp l of EDTA was added to stop the reaction and the solution 
was heated to 65°C for 10 minutes to denature the enzyme and stop it inhibiting the 
formation of cDNA in the next step. The sample was cooled on ice for 2 minutes before 
use.
2.5.4 Formation of cDNA
Complimentary DNA (cDNA) was formed from isolated total RNA using Taq-Man 
reverse transcription reagents (Applied Biosystems, Warrington, UK). Four hundred 
nanogrammes of total RNA were added to the suggested mixture of reverse transcriptase, 
RNAse inhibitor, dNTPs, random hexamers, buffer, magnesium and water to a volume 
of 20pl in a PCR tube; as directed in the manufacturers instructions. The tubes were 
centrifuged, in order to collect all contents in the bottom of the tube, and transferred to a 
Gene Amp 9700 thermal cycler (Applied Biosystems, Warrington, UK). The machine 
performed a single cycle of 25°C for 10 minutes, followed by 48°C for 30 minutes (for 
cDNA formation by reverse transcriptase), followed by 95°C for 5 minutes (for 
denaturing of reverse transcriptase enzymes), followed by a final step of 4 °C until the 
cDNA was removed from the machine.
2.5.5 Design of real time PCR primers
The messenger RNA (mRNA) sequences for the required angiogenic factors were 
retrieved from the National Centre for Biotechnology Information (NCBI) website. The 
sequences were blast searched back into the web site to check the identity of the 
sequences were correct and then compared to rat genomic sequences. The comparison 
with genomic DNA allowed the mapping of intron-exon boundaries within the mRNA
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sequence. The mRNA sequence and intron-exon boundary information was compared 
with primer sequences used by other authors and used to create new primer pairs using 
Primer Express v2.0 software (Applied Biosystems, UK). Primers were selected from 
the list of primers suggested by the software by choosing pairs where one primer 
overlapped an exon-exon boundary and the other primer was based within the adjacent 
exon. Primer pairs were especially chosen when the overlapping primer had only 5 to 7 
bases within the exon containing the non overlapping primer and when both primers had 
similar melting points. If a primer set fulfilling these criteria did not exist on initial 
searching of the sequence, the computer was directed to an area within the mRNA 
sequence which contained exon-exon boundaries that had been spanned with primers 
designed by other authors.
The VEGF primers were designed to span designated exon-exon boundaries within the 
VEGF sequence, in order to examine specific VEGF transcripts; as described previously 
in the rat (Tober, Cannon et al. 1998). The expression of all VEGF isotypes was 
examined by choosing a primer pair with one primer spanning the exon 2 to exon 3 
boundaries. The VEGF 164 isotype in the rat is formed by alternate splicing of the gene 
and lack of expression of exon 6. Therefore a primer pair was designed with one primer 
spanning the exon 5 to exon 7 boundaries. The careful design of primer pairs allowed 
the examination of the expression of different VEGF splice variants.
When the primer set had been designed, the sequences were BLAST searched back into 
the NCBI website to confirm that the primers identified the correct gene and did not 
additionally identify a different gene. Once all these criteria had been met, the sequences 
were sent to Sigma Genosys (Sigma, UK) for creation of desalted primers. Primers were 
diluted to lOOpM concentration with water for molecular biology, according to 
manufacturer suggestion, and then further diluted as corresponding forward and reverse 
primer pairs to a concentration of 2.5jiM. This working concentration was used with 
small aliquots stored at -20°C until required.
All primers were validated and investigated before use, as outlined in chapter 3.
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2.5.7 Real time PCR estimation of gene quantification.
The real time PCR method for estimating relative gene quantification was performed 
with a 7000 Sequence Detection System machine (Applied Biosystems, UK) and SYBR 
green (Applied Biosystems, UK) DNA binding dye. Beta actin was used as the control 
for relative quantification.
Two micro litres of cDNA was pipetted onto the side of a 0.2ml PCR tube and 1.5pl of 
2.5pM forward and reverse primer (sequences as in table 2.2) and 9pl of water for 
molecular biology (Sigma, UK) were pipetted onto separate areas of the same tube. 
12.5pl of SYBR green (Applied Biosystems, UK) was pipetted into the lid of the PCR 
tube and the cap firmly placed on the tube without disturbing the other solutions. The 
tubes were centrifuged immediately before placing into the 7000 machine, to avoid 
mixing until the very last opportunity (hot starting). The 2 duplicate cDNA 
amplifications were run in parallel with amplifications containing similar dilutions of 
total RNA and water controls (amplifications containing primers only- also known as no 
template controls). The RNA controls acted to highlight any amplification of genomic 
DNA with the primer sets and the water controls were present to highlight any DNA 
contamination of the solutions or plastics. The final dilution of total RNA in the control 
amplifications was similar to the final dilution of total RNA that would be expected to 
be found in the cDNA amplifications after reverse transcription. This matching of 
dilutions would allow direct comparison of the cDNA amplification plots to any 
amplification in control plots and therefore enable estimation of the severity or 
significance of any contamination. The final composition of the real time PCR 
amplification runs are outlined in table 2.3. In addition, certain primer sets (basic 
fibroblast growth factor, angiopoietin 1 and endostatin) required the addition of 
formamide 2%, to improve the specificity of binding of primers; as highlighted in table 
2 .2 .
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Table 2.2: Primer sequences for gene analysis by real time PCR and primers that 
required addition of formamide. (VEGF all, refers to the primers which analyse all 
isoforms of vascular endothelial growth factor.
Gene
analysed
Forward primer Reverse primer
Formamide
2%
Beta actin TGAAAAGATGACCCAGATCATGT AGGGACAACACAGCCTGGAT
VEGF all AGCCCATGAAGTGGTGAAGTTC GGTCTCAATTGGACGGCAAT
VEGF 164 GAGATGAGCTTCCTGCAGCATA GCTCACAGTGATTTTCTGGCTTT
HGF CAAAACAAGGTCTGGACTCACATG CTCCCAGAAGATATGACGGTCiT A A
bFGF GAAGAGAGAGGAGTTGTGTCCATCA CTCTTCTGTAACACACTTAGAAGCCAGC ✓
ANG1 AGAAGCAGAACTACAGGTTATATTTAAAGG T AGCAT AAGGGCGC ATTTGC S
Endostatin CTGC AGG ACCTCT AC AGC ATTG CCTCATCCTTCAGGTTGACGAT V
Table 2.3: Composition of cDNA amplifications and control amplifications
Component cDNA amplification RNA amplification Water control
cDNA 2pl - -
RNA - 2pl -
2.5pM primer pair 1.5pl 1.5pl 1.5pl
SYBR green 12.5pl 12.5pl 12.5pl
Water 9pl 9pl 9pl
The amplification mixtures were transferred to the 7000 Sequence Detection Unit and 
amplified by heating to 94°C for 5 minutes followed by 50 cycles of 94°C for 30 
seconds, 60°C for 30 seconds (annealing), 72°C for 2 minutes (elongation). The run was 
finished with a dissociation point estimation for the individual PCR products. The 
cycling temperatures for primer sets that required formamide were changed to an 
annealing temperature of 64°C for 30 seconds followed by an elongation step of 72°C 
for 30 seconds, in order to improve specificity and reduce binding of genomic DNA.
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The 7000 sequence detection system and ABI prism 7000 software calculated the 
normalised emission (Rn) of a sample by subtracting the emission signal of the SYBR 
green I from the emission signal passive reference dye ROX.
2.5.7 Validation of PCR primers.
After designing specific primers for real time PCR, the primers required thorough 
validation to confirm they were specific, only amplified a single product, did not 
dimerise and whether they would amplify genomic DNA.
2.5.7a Isolation of rat genomic DNA
Ten ml of blood was collected from 2 Sprague Dawley rats at the time of islet 
harvest and collected into citrated blood tubes (Sarstedt Monovette, Nuembrecht, 
Germany).The blood was transferred to a 50ml test tube and the cells were lysed 
and nuclear protein digested by using a blood and cell culture midi kit for 
genomic DNA isolation (Quiagen Ltd, UK). Briefly, 10 ml of blood was added 
to 30ml of ice cold water and 10ml of ice cold buffer containing 320mM 
saccharose, 5mM magnesium chloride, lOmM tris-hydrochloride and 1% triton 
X-100. The tubes were inverted to mix and incubated on ice for 10 minutes, to 
lyse all cells. The solution was centrifuged for 15 minutes 1300 x g at 4°C, the 
supernatant removed and the pellet rewashed in the saccharose buffer. The 
resultant pellet o f nuclei was resuspended in 5ml of 800mM guanidium 
hydrochloride containing 30mM EDTA, 30mM tris-hydrochloride, 5% tween-20, 
0.5% triton X-100, to lyse the nuclei, and digested with 95pof 20mg/ml protease 
for 45 minutes, to strip DNA of any associated protein. The lysate was then 
applied to an equilibrated Genomic-tip (Quiagen) column (a resin based 
purification column) and washed with 1M sodium chloride /15% ethanol solution 
containing 50mM MOPS at pH 7.0. The column was eluted with 5 ml of 1.25M 
sodium chloride /15% ethanol solution containing 50mM tris-hydrochloride at 
pH 8.0. The eluted DNA was precipitated with 0.7 volumes of isopropanol at 
room temperature, to avoid precipitation of salts, and centrifuged at 10,000g for
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20minutes at 4°C. The supernatant was aspirated, the pellet air dried and the 
DNA resuspended in 50pl of TE. DNA was quantified spectroscopically.
2.5.7b Validation of primers
The primer pairs were used for standard PCR amplification with cDNA, genomic 
DNA and water as template, to investigate their ability to amplify the different 
templates under specific conditions.
Two hundred nanogrammes of cDNA or genomic DNA was amplified by PCR 
with lOpl of Reddymix (AB Gene, Epsom, UK) pre-mixed PCR solution and 
1.5pl of 2.5pM primers in a 9700 thermal cycler (Applied Biosystems, 
Warrington, UK), at a final volume of 20pl. The thermal programme was 94°C 
for 3 minutes, to denature the DNA, followed by 50 cycles of 94°C for 30 
seconds, 55°C for 30 seconds (annealing), 72°C for 2 minutes (elongation). The 
run was finished with a further 5 minutes at 72°C before ending at 4°C. 
Annealing temperatures of 57°C, 60°C and 63.5°C were also explored.
Validation of primers was also carried out under real time PCR conditions, as 
outlined below.
2.5.7c Assessment of PCR products
PCR product (10pl) was loaded onto a 2% agarose gel in TBE containing 5pg/ml 
of ethidium bromide. Superladder lOObp ladder (AB Gene) was used to estimate 
the product size and the gel run at 150volts, variable current, for 50 minutes. The 
gel was visualised by an ultra violet imaging camera, Gel Doc 2000 (Bio Rad, 
Hertfordshire, UK) and images were analysed on Quantity One (Bio Rad) 
software.
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2.5.8 Analysis of amplification plots and relative fold gene expression
The raw data from the 7000 Sequence Detection Unit was collected at the time of 
amplification by ABI Prism 7000 (Applied Biosystems) software on a laptop associated 
with the sequence detection unit. The software displayed the amplification data 
graphically in the form of sigmoid plots of normalised emission signal from SYBR 
green DNA dye against cycle number (see figure 2.4). Analysis was only performed 
using plots which were sigmoid in form and parallel to the beta actin amplification plots 
used for reference. Sample amplification plots were excluded if the associated water or 
RNA controls showed evidence of amplification. In the rare case of amplification of 
RNA controls, seen only with occasional amplifications using endostatin, bFGF and 
ANG 1 primer pairs, the amplification plots were only used for analysis if there was 
over a 10 cycle difference in the Ct values between cDNA and RNA; corresponding to a 
1000 fold difference in cDNA to genomic DNA amplification.
2.5.8a Calculation of threshold cycle (Ct) values
The threshold cycle (Ct) values were calculated using the ABI prism 7000 
software. The selected amplification plots were analysed by setting the threshold 
at a point which bisected all the plots in their log phase of amplification (the 
green line in figure 2.4). This was often performed automatically by the software 
but occasionally had to be performed manually. The point of bisection of the 
amplification plot with the threshold line allowed the calculation of the cycle 
number at which the individual samples reached a similar stage of amplification, 
the threshold cycle (Ct). The calculated Ct values from all samples were 
collected for further comparative analysis.
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Figure 2.4: Amplification data expressed as signal against cycle number when 
displayed using ABI Prism 7000 software. The green line indicates the point of 
analysis used for calculating Ct values for individual samples.
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2.5.8b Calculation of intra sample differences in gene expression (ACf)
The relative quantification of gene expression with real time PCR relies on 
having a reference to compare for fold analysis. The first step requires the 
analysis of the difference of gene expression within a sample, when compared to 
a reference. For this series of experiments, beta actin was chosen as the reference 
(housekeeping gene) because hypoxia has little effect on the expression of this 
gene, unlike GAPDH which is up-regulated by hypoxia (Escoubet, Planes et al. 
1999; Zhong and Simons 1999) and hypoxia inducible factor (Graven, Bellur et 
al. 2003).
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The difference in the expression of a gene within a sample (ACt) was calculated 
by subtracting the Ct value of the control gene from the Ct value of the target 
gene (beta actin in this case).
ACt = Ct (target gene) -  Ct (control gene)
2.5.8c Calculation in inter sample differences in gene expression (AACtl 
The relative changes in gene expression under differing conditions are calculated 
by analysing the gene expression during the experiment relative to the gene 
expression found in control experiments. In this case, the control experiment was 
the gene expression of control islets.
The relative difference in inter sample gene expression (AACt) was calculated by 
subtracting the ACt of a gene in an experimental sample from the ACt of the 
same gene in a control sample.
AACt = ACt (gene y/control sample) - ACt (gene y/experimental sample)
The ACt for a gene in the control sample (either fresh islets or control cultured) 
was determined by calculating the average ACt from all the PCR runs of that 
particular gene. This ACt was used as the control sample ACt for calculating the 
AACt of that particular gene for each PCR run.
71
2.5.8d Calculating the relative fold change in gene expression
The AACt value for a gene within an experiment is the difference in the number
of PCR cycles between the expression of the gene in the experimental conditions
relative to the control conditions. Therefore, given that each PCR cycle doubles
the number of copies of the DNA specified by the primers, the fold expression
difference between the two samples can be expression as 2 to the power of the
AACt.
Relative fold change in gene expression = 2MCt
This assumption requires that the amplification kinetics of the experimental gene 
(gene y) and the control gene (beta actin) are comparable -  the two sigmoid 
amplification plots are parallel. In addition, the threshold has to be set at a point 
where each cycle is producing a doubling of PCR product -  most reliably during 
the middle exponential phase of the curves.
The final relative fold change in gene expression was calculated as an average of 
all analysis of a single gene under a specified condition (i.e. VEGF expression 
after DFO 1000 treatment).
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2.6 DNA molecular techniques
The initial project design required the use of in-situ hybridisation to examine the origin 
of endothelium with a Y chromosome probe and the site of growth factor expression 
using riboprobes. Although some of these techniques were not fully developed, the 
relevant sequences were sought, amplified and sequenced prior to use. This section will 
describe some of the common techniques used.
2.6.1 IMAGE clone selection
Sequences for the formation of riboprobes were chosen by searching the National Centre 
for Biotechnology Information (NCBI) website for appropriate and well matched 
Integrated Molecular Analysis of Genomes and their Expression (IMAGE) consortium 
clones. The clones were chosen to be either rat specific or mouse clones that were 
almost (greater than 90%) analogous to rat sequences.
2.6.2 IMAGE clones chosen
The following image clones were chosen for conversion into riboprobes:







2.6.3 Rat Y chromosome probe
The rat Y chromosome probe was supplied as a gift from Dr B Hoebe (RIMV, 
Netherlands). The probe was obtained as a plasmid and transformed into E Coli - One 
shot™ (Invitrogen, Gronigen, Netherlands)
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2.6.4 Broth amplification of plasmids
IMAGE clones were dilution streaked onto LB agar plates containing 50pg/ml 
ampicillin and incubated overnight at 37°C. Single colonies were picked from the plates 
with sterile microbiological loops and transferred to 2.5ml of LB broth containing 
50pg/ml ampicillin and incubated overnight at 37°C with continual agitation.
2.6.5 Isolation of plasmid DNA
Two millilitres of resultant broth were harvested and centrifuged at 800 x g in 2ml 
eppendorfs for 5 minutes RT. The supernatant was removed, the pellet dispersed by 
vortexing and then resuspended in 200pl of GTE. The bacterial cells were lysed by 
adding 400pl of bacterial lysis buffer (see Appendix 1) and mixed by gentle inversion of 
the tube in order to avoid shearing chromosomal DNA. The cell lysate was incubated on 
ice for 10 minutes and neutralised with 200pl 3M potassium acetate. The tube was 
mixed by inversion and further incubated on ice for 10 minutes. The mixture was 
centrifuged for 10 minutes at 15,000 x g RT in a microcentrifuge, in order to precipitate 
chromosomal DNA and protein, and 700pl of supernatant containing plasmid DNA was 
decanted by pipette. The supernatant was transferred to a 1.5ml eppendorf and 1ml of 
cold absolute ethanol was added, to precipitate plasmid DNA. The mixture was 
incubated on ice for 30 minutes and centrifuged for 15 minutes at 15,000 x g RT in a 
microcentrifuge. The supernatant was carefully aspirated and the resultant pellet washed 
with 200pi of cold 70% ethanol and centrifuged again at 15,000 x g RT for 10 minutes. 
The supernatant was aspirated, the tube recentrifuged briefly and the remaining 
supernatant removed. The pellet was air-dried and then resuspended in 50pl of tris- 
EDTA (TE) containing RNAse. This was kept at as a stock solution of DNA at -20°C 
and working concentrations of 1:200 dilutions in TE were taken from stock.
2.6.6 Glycerol stock of plasmids
The remaining 0.5ml of broth was mixed with 0.5ml 30% (v/v) glycerol in LB medium, 
to make a solution of 15% (v/v) glycerol in LB. The stocks were stored at -20°C.
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2.6.7 Digestion of plasmids
Plasmids were digested to check that plasmid DNA was present. Plasmids were mixed 
as below in a lOOpl PCR tube:
• 2pi of buffer (buffer B)
• lOpl of plasmid
• lpl of HINDIII
• 7pi of distilled water
The tubes were incubated for 30-60minutes at 37°C. The digest was then mixed with 6pl 
of 5X loading dye and loaded onto a 1.5% agarose gel in TBE containing 5pg/ml of 
ethidium bromide.
2.6.8 Check of plasmids bv PCR prior to broth amplification
Further single colonies from LB agar plates were transferred to lOOpl PCR tubes 
containing 20 pi PCR buffer (Quiagen, UK) and heat treated for 10 minutes at 94°C to 
kill the bacteria and denature bacterial proteins. The resulting DNA was used as a 
template in PCR reactions to check the integrity of plasmids prior to broth amplification.
2.6.9 Polymerase chain reaction (PCR) amplification
Plasmid DNA was amplified by PCR with Reddymix (AB Gene, Epsom, UK) pre-mixed 
PCR solution and M13 (AB Gene) forward and reverse primers in a 9700 thermal cycler 
(Applied Biosystems, Warrington, UK). The programme was 94°C for 3 minutes to 
denature the DNA followed by 30 cycles of 94°C for 30 seconds, 57°C for 30 seconds 
(annealing), 72°C for 2 minutes (elongation). The run was finished with a further 5 
minutes at 72°C before ending at 4°C.
2.6.10 Purification of PCR product
The PCR product was purified to remove excess primers and unincorporated bases using 
a Quiaquick gel centrifugation system (Quiagen GmbH, Germany).
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2.6.11 Estimation of PCR product length
PCR product (lOpl) was loaded onto a 1.5% agarose gel in TBE containing 5pg/ml of 
ethidium bromide. Superladder lOObp ladder (AB Gene) was used to estimate the 
product size and the gel run at 150volts, variable current, for 50 minutes. The gel was 
visualised by an ultra violet imaging camera, Gel Doc 2000 (Bio Rad, Hertfordshire, UK) 
and images analysed on Quantity One (Bio Rad) software.
2.6.12 Estimation of DNA concentration and purity
The concentration and purity of the PCR product was estimated by ultraviolet 
absorbance spectrophotometry, using the absorbance of 260nm light for estimation of 
DNA concentration and 280nm light as reference for protein contamination. Ratios 
above 1.8 were used as a cut off for uncontaminated samples. The samples were 
measured in a Gene-Quant (Pharmacia Biotech, Cambridge, UK) analyser.
2.6.13 Sequencing of PCR products
The PCR products were sequenced using the chain termination method, incorporating 
fluorochrome labelled di-deoxynucleotides and subsequent analysis by capillary gel 
electrophoresis in an automated genetic analyser. All products were sourced from 
Applied Biosystems, unless stated otherwise.
PCR product (20ng) was mixed with Big Dye Terminator v l . l  cycle sequencing solution 
and either M l3 forward or M13 reverse primers. The reactions were cycled in a 9700 
thermal cycler by heating to 96°C for 2 minutes followed by 30 cycles of 94°C for 10 
seconds(denaturing), 50°C for 5 seconds (annealing) and 60 °C for 4 
minutes(elongation). The final step brought the reaction temperature to 4°C until 
required.
The products were purified by ethanol precipitation and sequenced on an ABI Prism 310 
genetic analyser (Perkin Elmer). The results were analysed on Gene Scan and 
Sequencing Analysis software to provide a sequence of the PCR products.
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2.6.14 Confirmation of sequences of PCR products
The identity of the sequenced plasmid insert was confirmed by using the program 
BLAST (NCBI database) to compare with known sequences on the database.
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2.7 In-vivo desferrioxamine treatment studies
2.7.1 Effect of transplanting desferrioxamine treated islets on reversal of diabetes 
Islets were isolated as above, washed in CMRL, hand picked under a stereo microscope 
and transferred to a 90mm Petri dish for overnight incubation in 7ml of CMRL, DFO 
100 or DFO 1000. The next day, the islet cultures were examined for contamination and 
integrity of islets. Two different doses of islets were transplanted, either a very marginal 
dose of 350 islets or a less marginal dose of 500 islets. The islets for transplantation 
were hand picked, washed in ice-cold HBSS and resuspended in 0.2ml of HBSS 
containing 10% Lewis rat serum. The islets were then transplanted into the right branch 
of the portal vein (as described in chapter 2). Body weight and blood glucose were 
measured daily for 2 weeks and weekly for a total of 11 weeks. After that time, the 
animals were humanely killed by a rising concentration of inspired carbon dioxide. The 
liver and pancreas were harvested and stored for subsequent histological analysis with 
dual insulin and endothelial staining.
2.7.2 Histological analysis of desferrioxamine treated and control islets
At the time of liver harvesting, the right lobes of the liver were divided into three 
sections and individually embedded in wax blocks. Each block was sectioned and two 
representative sections from different levels of each block were used for analysis. A total 
of six sections from each animal and eighteen sections from each experimental group 
were used for analysis. The sections were analysed for qualitative morphology and 
quantitative analysis of vascular density, graft area and vascular area.
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2.8 Clinical islet transplantation
Clinical islet transplantation was undertaken in accordance with local ethics committee 
submission (appendix 3). The protocols used for recipient selection, islet isolation, 
transplantation and post transplant immunosuppression were in accordance with the 
original Edmonton protocol (Shapiro, Lakey et al. 2000). In brief, islet isolation was 
carried out on human donor pancreases with short cold ischaemic times using Liberase 
HI (Roche GmBh, Germany) or Collagenase NB/neutral protease mix (Serva 
Electrophoresis, Germany). Islets underwent a brief period of culture in modified CMRL 
culture media before being transplanted intra-portally via a transcutaneous and 
radiographically guided approach.
All patients received triple immunosuppression with Daclizumab (Roche 
Pharmaceuticals, Basel, Switzerland), sirolimus (Wyeth Phrama, USA) and low dose 
tacrolimus (Fujisawa, Japan), in accordance with the Edmonton protocol. Patients also 
received standard transplant prophylaxis, although our unit does not give 
cytomegalovirus (CMV) prophylaxis and patients were treated by premptive screening 
by PCR followed by directed therapy. Patients were followed post transplant at regular 
intervals with regular screening for infection, drug toxicity/efficacy and diabetic control.
2.9 Statistical analysis
All data was collected and analysed using Microsoft Excel for Windows 2003 
(Microsoft corp., USA). Simple inter-group comparative statistical analysis was 
performed with t-tests using the analysis tool pack within Microsoft Excel. More 
complex statistics and repeated measures were performed with repeated measures 
ANOVA and post hoc analysis using Statistica 6.0 for Windows (Stat-soft Inc., OK, 
USA). All data is expressed as mean plus one standard error, unless otherwise stated.
79
Chapter 3 -  Results: 
Validation and new techniques
3.1 Introduction
Pancreatic islets were originally discovered in 1869 by a Berlin medical student, Paul 
Langerhans (Langerhans 1937). Since the original description by Langerhans, pancreatic 
islets have been recognised to be a complex conglomeration of endocrine cells (Orci 
1976) with an intricate vascular anatomy (Bonner-Weir and Orci 1982; Brunicardi, 
Stagner et al. 1996). The complex structure and anatomy of islets enables the cells to 
communicate with each other and provide a coordinated response to glucose 
homeostasis (Weir and Bonner-Weir 1990). This structural conformation of islets 
appears to be important to their function and even after disruption, cultured islets cells 
tend to reaggregate into a similar pattern to that of native islets (Halban, Powers et al. 
1987). Although disrupted islets can be transplanted and do reform a network of blood 
vessels, the revascularisation of disrupted islets is incomplete and clinical outcomes are 
worse when compared to non disrupted islets (Beger, Cirulli et al. 1998). Therefore, the 
use of 6-cell lines or disrupted islets would not have provided sufficiently accurate data 
to study the revascularisation of transplanted islets and a source of fresh whole islets was 
required. The need for intact islets was further compounded by the requirement of a 
living recipient, in order to study the changes in endothelial architecture during the 
revascularisation of transplanted islets. Thus, an in-vivo model was required for 
experiments which examined islet revascularisation.
The isolation of islets from the whole pancreas is paramount to the success of post 
transplant outcomes (Nano, Clissi et al. 2005) and small changes to the isolation 
technique or consumables used can have a great impact on the function and survival of 
isolated rat islets (de Haan, Faas et al. 2004). The process of isolation and 
transplantation of pancreatic islets is complex and is not standardized between different 
investigator groups. Therefore, a certain amount of validation was required to optimise 
the isolation of pancreatic islets prior to transplantation. Once optimal islet isolation was
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achieved, a suitable site for transplantation was required. Although a number of authors 
have used the renal subcapsular site for transplantation and easy retrieval of transplanted 
islets (Carlsson and Mattsson 1993; Carlsson, Palm et al. 2000; Vasir, Jonas et al. 2001), 
this model is not clinically relevant. The use of the more clinically relevant intra-portal 
site for transplantation has been limited by the poor retrieval of islets but the selective 
right branch transplantation model (Juszczak M 2003), developed within our unit, 
provided a method for circumventing this problem.
The original technique of right branch transplantation was designed for male to male 
transplantation of syngeneic rats. The model was further adapted in order to track the 
origin of engrafting islet endothelium and sex mismatched transplantation with Y 
chromosome in-situ hybridisation was undertaken for demarcation of endothelial origin. 
Although sex mismatching does not adversely effect the outcome of immunosuppressed 
human allogenic solid organ transplants (Ellison, Norman et al. 1994), there is evidence 
from human allogenic stem cell grafts that sex mismatching may induce antibodies to 
the minor histocompatability antigens encoded by the Y chromosome (H-Y) (Spierings, 
Vermeulen et al. 2003; Miklos, Kim et al. 2004). Therefore, further validation was 
required to investigate whether the transplantation of syngeneic male rodent islets into 
non-immunosuppressed female rodent recipients would affect the outcomes after 
transplantation. In addition, the female recipients were smaller than male recipients and 
dose ranging experiments were required to evaluate the number of islets necessary to 
fully reverse streptozotocin induced diabetes in female recipients.
Islet transplant models provide useful clinical endpoints (changes in weight and blood 
glucose after transplantation) to assess the engraftment of islets but do not provide 
accurate assessment of the critical process of islet revascularisation. Histological 
assessment of islet grafts enables the visualisation of revascularisation but relies on 
accurate identification of structures to fully appreciate this important process. Direct 
visualisation of grafts under the kidney capsule (Carlsson, Palm et al. 2000) or dorsal 
skin fold (Vajkoczy, Menger et al. 1995) has allowed insight into revascularisation but 
are limited by graft clumping and lack of clinical relevance. Islets have been visualised
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within the liver after transplantation but studies are limited by lack of structural 
definition (Griffith, Scharp et al. 1977) or the need for serial sectioning to define graft 
and vascular area (Carlsson, Palm et al. 2001). A new staining technique was required to 
simultaneously define graft area and vascular anatomy in order to accurately quantify 
graft revascularisation. A specific marker of islet vasculature (Mattsson, Carlsson et al. 
2002) was used in combination with insulin staining in order to develop a novel dual 
staining method for accurately visualising intra-portally transplanted islets (Jones, 
Juszczak et al. 2005). The visualisation of transplanted islets with a dual staining 
technique had not been reported in the literature previously and optimisation of staining 
was required to gain accurate architectural definition of both endothelium and endocrine 
mass.
Although the clinical outcomes after transplantation are probably the most important, the 
in-vivo transplant techniques are influenced by multiple experimental factors and require 
large numbers to reduce the variability of the endpoint. In-vitro assessment of islets is 
important to reduce assessment variability by focusing on a single aspect and explore 
proof of concept. A number of the techniques used for the assessment of islets are based 
on standard culture and functional methods but further optimisation was required to 
customise islet viability and apoptosis assessments which were modified from reported 
techniques (Cattan, Bemey et al. 2001).
The assessment of growth factors required optimisation and new primers had to be 
designed and evaluated before use in experimental studies. Although a number of 
molecular techniques were already established within the laboratory, the gene expression 
assessed in this project had not previously been evaluated within the group. For this 
reason, new primer sets were designed and had to be evaluated before use and a 
description of the process is provided in order to verify the accuracy of analysis.
This chapter describes the modification or adoption of non standard techniques and the 
processes required to establish novel methods.
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3.2 Validation of common in-vivo techniques
The project required a number of common techniques which were based around the 
isolation and transplantation of islets. In order to perform these techniques it was 
necessary to standardise and validate the induction of diabetes with streptozotocin, blood 
glucose measurements, islet isolation and islet transplantation.
3.2.1 Validation of capillary blood glucose measurements
Diabetic and transplanted animals underwent regular estimations of blood glucose for 
verification of diabetes induction or monitoring of graft function. In order to reduce the 
stress and pain associated with repeated tail tipping and plasma glucose estimations, 
capillary blood glucose was measured using an Accu-Check Advantage II glucometer 
(Roche Diagnostics, Germany). As plasma glucose estimation is regarded as the gold 
standard for glucose measurement and the Accu-check was originally designed for 
human use, the method required validation.
Validation was achieved by collecting rat blood samples (in heparinised capillaries) at 
the same time as blood glucose measurement with the Acu-Check glucometer. Samples 
were collected during intra-peritoneal glucose tolerance tests and from a single non 
diabetic rat, to provide a range of glucose concentrations. Two male recipients and two 
female recipients were used as subjects. The rat blood samples were transferred to a 
200pl eppendorf, centrifuged lOmin xlOOg RT and analysed immediately on a Cobas 
Mira auto-analyser (Roche).
The capillary blood glucose measurements were lower than plasma levels, as expected, 
and within the range of 4.6 -  28.8mmol/l. Blood glucose measurements correlated well 
with the measured plasma estimations (R2 = 0.88, figure 3.1) and therefore, this 
technique was adopted to estimate blood glucose concentrations
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Figure 3.1: Correlation between blood glucose concentrations measured by the 
Accu-Check Advantage 11 glucometer and plasma glucose concentrations measured 
by the Cobas Mira auto-analyser.
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3.2.2 Validation of diabetes induction.
Diabetes was induced in 13 animals (3 male Lewis rats and 10 female Lewis rats) with 
55mg/Kg of STZ. The 3 male subjects were rendered diabetic with a reduction in mean 
body weight from 251.3g (± 10.9g) to 224.3g (± 15.8). The average random blood sugar 
post STZ was 27.4mmol/l (± 3.2). Of the ten female subjects, 4 died within 3 days of 
diabetes induction, with signs of rapid weight loss, dehydration and coma. The 
remaining 6 female subjects became diabetic, with a reduction in mean body weight 
from 194.0g (±2.21) to 174.8g (±2.0) and an elevation in mean blood glucose to 
30.3mmol/l (±1.5).
All animals were rendered diabetic by 3 days post STZ injection and all, bar the 4 
female animals who died, remained stable post diabetes induction for up to 10 days. The 
reason for the deaths in the female group was thought to be induction of severe diabetes 
due to a higher fat to total body mass ratio in female animals. Therefore, as STZ is 
lipophilic with a prolonged half life of active metabolites (130 hours in humans), the 
female rats receive a greater area under the curve exposure to STZ metabolites than
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males and are likely to be rendered more severely diabetic. The dose of STZ was 
subsequently reduced to 50mg/Kg for female rats and diabetes induction in females was 
more predictable, without further loss of subjects.
3.2.3 Validation of rat islet isolation
Rat islet isolation is an important step for both in-vitro and transplant model experiments. 
In order to optimise the technique and prove reproducibility of the isolation process, 
islets were isolated from rat male donors.
The first set of experiments was undertaken to maximise the Ficoll purification of islets 
from exocrine tissue within the pancreatic digest. This evaluation was required because 
two separate techniques were available within the laboratory, purification on Ficoll and 
purification on a stepped dextran gradient, and world literature also suggested a lower 
density of Ficoll for islet purification (1.077g/ml).
Pancreatic digests from 2 Sprague Dawley rats were split into thirds and applied to three 
different ficoll densities of 1.082g/ml, 1.084g/ml and 1.086g/ml. The resultant purified 
preparations were examined under a stereo microscope for purity and yield of islets.
The purified islet fraction from the 1.082g/ml gradient was of high purity but low 
quantity while the fraction from the 1.086g/ml gradient had a high quantity of islets but 
was of low purity, which limited hand picking of islets. It was therefore decided to use a 
1.084g/ml gradient and sacrifice some purity for a better yield of islets but not 
contaminate the preparation to the point at which hand picking of islets was hindered.
The next set of experiments examined the volume of collagenase used for distension and 
enzymatic digestion of the pancreas during isolation The use of larger volumes of buffer 
provides better distension of the pancreas and may help separate the endocrine/exocrine 
interface but the higher pressure within the pancreas when delivering larger volumes of 
collagenase may lead to damage of the islet and infiltration of collagenase into the islet, 
leading to fragmentation and damage to the islet during digestion. Therefore,
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experiments were undertaken using a standard dose of 5mg of collagenase P (Roche) 
dissolved in increasing volumes (3.3, 4 and 5ml) of HBSS. Islets were subsequently 
isolated and counted (Table 3.1).
Table 3.1: Comparison of islet yield when using different volumes of buffer infused 
with collagenase.
Volume of buffer used (ml)
Average number of islets 
isolated (+/- SE)
Number of isolations
3.3 499.9 (85.2) 6
4.0 366.8 (58.6) 4
5.0 270.5 (85.1) 6
These experiments showed that increasing the volume of buffer infused was associated 
with a stepwise reduction in yield, which was significant when comparing 3.3ml to 5ml 
volumes. Therefore, all further experiments were carried out using the 3.3ml volume of 
buffer for distension of the pancreas.
3.2.4 Validation of non selective intra-portal transplantation 
The investigation of islet transplantation requires a robust model with reproducible 
endpoints. The next set of experiments examined whether the transplant technique met 
this criterion.
The remaining 9 diabetic animals (3 male Lewis rats and 6 female Lewis rats) all 
underwent main branch intra-portal islet transplantation. Out of these 9 animals, one 
female recipient died during surgery and the remaining animals had successful islet 
transplants. The three male recipients each received a mean of 644 (± 14.7) islets, (Table 
3.2).
All animals had a fall in blood glucose post transplantation, although one recipient 
reverted to almost pre transplant blood glucose levels after 2 weeks. Two weeks after 
transplantation, the mean body weight of the three male recipients had risen from 224.3g
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(± 15.7) pre-transplant to 245.7g (± 12.5) and the mean random blood glucose had fallen 
from 27.4mmol/l (± 3.2) pre transplant to 16.0mmol/l (± 4.3) (Table 3.2).
The 5 female recipients received a mean of 691.2 (± 135.9) islets transplanted via the 
main branch of the portal vein (Table 3.2). All 5 recipients had a reduction in blood 
glucose. After 2 weeks post transplantation, the mean body weight increased from 
173.8g (± 3.0) pre transplant to 180.3g (± 6.0) and the mean blood glucose had fallen 
from 32.0mmol/l (± 1.0) to 9.7mmol/l (± 2.0).
Table 3.2: Weight and blood sugar of rats prior to and after transplantation during 






















Male 233 27 266 10.4
Male 234 21.8 248 13.2
Male 206 33.3 223 24.5
Female 175 33.3 174 9.8 195 5.5
Female 163 28.3 163 16.1 180 21.6
Female 174 33.3 181 11.6
Female 176 32 200 5.3
Female 181 33.3 184 5.7
3.2.5 Validation of sex mismatched right branch intra-portal transplantation 
With the success of the non selective male to female transplants, the next experiments 
were designed to investigate whether selective transplantation was feasible in the smaller 
female recipients, the dose of islets required to reverse STZ induced diabetes and 
whether a longer post-transplant course affected outcomes.
Five female recipients were rendered diabetic with streptozotocin and transplanted with 
male islets. Three of the recipients received a dose of 500 islets, one 850 islets and one
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1200 islets. One recipient from each group was sacrificed after 14 days, the original 
planned time for the right branch experiments, and a further two animals in the 500 islet 
group were sacrificed after five and seven weeks, in order to investigate any effect of 
sex mismatching on long term graft outcome.
The average weights of the animals fell from 195.2g (+/- 6.8) pre streptozotocin to 
173.4g (+/-6.6) on the day of transplant and then rose to 181.6g (+/-11.5) fourteen days 
after transplantation. The change in blood sugars post transplant is illustrated in figure
3.2.
Figure 3.2: Change in blood glucose after transplant in 5 diabetic female recipients 
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With the success of the sex mismatched main branch transplants, the experiments were 
next performed with right branch transplantation.
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3.2.6 Conclusions of in-vivo validation 
These experiments proved that:
1. Measurement of rat tail vein blood glucose with a hand held glucometer provided 
a good estimation of glucose concentration which was comparable to the gold 
standard but less traumatic to animals.
2. Stable induction of diabetes could be achieved with i.p. injection of STZ at a 
dose of 55mg/Kg in male rats and 50mg/Kg in female rats.
3. Isolation of islets was reproducible and optimised when using 3.3ml of buffer for 
injection of collagenase and 1.084g/ml ficoll density for purification
4. Diabetes could be reversed with the intra-portal transplantation of islets and male 
to female islet transplantation did not obviously affect the outcome in a 
syngeneic transplant model.
5. Selective right branch transplantation could be achieved in the smaller female 
recipients and a dose of over 500 islets was probably required to reliably achieve 
normalisation of glucose.
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3.3 Development of histological techniques
The histological examination of transplanted islets was an important end point for the 
analysis of engraftment. The large volume of histology sections, cost of sample 
processing and need for optimal staining necessitated a clear understanding of the 
processes of tissue handling and processing. The basic techniques were learned within 
the routine clinical histopathology service and further optimised for islet staining and 
graft analysis.
3.3.1 Tissue sectioning and mounting
The analysis of islet grafts required retrieval of recipient livers, fixation, sectioning and 
staining. The fixation was performed in 4% formaldehyde for short periods, in order to 
reduce the antigen retrieval required for subsequent staining. The sectioning of paraffin 
embedded livers proved difficult due to fracturing and crumpling of tissue, caused by the 
short retrieval time and nature of liver tissue. This required modification of the 
sectioning technique and, after some experimentation, it was found that wetting the 
tissue prior to cooling tissue blocks and cutting at an incident angle below 10° reduced 
damage to tissue.
Once good tissue sectioning was achieved, the tissue had to be mounted on coated slides 
The harsh processing required for immunohistochemistry and fluorescence often lead to 
the loss of tissue from slides and uncoated slides did not provide sufficient tissue 
adhesion. The slides were initially coated with Poly-l-lysine (Sigma Aldrich, UK), to 
improve adhesion, but tissue was still lost during processing. A combination of Poly-l- 
lysine and baking of slides at 65°C provided excellent tissue adhesion but unfortunately 
caused loss of the antigen necessary for the binding of B. Simplicifolia. The slide coating 
was changed to Vectabond (Vector Laboratories, UK) and tissue adhesion was found to 
be sufficient without the need for baking. Therefore, Vectabond coated slides were used 
with air drying for improving tissue adhesion.
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3.3.2 Histology assessment of intra-portal transplanted islets.
The examination of engrafting islets during the process of revascularisation required a 
robust and quantifiable method for imaging both the endocrine mass and the vascular 
endothelium within transplanted islets.
Initial histological analysis was undertaken with haematoxylin and eosin staining (figure
3.3 A). This basic staining provided a reasonable delineation between liver and 
transplanted islet tissue which could be used for analysing graft area but there was no 
clear delineating of endocrine area and endothelium was not clearly identified. Therefore, 
immunohistochemical techniques were used to analyse the different composition of the 
islets.
Sections were stained for insulin by immunohistochemistry (figure 3.3 B) which 
provided good visualisation of the 6-cell mass of islets. Unfortunately, the endothelial 
markers Factor VIII related antigen, CD31 and CD34 (figure 3.3 C, D and E, 
respectively) were limited by background peroxidase staining and inability to demarcate 
islet endothelium sufficiently.
Due to the difficulties of reliably identifying the transplanted islet endothelium, the 
endothelial marker was changed to the lectin Bandeiraea Simplicifolia{BS-1). This lectin 
binds to endothelial carbohydrates and is a more reliable marker of transplanted islet 
endothelium than CD31, CD34 or von Willebrand factor (Mattsson, Carlsson et al.
2002). In addition, the staining technique was changed from immunohistochemistry to 
immunofluorescence, in order to enable two colour staining for the simultaneous 
analysis of islet endothelium and 6-cell mass without the need for multiple enzymatic 
incubations.
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Figure 3.3: Serial sections 
of recipient rat liver (x 200) 
stained with:






Initial results with B. Simplicifolia staining did not achieve satisfactory delineation of the 
vascular endothelium. Multiple antigen retrieval techniques (including trypsin digestion, 
heat treatment in citrate buffer and heat treatment in Tris-EDTA buffer) were used 
without any improvement in staining. Therefore, the B. Simplicifolia - FITC staining 
complex was changed to biotinylated B. Simplicifolia with a secondary layer of 
streptavidin FITC, in order to provide amplification of signal and improve visualisation. 
Unfortunately, there was still no improvement in resolution.
After discussion with Goran Mattson (Mattsson, Carlsson et al. 2002), it became clear 
that he used antigen retrieval with neuraminidase O.lu/ml in 0.1 M sodium acetate, which 
was not highlighted in his original publication. Subsequent experiments using antigen 
retrieval with neuraminidase brought about the staining of islet endothelium with B. 
Simplicifolia but appeared to be variable, with some experiments staining and others not 
staining at all. After further experimentation, it was found that the slide baking step 
(incubation of slides at 65°C overnight) introduced to improve tissue adhesion to slides 
interfered with BS-1 staining. This issue was resolved by changing the adhesive coating 
of slides to Vectabond and avoiding the baking of slides by air drying.
The antigen retrieval of insulin with neuraminidase worked well but longer incubations 
appeared to cause some degradation of insulin signal. Therefore, a further experiment 
was undertaken to ascertain the optimum incubation time for tissue pre-treatment with 
neuraminidase (figure 3.4).
This experiment showed that an incubation time of ~21 hours was found to be optimal 
for both retrieval of insulin and BS-1. Shorter incubation times (1,2 and 4 hours) 
produced patchy BS-1 staining with good insulin retrieval but longer incubation times 
(48 hours incubation) produced no insulin staining.
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Figure 3.4:Neuraminidase antigen retrieval optimisation. Images are of rat liver 
transplanted with islets (x 200). The sections have been stained simultaneously with 
B Simplicifolia (green), insulin (red) and counterstained with DAPI (blue). The 




a 1 hour 
b 2 hours 
c 4 hours 
d 21 hours 
e 48 hours
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A further experiment was performed on neuraminidase treated tissue to optimise 
concentrations of biotinylated BS-1, FITC-streptavidin, mouse anti-insulin antibody and 
rhodamine-conjugated anti-mouse antibody. The first experiments used three different 
concentrations of BS-1 (lOpg/ml, 20pg/ml and 30pg/ml) and three different 
concentrations of FITC-Streptavidin (lOpg/ml, 20pg/ml and 30pg/ml), as set out in table
3.3. All the combinations produced staining of transplant islet endothelium, although the 
staining with lOpg/ml concentrations was patchy. A similar set of experiments were 
undertaken for insulin staining with three different concentrations of mouse anti-insulin 
antibody (1:1000, 1:500 and 1:100) and rhodamine conjugated sheep anti-mouse 
antibody (1:1000, 1:500 and 1:100). Although both antibodies were recommended for 
use at a concentration of 1:1000 by the manufacturer, the optimal concentrations for 
both antibodies was found to be 1:500. Therefore, the optimal dilutions needed to 
produce consistent staining were 20pg/ml of both BS-1 and streptavidin-FITC and 1:500 
dilutions of both mouse anti-insulin and rhodamine-conjugated sheep anti-mouse 
antibodies.
Table 3.3: Experimental design for optimising the concentration of biotinylated BS- 
1 and streptavidin-FITC.
Experiment 1: I  
Optimising BS-1 concentration |
m  Experiment 2:
1] Optimising step-FITC concentration
BS-1 cone Strep. FITC cone B■  BS-1 cone Strep. FITC cone
(pg/ml) (pg/ml) 1 H (fig/ml) (Hg/ml)
10 30 I m  30 10
20 30 I 11 30 20
30 30 I H 30 30
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3.3.3 Conclusions o f histological optimisation
These experiments proved that:
1. Tissue sections should be air dried and mounted on Vectabond coated slides to 
avoid tissue loss and poor staining with BS-1.
2. The immunohistochemistry techniques tested were not suitable for dual staining 
of endothelium and insulin in transplanted islets.
3. Dual fluorescent BS-1 and insulin staining provided good delineation of 
endothelium and B-cell mass in transplanted islets.
4. The optimal protocol for dual staining was:
a. 21 hours antigen retrieval with neuramidase.
b. 20pg/ml of both BS-1 and streptavidin-FITC.
c. 1:500 dilutions for both mouse anti-insulin and rhodamine anti-mouse 
antibodies.
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3.4 Development of in-vitro assays for growth factor protein expression
The initial aim was to assess the effect of desferrioxamine treatment on growth factor 
protein expression. This section describes the optimisation of protein assays and 
problems encountered when analysing growth factor protein expression.
3.4.1 Assay of VEGF protein expression
The analysis of VEGF in culture supernatants was straight forward and did not require 
dilution of the culture media. The cross reactivity of the mouse VEGF kit was well 
established and ELISA plates developed well.
3.4.2 Assay of bFGF protein expression
With the success of the VEGF protein estimation, the culture supernatants were analysed 
for other important angiogenic factors. Unfortunately, rat or mouse-specific ELISA’s 
were not available for bFGF and HGF but a number of authors had reported the use of 
human-specific ELISA kits from R&D to assay rat bFGF (Kobayashi, Hamano et al. 
2000; Li, Khosla et al. 2000; Neuner-Jehle, Berghe et al. 2000) and the manufacturers 
suggested that the kits were sufficiently cross reactive with rat bFGF. Therefore, the 
human specific ELISA for bFGF (R&D Systems) was used to analyse rat bFGF levels in 
culture supernatants.
The initial results were positive and suggested that desferrioxamine treatment up 
regulated bFGF (figure 3.5) but the values were variable, with development of signal in 
only a few ELISA plate wells (table 3.5). These results did not provide reliable evidence 
of bFGF expression and it was initially thought that the poor signal was due to the 
concentration of bFGF in supernatants being below the sensitivity of the assay. The 
experiments were repeated with 100 and then 200 islets per well but the increase in islet 
number did not improve the signal. In order to rule out the effect of freeze thaw cycles, 
the experiments were repeated with fresh supernatants from cultured islets, but there was 
still no signal. Finally, experiments were performed using 350 islets in culture with 
concentration of the supernatant 10 fold using a Microcon YM-3 centrifugal filter unit
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(Millipore, Watford, UK). This assay was run in parallel with lysates from cultured islets. 
The experiment provided a good signal from lysed and concentrated samples with 
estimated concentrations of bFGF in culture supernatants of 2.3pg/ml and 2.9pg/ml for 
the DFO 100 and control cultures, respectively. The bFGF signal from lysed islets was 
better and the assay involved fewer steps than that from concentrated supernatants. 
Therefore, the technique of islet lysis was used for the further assays of bFGF protein 
estimation.
Figure 3.5: Mean bFGF concentration in supernatants from islet culture^ after 
overnight incubation in increasing concentrations of desferrioxamine (DFO 10 
=desferrioxamine lOpM, DFO 100 = desferrioxamine lOOpM and DFO 1000 = 













■  DFO 10
□  DFO 100
□  DFO 1000
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Table 3.4: ELISA plate readings of bFGF concentration (pg/ml) in supernatants 
from islet cultures after overnight incubation in increasing concentrations of 
desferrioxamine.
Experiment Control DFO 10 DFO 100 DF01000
1 0 0 0 46.94
2 0 1.5 0 0
3 0 5.02 0 21.18
4 0 0 0 8.22
3.4.3 Assay of HGF protein expression
A human HGF ELISA (R&D Systems) did not indicate evidence of HGF within the 
culture media, despite increasing the dose of cultured islets. In view of the mRNA 
expression results, see below, the protein assay was not pursued further.
3.4.4 Assay of H IF-la concentrations
The hypothesis for treating islets with desferrioxamine is to up regulate H IF-la and the 
down steam hypoxia response molecules. Desferrioxamine treatment does up regulate 
VEGF, as shown below, but the mechanism is only presumed unless the up regulation of 
HIF-la can be proven. An assay for H IF-la was required at the protein level, as the up 
regulation is due to reduced destruction by proteosomes and occurs post translation. 
HIF-la protein assays are not readily available and therefore, the duo set developmental 
sandwich ELISA for mouse/human total H IF-la (R&D systems) was tried to quantify 
protein expression.
Overnight cultured islets were lysed in lysis buffer #11 and assayed immediately. The 
experiments with 100, 200 and 350 islets or the supernatant from a 350 islet culture did 
not give a signal. It was presumed that the assay was either not sufficiently specific for 
rat HIF-la, despite the highly conserved structure between species, or the level of HIF- 
la  in the samples was below the sensitivity of the assay. The escalation of islet quantity 
was not justifiable, given the animal source of the islets, and it was decided to use the 
assay with desferrioxamine treated human islets, where a high dose of islets could be
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used and the specificity of the assay would be correct. Unfortunately, there were no 
suitable islet preparations available after this time and there was insufficient time left to 
establish a western blot analysis technique for rat HIF.
3.4.5 Conclusions from in-vitro assay of growth factor protein expression 
These experiments proved that:
1. Vascular endothelial growth factor protein expression can be easily analysed in 
islet culture supernatants.
2. Basic fibroblast growth factor should be analysed from lysed cells.
3. Hepatocyte growth factor and H IF-la ELIS As are not sufficiently sensitive or 
cross reactive to analyse the protein expression of these factors in cell culture 
supernatants.
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3.5 Development of molecular techniques
Although molecular methods were used within the laboratory, they had not been applied 
to the study of islets before. This section will examine the reasoning for choosing 
specific methods and the work up of the primer sets.
3.5.1 Isolation ofRNA
Ribonucleic acid (RNA) is usually separated from DNA and cellular proteins using its 
specific physico-chemical properties by phenol chloroform extraction. This technique 
was originally described by Chomczynski and Sacchi in 1987 and a variety of simplified 
methods have been designed since the publication of the original method (Chomczynski 
and Sacchi 1987).
RNA was initially isolated in accordance with the original Chomczynski and Sacchi 
protocol but the methodology was time consuming and the purity and quality ofRNA 
was poor (See table 3.5). The ratio of absorbance of 280nm to 260nm was often low 
(values 0.9-1.2) and samples of isolated RNA frequently amplified by PCR, suggesting 
unacceptable DNA contamination. The RNA isolation methodology was therefore 
changed to a GenElute mammalian RNA isolation kit (Sigma Aldrich, UK), which is 
based on a silica gel system for purification. This technique reduced the time required 
for purification ofRNA and increased yield but did not improve the purity. Therefore, 
the isolation technique was changed back to a phenol/chloroform based isolation 
technique (TRIzol reagent from Invitrogen) but used a premixed guanidium/phenol 
mixture. The change in technique improved RNA purity, although the yield was not as 
good as the silica gel based technique.
When the RNA extraction of fresh islets was compared to cultured islets, it appeared that 
RNA purity and content were much better in fresh islets (table 3.6). Although a number 
of the steps involved in RNA extraction were varied, the RNA ratio could not be 
improved in the cultured islets. It was unclear whether this observation was related to 
culture but after changing the chloroform to fresh stock, the ratio was improved when 
isolating RNA from hypoxic islets.
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Table 3.5: Analysis of different RNA purification methods. Each isolation was 
tested by using overnight cultured islets isolated from a single rat. RNA was diluted 







Number of isolations 5 4 4
RNA conc. (pg/ml) 78.9 (±37.5) 188.6 (±38.1) 122.2 (±15.1)
Ratio 1.039 (±0.06) 1.16 (±0.04) 1.50 (£0.06)
Protein conc. (mg/pl) 3.32 (±0.31) 2.75 (±0.48) 0.75 (±0.15)
Table 3.6: Analysis ofRNA isolated from fresh, control cultured, desferrioxamine 
treated and hypoxic cultured islets. RNA was diluted in a final volume of 50fil. 









RNA conc. (pg/ml) 482.2 108.9 102.6 134 490.8
(91.7) (25.4) (30.1) (51.3) (64.5)
Ratio 1.70 1.60 1.55 1.55 1.73
(0.02) (0.03) (0.03) (0.03) (0.02)
Protein conc. 1.83 0.5 0.63 0.75 0.46
(mg/pl) (0.25) (0.18) (0.21) (0.22) (0.07)
Purity 93.3 88.3 86 86 95.8
(1.13) (1.71) (1.78) (1.74) (1.4)
3.5.2 Additional primer sets.
A number of primer pairs were evaluated for examining the expression of key 
angiogenic factors (table 3.7) before selecting the final primer pairs, as described in 
chapter 2. All primer pairs were selected in accordance with the methodology outlined in 
chapter 2
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Table 3.7: Primer pairs evaluated but not suitable for final experiments. Figures in 
brackets refer to additional primer pairs analysed, not different molecules.
Growth
factor
Forward primer Reverse primer
bFGF (1) AGTTGTGTCCATCAAGGGAGTGT TGGACTCCAGGCGTTCAAAG
bFGF (2) GGCTTCTAAGTGTGTTACAGAAGAGTGTT GAGT ATTTCCGTGACCGGT A AGTG
bFGF (4) GCTGGCTTCTAAGTGTGTTACAGAAGAGT CAGTGCCACATACCAACTGGAGTA
HGF GTGTCAGCGTTGGGATTCG TTGAAGTTCTCGGGAGTGATGATGTC
VEGF AATGCAGACCAAAGAAAGATAGAACA CGCTCTGAACAAGGCTCACA
ANG1 (1) GCCTGTGGCCCTTCCAAT TGGTTTTGCCC 1W  AGTGTA
ANG1 (2) TAACAGGAGGTTGGTGGTTTGA TTTGCCCT GC AGTGT AGAAC A
ANG1 (4) T AAC AGG AGGTTGGT GGTTT G A T GGTTTT GCCCT GC AGT GT A
Endostatin CCTCT AGGCTGC AGGACCTCT A GGTTGACGATGGGCACAGA
18S CCTGAGAAACGGCTACCACATC GGGT CGGG AGTGGGT A ATTT
GAPDH(l) TGCCAAGTATGATGACATCAAGAAG GT AGCCC AGGATGCCCTTTAG
GAPDH(2) GAGAAACCTGCCAAGTATGATGACA AGCCCAGGATGCCCTTTAGT
3.5.3 Formation of cDNA
Two different methodologies were evaluated for the formation of cDNA. The first was a 
bead technique using “Ready-to-go you-prime first-strand beads” (Amersham 
Biosciences, Buckinghamshire, UK). This technique involved incubating 2pg of total 
RNA and 0.2pg of random hexamers (Amersham Biosciences, Buckinghamshire, UK) 
in 30pl of water, with two beads containing dNTPs, reverse transcriptase and RNAse 
inhibitors. The reaction was incubated for 1 hour and subsequent cDNA used for both 
standard PCR and real time PCR. Although this technique did produce amplifiable 
cDNA, the real time amplification was poor and produced distorted amplification curves 
that were unacceptable for real time PCR analysis. The Taq-Man reverse transcription 
reagents (Applied Biosystems, Warrington, UK) were evaluated and found to provide 




Contamination of real time PCR reactions with DNA is an important issue, as any 
amplification in addition to cDNA will lead to an increase in SYBR green signal and 
distortion of the relative quantification of gene expression. The source of DNA 
contamination is two fold. Firstly, DNA contamination could be exogenous from 
external contamination (i.e. from poor handling, contamination of water and reagents, 
contamination of plastic ware and contamination of work environment etc). Secondly, 
contamination could be endogenous (i.e. genomic DNA contamination of the RNA). 
During the evaluation of primer pairs, both types of contamination were identified, 
figure 3.6
Figure 3.6: Gel electrophoresis of PCR products using primers (from left to right 
GAPDH, beta actin, VEGF all, VEGF 164, bFGF, HGF, ANG1 and Endostatin). 
Lane 1-8 are water controls, 10-17 have RNA only as a template and 19-27 have 
cDNA as template. Lane 9 and 18 are lOObp ladders. Exogenous DNA 
contamination can be seen by amplification of the water control lane 7 and 
endogenous contamination is seen by amplification of the RNA lanes 10-12 and 14-
17.
Water template RNA template cDNA template
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3.5.4a Reduction of exogenous DNA contamination 
The amplification of water controls, as above, suggested exogenous DNA 
contamination of the PCR reactions. The source of the contamination was 
probably a combination of the water used for diluting reactions, plastic ware and 
handling of samples. The water used for RNA and PCR reaction dilution was 
initially double distilled water which had been DEPC treated and autoclaved. It 
became clear that this was a major source of contamination and was probably 
due to the use of laboratory glassware which had been contaminated with rat 
genomic DNA whilst being used for buffers during other rat experiments. 
Therefore, the water source was changed to “water for molecular biology”
(Sigma Aldrich, UK), which was certified DNA, DNAse and RNAse free, and 
was stored in fresh plastic tubes. All plastic ware was changed and only 
unopened bags were used with no handling, other than with clean forceps. In 
addition, all primers and reagents were replaced and the place of experimentation 
was changed to a clean area where no rat experiments were performed.
3.5.4b Reduction of endogenous DNA contamination
Genomic DNA contamination ofRNA samples was evident by the amplification 
ofRNA samples by standard PCR, as above. A number of different RNA 
extraction techniques had already been tried to reduce contamination but ratios of 
1.6-1.7 were still achieved. The issue was whether to reduce DNA contamination 
ofRNA or increase the specificity of the PCR primers for cDNA, so that only 
cDNA was amplified and not genomic DNA. Both techniques were employed 
and the improved specificity of PCR primers is described later in this chapter.
The reduction of genomic DNA contamination in RNA samples was achieved by 
adding a DNAse step to the RNA extraction protocol, before formation of cDNA. 
This additional step reduced DNA contamination and PCR amplification of RNA, 
as shown in figure 3.7.
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Figure 3.7: Reduction of genomic DNA contamination by DNAse treatm ent 
of RNA. The image shows a gel electrophoresis of standard PCR products 
amplified with beta actin primers. Lane 1 is RNA treated with DNAse, lane 
2 is non treated RNA, lane 3 is a lOObp ladder and lane 4 and 5 are water 
controls.
1 2 3 4 5
After the reduction in DNA contamination with DNAse, the next step was to 
show that DNAse treatment of the RNA sample did not interfere with cDNA 
formation, concentration or amplification. Real time PCR was used to examine 
the effect of DNAse treatment by running parallel real time PCR amplifications 
ofRNA versus DNAse treated RNA versus cDNA formed using untreated RNA 
versus cDNA formed using DNAse treated RNA. The same original RNA 
sample was used for each parallel PCR amplification and all the dilutions were
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carefully calculated so that the same concentration of original isolated RNA was 
used in each reaction, therefore allowing direct comparison of all groups.
Figure 3.8: Real time PCR amplification with HGF primers using cDNA from 
untreated RNA as a template (red curve), cDNA from DNAse treated RNA as a 
template (blue curve), untreated RNA as a template (purple curve) and DNAse 
treated RNA as a template (green curve).
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This experiment showed that DNAse treatment reduced genomic DNA 
contamination of RNA without effecting the concentration or amplification of 
cDNA (figure 3.8). In addition, even without DNAse treatment, the amplification 
of genomic DNA in the RNA sample was less than the amplification of cDNA 
(figure 3.8). When calculated from this example, the genomic DNA amplified 16 
fold less than the cDNA.
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3.5.5 Evaluation of primers
Due to the problems with genomic DNA amplification, the primer sets were redesigned 
to try to improve the specificity of binding and stop the amplification of genomic DNA. 
The redesigned primers were reevaluated for their efficacy, specificity and amplification 
kinetics.
The first step was to ensure that the primers amplified cDNA and evaluate whether there 
was amplification of genomic DNA. A single standard PCR reaction was undertaken 
with the primer sets and either genomic DNA, isolated from rat blood, or cDNA from 
RNA isolated from islets. The cDNA experiments amplified a single product, important 
for real time PCR analysis, but the genomic DNA amplifications also amplified; 
although mixed products were seen with VEGF 164 and HGF primers when amplifying 
genomic DNA (figure 3.9)
Figure 3.9: PCR amplification of genomic DNA (lanes 2-9) and cDNA (lanes 11-18) 
with PCR primers (GAPDH- lane 2 and 11, beta actin- lanes 3 and 12, VEGF all­
lanes 4 and 13, VEGF 164- lanes 5 and 14, bFGF- lanes 6 and 15, HGF- lanes 7 and 
16, ANG1- lanes 8 and 17, and endostatin - lanes 9 and 18).
1 2 3 4 5 6 7 8 9 10 11 1213141516 171820
Genomic DNA template cDNA template
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Following on from this experiment, the conditions o f the PCR reaction were altered to 
reduce amplification o f genomic DNA, The first step was to increase the annealing 
temperature o f the PCR cycle to a point closer to the melting temperature o f the primers. 
This change to the PCR cycle should make the primers more specific for cDNA, due to 
the overlap of one primer across an exon-exon boundary, and avoid amplification o f 
genomic DNA, These experiments were performed with genomic DNA as a template 
and annealing temperatures o f 57°C and 60 °C, The increased annealing temperatures 
made no difference to the amplification o f genomic DNA with primers, except HGF and 
VEGF 164 where amplification was reduced or abolished (figure 3.10).
Figure 3.10: PCR amplification of genomic DNA with different annealing 
temperatures, 57°C and 60 °C. Lanes 1,10 and 10 are lOObp ladder. The primer 
pairs used in the remaining lanes are: GAPDH- lanes 2 and 11, beta actin- lanes 3 
and 12, VEGF all- lanes 4 and 13, VEGF 164- lanes 5 and 14, bFGF- lanes 6 and 15, 
HGF- lanes 7 and 16, ANG1- lanes 8 and 17, and endostatin- lanes 9 and 18.
•enomic DNA tempi* 
Annealing temp. 6(
Genomic DNA templa 
Annealing temp. 57
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These primer pairs were used for the collection of gene expression data, as outlined in 
chapter 4. All primers worked well during real time PCR with no amplification of 
DNAse treated RNA, under the predetermined PCR cycle conditions. Unfortunately, the 
bFGF, Angl and endostatin primers showed amplification in the control RNA samples. 
Therefore, this data was discarded and the primers for these growth factors were 
redesigned.
The genomic structure and mRNA sequence of bFGF, Ang-1 and endostatin were re­
scrutinised and further primer sets were designed. Two bFGF primer pairs were 
redesigned and reordered while a single primer pair was reordered for Angl and a 
further primer pair created from the forward primer of the first Angl pair and the reverse 
primer from the second Angl primers. The new primer pairs were further evaluated and 
optimized.
Initial experiments with the new primers gave similar results (figure 3.11) but further 
optimization with increased annealing temperature to 63.5°C and addition of deionised 
formamide to a final concentration of 2%, increased the specificity of primer binding 
and stopped genomic DNA amplification of the new primers (figure 3.12). 
Unfortunately, the addition of deionised formamide reduced the efficiency of the beta 
actin primers and further control amplifications with beta actin were undertaken without 
the addition of formamide. These new primer sets were used to rerun the real time PCR 
evaluation of bFGF, Angl and endostatin gene expression in the experimental samples.
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Figure 3.11: Electrophoresis gel of PCR products from amplification ofRNA (lane 
2-6) and cDNA (lane 8-12) using redesigned Angl and bFGF primers. Lanes 1 and 
7 are lOObp ladder. The other lanes are with the following primers: Beta actin- lane 
2 and 8, bFGF (3)- lanes 3 and 9, bFGF (4)- lanes 4 and 10, Angl (3)- lanes 5 and 11, 
Angl (4)- lanes 6 and 12.
RNA template cDNA template
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Figure 3.12: Electrophoresis gel of PCR products from amplification ofRNA 
template (lanes 1-4) and cDNA template (lanes 6-9), in the presence of 2% 
deionised formamide and using annealing temperature of 63.5°C. The following 
primers were used: beta actin- lanes 1 and 6, bFGF (3)- lanes 2 and 7, Angl (3)- 
lanes 3 and 8, endostatin- lanes 4 and 9.
RNA template cDNA template
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3.5.6 Selection of a control primer pair
The use of real time PCR for quantifying the relative expression of target genes relies on 
a suitable control (or housekeeping) gene whose expression is not altered by the 
experimental conditions. Three candidate control genes were selected, beta-actin, 
GAPDH and 18S. All three genes had been used before by other authors in similar 
experiments and all genes were evaluated for use as controls.
The 18S primer pairs were discarded first. Despite two different primer pairs being 
evaluated, the 18S primers amplified genomic DNA and the amplification curves 
produced by real time PCR had different kinetics to the primers for other target genes.
The second primer pair to be discarded was GAPDH. Despite having good amplification 
curves for real time PCR, the expression was altered under differing experimental 
conditions when compared to the other two control primers. This is probably because 
GAPDH is up-regulated by hypoxia (Escoubet, Planes et al. 1999; Zhong and Simons 
1999) and hypoxia inducible factor (Graven, Bellur et al. 2003). The up-regulation of 
GAPDH by hypoxia and HIF is consistent with our observations, where GAPDH gene 
expression was up-regulated by iron depletion; figure 3.13
Beta actin was also compared to 18S expression in a small number of amplifications 
where reasonable 18S curves could be achieved and Ct was evaluated at the threshold 
point. These two experiments showed there was no significant change in the ACt 
between beta actin and 18S when islets were treated with desferrioxamine. (cc ACt -9.32 
(0.28), DFO 100 ACt -9.62 (0.53), DFO 1000 ACt -9.43 (0.37))
Therefore, these experiments suggested that there was a significant up regulation of 
GAPDH in response to desferrioxamine treatment but 18S and beta actin were probably 
unchanged. Beta actin was subsequently used as the control (housekeeping) gene, as 
expression was stable under iron depletion, the primer pairs did not preferentially 
amplify genomic DNA and the amplification kinetics were similar to the experimental 
target genes.
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Figure 3.13: Relative change in GAPDH expression in control culture and 
desferrioxamine treated islets when compared to fresh islets, calculated by using 
beta actin as control. All changes in expression were significant at the level p< 0.01.
Control Culture
3.5.7 Conclusion from the development of molecular techniques
These experiments proved that:
1. TRIzol was the most effective and reproducible method for isolating RNA from 
islets.
2. Exogenous DNA contamination could be eliminated by careful handling and use 
of certified DNA free consumables and solutions.
3. Endogenous DNA contamination could be eliminated by:
a. Addition of a DNAse step before cDNA formation
b. Careful PCR primer design
c. Adjustments to PCR amplification conditions
4. Beta-actin was the most appropriate housekeeping gene
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3.6 Development of islet apoptosis assay
Apoptosis is an important endpoint for the evaluation of islet “well being” and previous 
authors have suggested that increased H IF-la expression in islets is associated with 
increased apoptosis (Moritz, Meier et al. 2002). A number of problems were 
encountered while assessing apoptosis in dispersed islets by flow cytometry with 
annexin V (AV) and propidium iodide (PI), a methodology suggested by (Cattan, 
Bemey et al. 2001). The AV/PI technique is designed to detect early apoptosis in cells 
and should differentiate between healthy, apoptotic and non viable/late apoptotic cells. 
The assay relies on the binding of a fluorochrome tagged AV to phosphatidyl serine 
residues on the cell surface. Phosphatidyl serine is phospholipid which is translocated 
from the inner part of the cell membrane to the outer surface in early apoptosis and 
identifies the apoptotic cell for phagocytosis by macrophages (Fadok, Voelker et al. 
1992). Propidium iodide is a cell exclusion dye and is unable to enter viable cells. In 
non-viable cells, propidium iodide enters the cell, binds to DNA and the complex emits 
light in the red/orange spectrum when excited by blue light (488nm). Therefore, the 
assay should produce three populations of cells:
Cell population Signal detected
AV PI
Healthy viable cells dim dim
Early apoptotic cells bright dim
Late apoptotic/non viable bright bright
When islets were assayed using this methodology, the unstained control cells produced a 
good baseline signal but negative and positive control samples did not produce good 
bright signals for either annexin V (FITC -  conjugated) or propidium iodide positive 
cells. An increase in voltages did not augment the disparity between bright and dim 
signals and the histogram of sensors produced a picture of signal overlap (Figure 3.14), 
despite a high level of compensation (-30-40%) and choosing sensors with disparate 
wavelengths.
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Figure 3.14: A histogram plot of FL1 
(annexin V-FITC) against FL3 
(propidium iodide) when analysing dual 
stained cells. The histogram shows 
overlap of signal between sensors 
therefore producing a linear pattern on 
the histogram.
Repeat experiments produced similar histograms, regardless of alterations in sensor 
voltages and compensation. A check of the flow cytometer proved that all the band pass 
and dichroic long pass filters were correctly positioned, so the machine was checked 
with a known positive control for FL1. Due to the small number of cells obtained from 
dispersed rat islets and the possibility of interference from poorly dispersed cells (i.e. 
more than one cell passing the laser at a time), peripheral blood mononuclear cells were 
chosen as experimental cells and CD4-FITC was chosen as a reliable positive control for 
the FL1 sensor. Peripheral blood mononuclear cells were also used to reassess the AV/PI 
kit, with positive control cells induced by incubation with hydrogen peroxide (Figure 
3.15). In addition, the cell exclusion dye was changed to 7AAD, a marker with a 
significantly higher wave-length of emission spectra than FITC, which can be detected 
by the FL4 sensor and allow a greater disparity between the two positive emission 
spectra.
The 7AAD cell exclusion dye (Beckman Coulter, UK) produced a bright signal and, 
when compared to the PI from the Roche Diagnostics kit and fresh PI from our own 
laboratory, it was found that the Roche Diagnostics PI was the only chemical not to 
provide a bright signal. We concluded that the problem with the PI signal was probably 
due to the concentration or integrity of the PI supplied by Roche Diagnostics and 
therefore, further experiments were carried out with freshly made PI.
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Figure 3.15: Flow cytometry histograms from experiments with peripheral blood 
mononuclear cells. Each panel consists of 4 histograms which are, from left to right; 
forward scatter versus side scatter, signal count versus signal intensity on FL1 
sensor (FITC), signal count versus signal intensity on FL2 sensor (PI) and signal 
intensity on FL1 sensor versus signal Intensity on FL2 sensor. Row a: histograms 
for unstained cells. Row b; histograms for CD4 -  FITC stained cells, proving the 
FL1 sensor works with limited overlap into FL2. Row c: histograms for hydrogen 
peroxide treated peripheral blood nononuclear cells stained with A V-FITC and PI, 
proving the apoptosis assessment can work on cells which do not require prior 
dispersal.
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Figure 3.16: Flow cytometry histograms from experiments with dispersed islets. 
Each panel consists of 4 histograms which are, from left to right; forward scatter 
versus side scatter, signal count versus signal intensity on FL1 sensor (AV-FITC), 
signal count versus signal intensity on FL3 sensor (PI) and signal intensity on FL1 
sensor (AV-FITC) versus signal intensity on FL3 sensor. Row a: unstained cells, b : 
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With the success of running the apoptosis protocol on peripheral blood mononuclear 
cells, dispersed islets were re-assayed with AV-FITC and fresh PI (Figure 3.16). 
Unfortunately, the AV-FITC signal did not show any improved disparity between bright 
and dim signals, although there was some positive signal shift in stained cells. This was 
further compounded by some overlap of the FITC signal into FL2 and FL3 that proved 
difficult to compensate for. Although the dual stained plots (Row d, Figure 3.16) appear 
reasonable, the level of apoptosis appears too high with poor population discrimination 
between AV-FITC bright and dim and a poorly compensated population overlapping 
into the FL3 (PI) positive population. The two issues compounded to distort the data 
from the assay and so the cell viability dye was changed back to 7AAD. The change 
back to 7AAD limited any spectral overlap of AV-FITC into FL4 (the sensor used for 
7AAD analysis) and provided better delineation between the different populations. In 
addition, the FL1 (AV-FITC) voltage was increased and FL4 (7AAD) voltage was 
reduced to a minimum, in order to reduce any spectral overlap (figure 3.17). Therefore, 
the apoptosis assay was performed using AV-FITC and 7AAD.
Figure 3.17: Apoptosis assessment of dispersed islets using AV-FITC and 7AAD. 
The histograms are, from left to right; forward scatter versus side scatter, signal 
count versus signal intensity on FL1 sensor (AV-FITC), signal count versus signal 
intensity on FL4 sensor (7AAD) and signal intensity on FL1 sensor (AV-FITC) 
versus signal intensity on FL4 (7AAD) sensor.
F l l  LOOSS F L 4  LOO
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3.7 Assessment of islet viability
The AV/PI method for the assessment of apoptosis in islets was not thought to provide 
an accurate representation of islet well being, due to apoptosis induction during islet 
disruption and the issues of signal discrimination. Therefore, islet viability was 
investigated as an endpoint to study the effects of desferrioxamine treatment on the 
integrity of islets.
The main limitation to assessing viability was the availability of large numbers of islets. 
Although measurement of viability in human preparations is assessed by the percentage 
of viable islets, this technique could not be translated to the experimental situation as 
large numbers of islets would be required to gain sufficient sample. Because each rat 
isolation only provides 400-500 islets, a large number of rats would be required purely 
for viability assessment, leaving few islets for experiments. The flow cytometry method 
using disrupted islets and PI can be performed on small numbers of islets but the 
disruption of islets was thought to reduce cell viability, as outlined above. The 
assessment of whole islets obviates the disruption issue but requires imaging of cells 
within the three dimensional structure of islets. The standard cell exclusion dye, trypan 
blue, could not be used for these experiments as interpretation of staining within a three 
dimensional structure by plain light microscopy techniques would be almost impossible. 
Therefore, two colour fluorescent viability of whole islets was employed and compared 
to the flow cytometry technique.
3.7.1 Flow cvtometrv method
The dispersed islets stained well with propidium iodide, producing similar traces to the 
FL3 graph in the above section. There was good distinction between PI bright (non 




Initial experiments with fluorescein diacetate and acridine orange were undertaken to 
establish a quantitative measurement for the viability of cells within a small population 
of islets. These experiments were undertaken using a similar methodology as described 
in chapter two but two different viability dyes were used at different concentrations, 5pi 
fluorescein diacetate (1 pg/ml in acetone) or 1 pi of acridine orange (either 2mg/ml,
0.2mg/ml or 0.02mg/ml). The slides were counterstained with 2.5pl of propidium iodide 
(250pg/ml).
The fluorescein diacetate staining showed poor penetration into the core of the islets and 
did not provide visualisation of individual cells within the islet, therefore making 
assessment of the percentage of viable cells impossible (figure 3.18, Row a). Acridine 
orange (AO) penetrated into the islets better than fluorescein diacetate and highlighted 
the viable nuclei well but higher concentrations (2mg/ml and 0.2mg/ml) were associated 
with an increase in background fluorescence (figure 3.18, Row b). This higher level of 
background orange/red fluorescence interfered with the PI assessment of viability and 
the increased orange/green fluorescence hindered the counting of viable cells. The 
background fluorescence could not be reduced by washing of the cells prior to analysis 
and therefore lower doses of acridine orange were used for experiments. The lower 
concentrations of AO did not interfere with PI assessment of viability but nuclei of live 
cells were not highlighted in green, although viable cells could still be counted by green 
cytoplasmic fluorescence (figure 3.18, Row c). This allowed the imaging and counting 
of live cells within a focal plane.
3.7.3 Conclusions from assessment of islet viability 
These experiments showed that:
1. Islet viability could be reliably assessed using flow cytometry with PI.
2. Islet viability in whole islets could be assessed with low concentration AO and PI, 
by counting the number o f viable cells within a focal plane.
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Figure 3.18: Assessment of viability in whole islets stained with; Row a: Fluorescein 
diacetate and propidium iodide (H2O2 treated), Row b: High dose acridine orange 
(~200ng/ml) and propidium iodide (control fresh) and Row c: Low dose acridine 
orange (~2ng/ml) and propidium iodide (control fresh).
Green fluorescence Red fluorescence
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3.8 Development of in-situ techniques
The exploration of endothelial origin and the site of growth factor expression required 
the use of in-situ techniques. The in-situ techniques were not established within our 
laboratory and were learned at Cancer Research UK and the department of Molecular 
Medicine at University College London. The development of these methods are 
described within their own section because the techniques relied on a hybrid of 
molecular biology and histology. Unfortunately, no meaningful results were derived 
from these methods but a brief description of the development process will be listed here.
3.8.1 RNA in-situ hybridisation
RNA in-situ hybridisation requires the formation of cDNA labeled probes which are 
hybridised to mRNA within tissue sections, in order to spatially describe the point of 
formation of target proteins. The technique was learnt within the department of 
Molecular Medicine at University College London and IMAGE clones were purchased 
for the relevant mRNA sequences. The IMAGE clones were initially broth amplified and 
extracted plasmid was further amplified by standard PCR techniques with M13 primers. 
The PCR products were sequenced and found to be of the correct sequence. Some of the 
PCR products are illustrated in figure 3.19.
I encountered two problems with the PCR amplification of plasmids. Firstly, two 
plasmids were empty vectors, although the glactosidase gene was disrupted. The second 
problem related to GC rich sequences which required the addition of Q (Quiagen, UK) 
and switch to Quiagen PCR amplification products.
Unfortunately, after collecting the sequences it was decided that the technique would be 
difficult to transfer to our laboratory and I decided to focus more on the use of 
desferrioxamine.
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Figure 3.19: Gel electrophoresis of purified IMAGE clone sequences. Lane l:Ang 2, 
lane 2:bFGF, lane 3:Ang 1, lane 4:TGFp, lane 5: VEGF, lane 6 and 7 are empty 
vectors from sequences supplied as human and rat insulin respectively.
1 2 3 4 5 6 7
3.8.2 Fluorescent in-situ hybridisation of the Y chromosome 
A method was required for tracking the origin of transplanted islet endothelium. I 
considered the use of xenogenic models, green fluorescent protein animals and reporter 
genes, such as LacZ, but there was limited experience or scope to transfer these 
techniques to our laboratory. I therefore tracked the use of Y chromosome FISH to a 
group within cancer research UK and visited the lab to learn the technique. Their initial 
results with mouse Y chromosome FISH was good and after some optimisation, they 
managed to use the rat Y chromosome sequence to set up the technique.
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The rat Y chromosome sequence was sourced from Dr Barbara Hoebe in the 
Netherlands and was supplied in a pUC13 plasmid. Initial attempts to insert this vector 
in to E Coli and amplify the sequence by broth failed. Therefore, the sequence was 
directly amplified by standard PCR using Reddymix PCR master mix (AB Gene, Epsom, 
UK) and Ml 3 primers. The PCR product was just over lkb and sequencing confirmed 
the product to be the rat Y chromosome sequence with accession number X80155.1. As 
the sequence was lkb and probes of 200-500bp are required for in-situ hybridisation, the 
sequence was digested with DNAse to develop short segments of the probe for 
hybridisation. Initial experiments were performed by incubating 1 pg of the 1 kb probe 
with DNAse (Invitrogen, UK) for varying periods of time and analysing the digests by 
gel electrophoresis. The incubation times of 7.5, 15 and 22.5 minutes led to complete 
digestion of the lkb probe and subsequent incubation times were reduced to 1, 2 and 5 
minutes. Unfortunately, the 1 and 2 minute times did not produce sufficient digestion 
and 5 minutes digestion times caused complete digestion of the Y sequence (figure 3.20). 
Despite trying a variety of different time points, a reproducible digestion could not be 
achieved and I noticed that M 13 amplification of the Y sequence had now produced a 
number of different products (figure 3.20).
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Figure 3.20: DNAse digestion of rat Y sequence. Lane 1 is the lkb sequence 
amplified by M13 primers. Lane 2,4 and 5 are the same sequence digested with 
DNAse for 1,2 and 5 minutes respectively. Lane 3 is a lOObp ladder.
The DNAse digestion did not allow the formation of small fragments for staining and 
therefore internal primers were designed using Primer Express (Applied Biosystems) 
software and the sequence of the Y probe. Five sets of internal primers were created 
with products of 200-500bp which were distributed at different points within the Y 
probe. The primers and products are outlined in table 3.8.
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Table 3.8: Internal primers of the Y chromosome and their product length.
Primer
number
Forward primer Reverse primer
Product
length
1 CCCCTTTTTTCCTTTT AC AAA TCTCTTCAGCTTCAAACTCAAGT 204bp
2 TCGTTCCAAGCGGCA GCTCTTCCCCCTTGGAGA 215bp
3 CTTGAGTTTGAAGCTGAAGAGAA TGCCGCTTGGAACGA 377bp
4 GCCCCTTTTTTCCTTTT AC A TGCCGCTTGGAACGA 555bp
5 CTTGAGTTTGAAGCTGAAGAGAA GCTCTTCCCCCTTGGAGA 577bp
In view of the multiple products from the amplified Y probe, sequences were amplified 
directly from the plasmid. All of these primers produced the correct product lengths 
when the y probe was amplified by standard PCR (figure 3.21).
Figure 3.21: Y probe amplification using different primers and standard PCR.
Lane 2: M13 primer, Lane 3: prim er 1, Lane 4: primer 2, Lane 5: primer 3, Lane 6: 
primer 4, Lane 7:primer §. Lanes 1 and 8 are lOObp ladder.
1 2 3 4 5 6 7 8
127
These primers were subsequently used for the formation of digoxegenin labeled 
sequences and anti-dig Fab fragments were used as a second layer, in order to amplify 
the signal. The first experiments were designed to optimize digestion time with pepsin 
and time points of 1,2,5,10 and 15 minutes were used. The 15 minute time point caused 
over digestion of tissue and loss of cellular architecture. The lower time points did not 
have obvious staining within nuclei. Further experiments were carried out using 
different pepsin digestion times, different probes, increasing concentration of probes and 
Fab fragments. The 12 minute digestion time with the 577bp probe from primer set 5 
gave the best signal but the signal remained weak and did not obviously stain fusiform 
nuclei of endothelium (figure 3.22). In addition, not all cells stained with the Y probe 
which probably reflects levels of tissue sectioning, where the part of the nucleus 
containing the Y chromosome may not have been on the tissue section.
3.8.3 Conclusions from in-situ hybridisation techniques
1. The Y chromosome probe could be amplified from plasmid and was of correct 
sequence.
2. Small probe lengths were best formed by internal primer sets
3. Signal amplification was poor and further optimization is required before using 
as a robust technique.
4. The sectioning levels of tissue may reduce accuracy o f male cell identification.
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Figure 3.22: Y chromosome FISH of female (F) and male (M) hepatic tissue. The 
male nuclei are stained with small dots within the centre of the nuclei (white arrow). 
The staining was not 100% consistent and the compact fusiform nuclei of 
endothelium was not obviously stained (red arrow).
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3.9 Discussion
3.9.1 Islet transplant model
In-vivo models are the mainstay of islet transplant research and are necessary for proof 
of principle when manipulating islet engraftment. These experiments provided evidence 
for the reproducibility of our transplant model and the additional step of transplanting 
islets only into the right branch of the portal vein. The right branch technique was 
further extended to allow sex mismatching and good resolution of blood glucose post 
transplantation was achieved in female recipients. These results suggest that the sex 
mismatching does not affect the clinical outcome after transplantation and there is little 
evidence of sensitisation to the minor H-Y antigen. The initial difficulties experienced 
with the technique were probably related to the small size and frailty of female 
recipients, caused by high doses o f streptozotocin and halothane anaesthesia. The 
55mg/Kg dose of streptozotocin, used for inducing diabetes in male recipients, proved 
too high and resulted in some female recipients dying from severe diabetes. This 
complication is likely to be due to the high fat to lean body mass ratio of female animals 
(as streptozotocin is lipophilic) and the dose reduction resulted in a safer induction of 
diabetes in female recipients. These experiments provided evidence to suggest that our 
optimised model was a robust and reproducible technique for the examination of islet 
transplantation.
The resolution of blood glucose is an important endpoint for assessing the engraftment 
of islets but does not examine the mechanisms involved. The extension of our islet 
transplant model to include histological evaluation provides further endpoints for the 
analysis of islet engraftment. The poor delineation of islet endothelium has previously 
limited such studies but was resolved by using a specific marker (Mattsson, Carlsson et 
al. 2002). When endothelial delineation was combined with simultaneous insulin 
staining, the composite image provided accurate structural observation of the whole 
transplanted islet. The initial variability in BS1 staining was reduced by optimization in 
antigen retrieval and tissue processing, with particular attention to heat treatment. The
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subsequent model has provided a robust technique for the assessment of native and 
transplanted islets.
3.9.2 Growth factor analysis
The hypothesis for desferrioxamine up regulating growth factor expression in islets is 
that it exerts its effects through the altered expression of hypoxia inducible factor. 
Hypoxia inducible factor is a heterodimeric transcription factor composed of two basic 
helix-loop-helix domains (Lando, Gorman et al. 2003). The two domains consist of an 
alpha subunit, which has three different isoforms, and a beta subunit. The regulation of 
HIF-1 expression by oxygen is brought about by hydroxylation of proline resides in the 
oxygen dependent domain of the alpha subunit by HIFa prolyl-hydroxylase (HPH) 
(Jaakkola, Mole et al. 2001). The hydroxylated alpha subunit is then ubiqitinylated by 
the von Hippel-Lindau protein (Maxwell, Wiesener et al. 1999) and subsequently 
destroyed by proteosomes. HIF-1 expression is also regulated by the oxygen dependant 
hydroxylation of asparginine residues by factor inhibiting HIF (FIH-1) within the 
COOH-terminal transactivation domain (CAD) which acts to inhibit the recruitment of 
the p300 transactivator necessary for transcription of HIF-1 activated genes (Lando, Peet 
et al. 2002; Maxwell 2003).
The mechanism of action of altered angiogenic factor expression with desferrioxamine is 
a reduction in the activity of HPH which leads to limitation of the first step required for 
eventual destruction of H IF-la by proteosomes (Jaakkola, Mole et al. 2001) and 
inhibition of FIH-1 which limits the inhibition of HIF transcription activation (Lando, 
Peet et al. 2002; Maxwell 2003). This mechanism is post translational and therefore 
required a protein or HIF-DNA binding assay to examine the hypothesis in islets. A 
change in HIF-1 protein concentrations due to DFO treatment would have been an 
important observation to support the hypothesis for altered growth factor expression 
within islets. Unfortunately, I was unable to detect HIF-1 expression with the 
developmental ELISA due to either the quantity of HIF-1 in cell lysates or cross 
reactivity of the assay. An increase in rodent islet number would not have been practical 
or ethically justifiable and sufficient human material was not available. An alternative
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approach would have been western blot analysis of protein with specific HIF-1 
antibodies which may be more sensitive and specific for rat HIF-1. Another cause for the 
inability to detect HIF-1 with the developmental assay may have been the rapid 
degradation of HIF-1 during cell lysis. In the presence of oxygen, HIF has a half life of 
less than 1 minute (Yu, Frid et al. 1998) and it is possible that HIF-1 may have been 
rapidly metabolised during cell lysis, despite the presence of protease inhibitors and 
incubation on ice. Therefore, HIF-1 may not have been present in the cell lysates at the 
time of assay with the developmental kit.
Unfortunately, time and the availability of a suitable assay limited the ability to analyse 
the expression of HIF-1. Due to the lack of a protein assay, I have relied on the 
published literature within this area to reinforce the mechanism of DFO up regulating 
HIF-1 and subsequent down stream growth factors (Wang and Semenza 1993; Wang, 
Jiang et al. 1995; Cooper, Lynagh et al. 1996; Gleadle and Ratcliffe 1997; Linden, 
Katschinski et al. 2003).
The analysis of VEGF protein in culture supernatants did not require additional 
optimisation and supernatant dilution was not required before analysis by ELISA and no 
VEGF expression in the culture medium. Unfortunately, the protein analysis of other 
growth factors was not as simple and the bFGF estimations required considerable 
optimisation before analysis could be performed. The HGF ELISA did not detect any 
HGF in the culture supernatant and was probably due to poor cross reactivity of the 
human HGF ELISA or the low levels of HGF in culture supernatants.
3.9.3 Islet integrity analysis
Islet viability is integral to assessing islet well being before transplantation and is usually 
measured in a population of islets by either calorimetric (Kumar, Delfino et al. 1994) or 
fluorescent visualisation (Bank 1987; Miyamoto, Morimoto et al. 2000; Barnett, 
McGhee-Wilson et al. 2004). These methods either rely on a cell exclusion dye alone 
(trypan blue), a chemical which is diffusible and undergoes a change within viable cells 
to produce a colour (MTT test) or a combination of the two (fluorescein
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diacetate/propidium iodide or acridine orange/propidium iodide). The tests allow rapid 
assessment of viability within a population of islets (Bank 1988) but require large 
numbers, at least 200, to accurately sample the population. The number of islets required 
for viability assessment precludes the use of this technique for rodent models and 
therefore, a new method was necessary for assessing the viability of cells within islets. 
These experiments demonstrated that islet viability could be assessed in a small 
population of islets and the measurement of cellular viability within islets could be 
measured both manually in intact islets and automatically in dispersed islets.
Islet viability provides a gross assessment of cellular well being but more subtle 
processes leading to islet death may not be obvious whilst performing such crude 
analysis. Apoptosis assessment provides a more subtle analysis of islet wellbeing and is 
able to quantify less obvious insults that lead to programmed cell death. Unfortunately, 
apoptosis assays are hard to perform on islets because they are not single cells but a 
conglomeration of cells. Some authors have suggested using flow cytometry with 
annexin V and propidium iodide on disrupted islets (Cattan, Bemey et al. 2001) but this 
method reports a high rate of apoptosis (-20%), which does not fit with the rate of loss 
of islets in culture or the percentage of apoptotic nuclei (small bright nuclei on PI 
staining) visualised in whole islets. Our experience with this technique would suggest 
that a high level of annexin V binding to disrupted islets is probably due to exposure of 
phosphatidyl serine residues on the membranes of islet cells during the disruption 
process. This would explain why disrupted islets produce a non-specific increase in 
annexin expression with no clear population of bright or dim annexin stained cells, 
which contrasts with the two clear populations generated by analysis of peripheral blood 
mononuclear cells. In addition, the disruption of cellular adhesion molecules has been 
shown to induce apoptosis in adherent cells (Erez, Zamir et al. 2004) and in islets, a 
study using confocal microscopy suggested that disruption non significantly increased 
apoptosis from 11.5% to 17.9% (Boffa, Waka et al. 2005). Therefore, the disruption 
process may induce programmed cell death and probably overestimates the level of 
apoptosis within islets.
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The annexin V/PI method for assessing islet apoptosis is fraught with difficulties and 
probably overestimates the rate of apoptosis within islets. A technique using TUNEL or 
caspase analysis may represent a better technique.
3.9.4 In-situ techniques
In situ hybridization is a difficult technique to master and further optimization is 
required before the Y chromosome technique can be used to track endothelial origin.
The signal within the nuclei was weak but the observation of a signal meant that the 
probe was entering the nuclei and further optimization of hybridisation was not required. 
Therefore, the signal needed to be amplified and may have been achieved by using a 
different colour or fluorophor, as red may have been of significantly disparate 
wavelength and shown up better on the blue nuclear background. Secondly, the entire 
lkb sequence was not used as a probe and if this size of probe could be hybridised into 
the cell, this option may have increased the signal intensity. Nick translation of the probe 
with random cutting could also have painted the Y chromosome better than specific 
short sequences and may have provided a better method for greater chromosome 
localisation. After achieving greater chromosome hybridization, signal amplification 
could also be achieved by either using a higher power of fluorochrome excitation, such 
as confocal microscopy, or by using immunohistochemistry instead of using 
fluorescence. Even with optimal visualization, the issue of slicing through nuclei may 
make the technique less reliable and a large number of sections would need to be imaged. 
If this was the case, a cytosolic marker such as GFP may be a better way to reliably 
delineate endothelial origin.
3.9.5 Conclusions
These experiments optimized the techniques necessary for the investigation of islet 
transplantation and were used as the basis of the experiments outlined in the following 
chapters.
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Chapter 4 -  Results;
The revascularisation of intraportallv transplanted
islets
4.1 Introduction
The lack of functional vasculature within islets during the immediate post transplant 
period is the most likely cause for the large loss of islet mass post transplantation 
(Menger, Yamauchi et al. 2001). The revascularisation of transplanted islets is probably 
key to initial 6-cell mass survival and a better understanding of the structural changes 
during this period is required in order to improve islet survival.
The original description of transplanted islet revascularisation was published in 1977 
using a rat model of intraportal transplantation (Griffith, Scharp et al. 1977). The 
morphology of the islets was described by using a series of different stains for the 
various cellular components within islets and compared to haematoxylin and eosin and 
electron microscopy images, in order to identify vascular structures. Transplanted islet 
revascularisation has subsequently been described using dorsal skin fold models with 
direct in-vivo visualisation of the graft (Vajkoczy, Menger et al. 1995; Beger, Cirulli et 
al. 1998) and in kidney subcapsular models with retrieval of the graft and 
immunohistochemistry staining with Bandeiraea Simplicifolia (Carlsson and Mattsson 
1993; Carlsson, Palm et al. 2002; Mattsson, Jansson et al. 2003). Both these techniques 
have their advantages but do not allow simultaneous visualisation of both endothelium 
and endocrine mass. The dual Bandeiraea Simplicifolia and insulin fluorescent staining 
enables simultaneous imaging of both components allowing accurate analysis of islet 
structure and estimation of vessels per endocrine area. This technique has been further 
enhanced to estimate the percentage vascular area of islets (as defined by the ratio of 
endothelial to endocrine area), calculate vascular densities and branching index. This 
novel staining technique combined with image processing has now facilitated the 
quantitative analysis of islet revascularization and should enable direct numerical 
comparison of methods used to alter revascularization.
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The application of these new staining and analysis techniques to pancreatic tissue has 
allowed the visualization and quantification of islet vasculature within the native 
pancreas. Native pancreatic islet vascular architecture is complex (Bonner-Weir and 
Orci 1982) and analysis of islets within the pancreas facilitates direct quantitative 
comparison with islets post transplantation. The changes in islet vasculature after 
transplantation have been examined using a variety of models and have suggested that 
islets revascularise poorly with decreased oxygen tensions and capillary density when 
compared to native islets (Carlsson and Mattsson 1993; Carlsson, Palm et al. 2000; 
Carlsson, Palm et al. 2001; Carlsson, Palm et al. 2002; Jansson and Carlsson 2002; 
Mattsson, Jansson et al. 2002). Although one study did look at the change in vascular 
density after intra-portal transplantation (Mattsson, Jansson et al. 2002), most of the 
studies have been performed in kidney subcapsular models. However, kidney 
subcapsular and dorsal skin fold transplantation of islets may not provide an accurate 
model for the assessment of islet revascularization. Therefore, the selective intra-portal 
transplant model and dual insulin/endothelial staining technique was applied to analyze 
changes in islet vasculature post transplantation. This chapter describes the application 
of this model to analyze post transplant changes in vascular architecture of intra-portally 
transplanted islets.
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4.2 Change in clinical parameters post sex-mismatched right branch
transplantation
Diabetes was induced with STZ in 30 female Lewis rats. The animals had a mean body 
weight 190.6 (±1.9)g at the time of streptozotocin injection which fell to 174.4 (±1.3)g 
with a mean blood glucose of 26.2 (±0.8) mmol/1, at the time of transplantation.
Islets were isolated from 60 male Lewis rats (~250-280g) and transplanted into the right 
portal branch of the female Lewis rats. The females received a mean dose of 752 (+/- 
33.3) freshly isolated, hand picked islets. Four recipients were sacrificed while under 
anaesthetic fifteen minutes after transplantation and the remaining recipients were 
humanely killed at various time points (1, 3, 5, 7, 14 and 30 days) after transplantation. 
The mean changes in blood glucose and weight for all recipients are displayed 
graphically in figure 4.1 and 4.2.
Figure 4.1: Change in mean blood sugar over time in all female recipients of male 







Figure 4.2: Change in mean weight over time in all female recipients of male islets 
via the right branch transplant method. Values are expressed as mean plus
standard error. The sharp rise in weight on the first post operative day probably 







Four animals were sacrificed at each time point, except for 14 and 30 days, where 5 
animals were sacrificed. The livers were retrieved, processed and analysed histologically 
for vascular density, branching index, endothelial and insulin area. Four native 
pancreases were removed from healthy male rats and processed in a similar way for 
analysis of native islets.
The blood glucose concentrations of transplanted diabetic female recipients corrected in 
a similar fashion to previous experiments with male right branch transplant recipients 
which suggests that sex mismatching did not significantly affect clinical outcomes.
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4.3 Qualitative histological analysis of native islets
Native pancreases from four healthy male rats were embedded into single blocks and 
sectioned at 4pm. The sections were stained with the dual endothelial and insulin stain 
and analysed as outlined in materials and methods. This method highlighted 
endothelium in green, insulin in red and nuclei in blue. The images in this chapter use 
the same colour scheme to identify structures.
Low power views of the native pancreas (figure 4.3) showed good delineation between 
endocrine and exocrine tissue with clear visualisation of vascular endothelium. There 
was weak background FITC staining of exocrine tissue and some FITC staining of the 
red blood cells within vessels. Areas of dystrophic calcification were also seen 
distributed throughout the pancreatic stroma, as visualised in the lower left hand comer 
of figure 4.3a.
Islets were widely distributed throughout the pancreas and were of varying size, even 
when the effects of different sectioning levels through islets were taken into account.
The large islets within the pancreas were generally larger than those seen within the liver 
post transplant. In addition, the islets within the pancreas had a ring of non-stained (no 
insulin or background FITC staining) cells around the endocrine core, which is not seen 
in intra-portally transplanted islets. It is impossible to define these cells without further 
immunohistology but it is probable that these cells represent the non beta cell mantle of 
the islet.
The endothelial staining highlighted both large arteries and veins within the pancreas 
and small capillaries within islets. The most striking vascular observation was that the 
vessels appeared smaller and less numerous within native islets when compared to islets 
transplanted to the liver. This was particularly noticeable within the smaller islets, where 
blood vessels were scarce and barely visible.
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Figure 4.3: Low power (xlOO) view of native islets within a rat pancreas. The islets 
(I) are stained with insulin in red and endothelium in green. The other visible 
structures within the pancreatic stroma (PS) are a pancreatic arteriole (PA) and 
pancreatic ductules (PD).
140
When islets were visualised at higher magnification, the different vascular networks 
became clearer. The smaller islets, under 100pm, had a rim of surrounding blood vessels 
arranged circumferentially around the insulin positive cells. The circumferential blood 
vessels were connected to blood vessels on the opposite side by large vessels traversing 
the central beta cell core of the islet. Although there were one or two branches within the 
central core, there was no obvious glomerular network of vessels- see figure 4.4. The 
large sized islets (over 250pm) had a different vascular architecture with a less 
discemable network of circumferential vessels around the beta cell core, although there 
was evidence of some circumferential vessels outside of the non staining mantle of cells 
(figure 4.6). In the core of the large islets, there was an obvious glomerular like network 
of fine blood vessels with few large traversing vessels. The mid or average sized islets 
(150-200pm) had a mixture of the two different vascular arrangements (figure 4.5).
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Figure 4.4: High 
magnification view 
(x400) of small (50- 
100pm diameter) 
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Figure 4.5: Average 
sized (150-200pm) 
native islets within 
the rat pancreas. 
Image (a) and (b) are 




(c) and (d) are two 
different islets at 
400x magnification.
Figure 4.6: Large 
sized (250pm + )  
native islets within 
the rat pancreas. 
Image (a) and (b) are 




(c) and (d) are the 




4.4 Qualitative histological analysis of engrafting transplanted islets.
The original description of intra-portal islet engraftment suggested that islets 
revascularise in a sequential and coordinated fashion (Griffith, Scharp et al. 1977). The 
first stage of analysing engraftment was to examine the stained liver sections for gross 
morphological changes in islet structure, before trying to quantify the changes.
4.4.1 Recovery of islets from transplanted recipients
Right branch liver lobes from each recipient were divided into three separate blocks.
The first block contained the entire right anterior lobe and second and third blocks 
contained the right posterior lobe, which had been divided in half antero-posteriorly. The 
tissue was sectioned at 4pm thickness, stained with the dual insulin and endothelium 
staining and analysed as outlined in Chapter 2. At least 10 islets were examined from 
each animal and subsequent deeper sections were cut from the blocks if there were 
insufficient islets visualised after analysing one section from each block. Only islets with 
an area over 1000pm2 were used for analysis, in order to reduce bias of over/under 
representing endothelium.
A total of 428 transplanted islets were analysed, with an average of 61.1 (±3.1) islets per 
time point and 14.3(± 0.61) islets per animal. Each section contained average of 4.5 
(range 0 to 14 islets per section) analysable islets with significantly less islets in sections 
from the right anterior lobes than the right posterior lobes; 3.0 islets per section in right 
anterior lobes, 5.8 islets per section (p=0.001) in the lateral division of the right posterior 
lobe and 4.7 islets per section (p=0.018) in the medial division of the right posterior 
lobes. This difference was thought to be flow mediated at the time of transplantation, as 
the branch of the portal vein supplying the right anterior lobe comes off the right branch 
of the portal at right angles and therefore limits flow to this lobe during transplantation.
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4.4.2 The dav of transplantation
On the day of transplantation, islets could be clearly visualised in the portal vein-figure 
4.7. On the lower power sections (Figure 4.7 (a) and (b)), large islets can be seen to have 
embolised in the branches of the portal vein up to a point of bifurcation. The hepatic 
artery and a biliary duct can be clearly seen to the left of the islet in the lower part of 
figure 4.7b, confirming the location of the embolised islet to the portal triad. The size of 
the portal vein, in comparison to the surrounding artery and biliary duct, suggests some 
distension of the vein in response to the embolised islet, although the elongated shape of 
the islets would also suggest some compression of the islet architecture. The portal vein 
is completely occluded by the embolised islet and some sections show the early 
formation of thrombus within the vein. In figure 4.8a, the hepatic veins are clearly 
visualised either side of the embolised islet and the surrounding hepatic architecture is 
normal with no associated hepatic vaccuolation.
Despite the compression of the islet, the general architecture is preserved. The insulin 
staining within the islet is bright and very little exocrine tissue is seen around the islet. 
The islets have bright endothelial staining and obvious vascular channels can be seen, 
which appear to be of a similar distribution and density to native islets.
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Figure 4.7: Islets on the day of transplantation. All images are of different islets. 
Images (a) and (b) are at lOOx magnification, (c) and (d) at 200x magnification and 
(e) and (f) at 400x magnification.
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4.4.3 One dav post transplantation
One day after transplantation, the islets are still fully occluding the branches of the portal 
vein- figure 4.8. The islets have not migrated out of the portal vein branches and are still 
surrounded by the endothelial staining of the vennule walls. The lumens of the portal 
vennules close to embolised islets are occluded by thrombus and there is no evidence of 
recannilisation. The liver architecture surrounding islets is now grossly vaccuolated, as 
seen in figure 4.8a, although the liver structure does not appear to be distorted.
The insulin staining of islets appears bright and generally homogeneous, with no 
obvious areas of cellular death. The BS-1 staining within islets is generally sparse and 
most islets do not have evidence of stained endothelium. Of the islets that do have BS-1 
staining, the pattern is similar to islets visualised on the day of transplantation. There is 
no evidence of endothelial invasion or revascularisation at this early time point.
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Figure 4.8: Islets one day after transplantation. Images (a) and (b) are the same 
islet at lOOx magnification and 400x magnification, (c) (d) and (e) are at 200x 
magnification and (f) is at 400x magnification.
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4.4.4 Three days post transplantation
After three days post transplantation (figure 4.9), the islets have started to migrate into 
the hepatic architecture. The portal vein still has evidence of thrombus, although the 
portal vein has already recannilised in some places and has formed new endothelium 
over the surface of the islet, as seen in figure 4.9a and b. The hepatic architecture 
surrounding engrafting islets is still vaccuolated but the rest of the liver architecture is 
normal with clearly demarcated hepatic arteries and veins.
The insulin staining within the engrafting islets is generally bright with good integrity of 
the beta cell mass, although some islets have areas which have lost insulin staining and 
appear degranulated- figure 4.9e. There are also areas of aggregated cells within the liver 
which have no insulin staining (figure 4.10) but appear to be embolised tissue, as seen 
by their close proximity to the portal triad (figure 4.10b). The cellular nuclei of these 
cells are swollen, which would suggest an element of necrosis. It is unclear whether the 
tissue is embolised islets which are necrotic or whether it is exocrine tissue which has 
been injected and embolised with the transplanted islets.
The engrafting islets (figure 4.9) have a paucity of vascular endothelium within the 
centre of the islet although there is endothelium around the outside of the beta cell mass. 
The circumferential endothelium is starting to form vessels (figure 4.9c and d) and 
endothelial cords can be seen invading into the beta cell mass of some islets (figure 4.9 b, 
d, e and f)- These cords tend to be long unbranching structures and some appear to have 
double contouring, suggesting early blood vessel formation. Within the centre of the 
islets there appears to be areas of reduced staining between some of the insulin positive 
cells (figure 4.9c and f). It is unclear whether these may have been original native 
vascular channels which have been left devoid of endothelium or represent possible 
regression of beta cell mass.
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Figure 4.9: Islets three days after transplantation. Image (a) and (b) are the same 
islet at lOOx and 400x magnification. Images (c), (d), (e) and (f) are all different 
islets at 400x magnification. A hepatic arteriole (HA), hepatic ductule (HD) and 
portal vennule (PV) are clearly visualised in the low power view. The surrounding 
hepatic stroma (HS) appears vaccuolated. Non branching early vessels (EV) are 
clearly seen in some sections.
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Figure 4.10: Liver sections 3 days after transplantation showing probable 
unengrafted islets. Both images are of different islets at 400x magnification.
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4.4.5 Five davs post transplantation
Five days after transplantation (figure 4.11), the islets have migrated further into the 
hepatic tissue but still remain in close contact with the portal triad- figure 4.1 la  and b. 
The surrounding liver tissue looks less vaccuolated and although the portal vein still has 
evidence of thrombus in places, recannilisation is well underway in a number of areas.
The endocrine portion of the islets now looks more heterogeneous with patchy insulin 
positive staining and larger gaps between insulin positive cells with the feeling of cell 
loss between islands of beta cells- figure 4.1 Id. Some islets have areas which are devoid 
of insulin staining and appear to be non viable (figure 4.1 lc). As seen at 3 days, there 
are also a number of areas of embolised tissue which are devoid of insulin and appear 
non viable (not shown).
The endothelial staining is now seen toward the centre of the islet and discrete vascular 
channels are discemable in some islets (figure 4.1 If), although most BS-1 appears to be 
cords of cells. The pattern of staining has a branching architecture and an early network 
is starting to form in most islets. BS-1 positive staining is also seen within non insulin 
positive areas of the islet (figure 4.1 lc), although the staining appears to be random and 
it is not clear whether this represents endothelium or inflammatory cell infiltrate.
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Figure 4.11: Islets § days post transplantation. All images are of different islets. 
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4.4.6 Seven days post transplantation
After seven days post transplant (figure 4.12), the islets have fully migrated into the 
hepatic architecture and remain in close contact with the portal triads- figure 4.12a,c and 
d. The orientation of the islets appears to be along the portal vein, instead of directing 
down the hepatic sinusoids, and most portal vein branches have recanilised. The 
surrounding hepatic tissue now looks normal and vaccuolation is scarce.
The islets appear to be more organised than the day 5 islets, with smaller gaps between 
the insulin positive cells. The insulin staining within the islet is more homogeneous and 
staining is now bright. Some islets still have areas without insulin staining, although they 
are smaller and less frequent than day 5 islets- figure 4.12 e and f. In addition, the areas 
of non-viable cells with no insulin staining are scarce and small.
The endothelial staining has reached the centre of the islet and vascular channels are 
present toward the centre of the islets. The vascular channels have formed a network of 
vessels, although not all areas are fully organised.
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Figure 4.12: Islets 7 days post transplantation. Images (a) and (b) are the same 
islets at 200x and 400x magnification, respectively. Images (c) and (d) are the same 
islets at 200x and 400x magnification, respectively. Images (e) and (f) are different 
islets, both at 400x magnification.
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4.4.7 Fourteen davs post transplantation
The islets appear to have fully engrafted by two weeks after transplantation (figure 4.13). 
Islets are still closely associated with the portal vein and are orientated in parallel with 
the direction of the portal triad (Figure 4.13a and 4.13c). The liver architecture is normal 
with some vaccuolation of hepatocytes in areas close to the islets.
The beta cell mass of the islet is well defined with bright staining of the insulin positive 
cells and no areas of non insulin staining. The islets appear well organised and there are 
no gaps between the insulin positive cells. Interestingly, there is no rim of non staining 
cells, as seen in native islets, but there are a number of cells which are insulin positive 
just outside the well circumscribed area of the islet. It is not clear from this staining 
alone whether these are islet derived cells which have been stranded by dying beta cells 
around them or whether these are hepatocytes which are staining for positive insulin, 
either due to insulin uptake or phenotypic change.
The vascular architecture of the engrafted islets is complete with the reformation of a 
complex glomerular like vascular network throughout the islet. All the endothelial 
staining appears to be in the form of tubular like structures (endothelialised blood 
vessels) and covers the whole islet. The islets are smaller than native islets but the 
vascular density seems to be greater than that seen in the native pancreas.
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Figure 4.13: Islets fourteen days post transplantation. Images (a) and (b) are the 
same islets at lOOx and 400x magnification, respectively. Images (c) and (d) are the 
same islets at lOOx and 400x magnification, respectively. Images (e) and (f) are 
different islets at 400x magnification. The low power view (a) shows a normal 
hepatic stroma with clearly visible hepatic arteriole (HA), bile ductule (BD) and 
hepatic vennule (HV).
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4.4.8 Thirty davs post transplantation
After one month post transplantation (figure 4.14), the islets have changed very little 
since day 14 in their gross morphology. The islets are still closely associated with the 
portal triad (4.14a, b and c) and the surrounding hepatic architecture is normal with 
minimal vaccuolation of hepatocytes.
The insulin staining is homogeneous and bright with obvious demarcation between 
hepatic tissue and beta cell mass. There are no areas of non insulin staining within the 
islet. The vascular architecture within islets is still a complex branching network and has 
not changed any further since day 14, although the network appears more extensive and 
vessels are smaller in calibre.
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Figure 4.14: Islets thirty days post transplantation. Image (a) is at lOOx 
magnification. Images (c) and (d) are the same islets at 200x and 400x 
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4.5 Quantitative analysis of native and transplanted islets.
The qualitative analysis of transplanted islets suggested that engrafted islets were 
smaller than native islets and that there was an obvious change in endothelial content 
and structure during the engraftment process. In order to develop a tool for analyzing 
modification of engraftment, these changes would have to be quantifiable and significant. 
Therefore, the images were analysed using image J software, as described in materials 
and methods, to see if there were any quantitative changes in the vascular architecture 
post transplantation.
4.5.1 Islet area in native and transplanted islets
The average area of islets was significantly reduced on the day of transplant when 
compared with native islets (figure 4.15) and slowly increased post transplant toward 
native levels. Although transplanted islets did not fully return to the area of native islets, 
there was no significant difference between transplanted and native islets after 7 days 
post transplantation.
The changes in islet area from one time point to the next were not significant but when 
changes were compared with the time point two places ahead, all changes were 
significant until day 7 was used as the reference. These results suggest that islets are 
smaller after transplantation, probably due to compression and loss of beta cell mass but 
remodel and increase in size until day 7 post transplant.
4.5.2 Percentage of islet comprised of endothelium
When compared to native islets, the percentage of the islets comprised of endothelium 
was significantly reduced on the day of transplantation and one day after transplantation 
but increased to a significantly higher level from day 3 onwards (figure 4.15).
The changes from one time point to the next were all significant except the change 
between day 7 and 14. In addition, the reduction in percentage vascular area from day 14 
to 30 was also significant (p<0.001).
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4.5.3 Vascular density measurements
Both measurements of vascular density showed an initial fall after transplantation, 
followed by a rise to levels above that found in native islets. The two different methods 
did differ in the rate of increase in vascular density after transplantation, which reflects 
the nature of the vasculature formed early in the revascularisation process.
4.5.3a Branch counting method
Using the branch counting method, the vascular density was 1358(±50) vessels 
per mm2 in native islets and fell immediately after transplantation to reach a 
nadir on the first day post transplantation before increasing to values above 
native islets on day five and progressively increasing up to day 30 post 
transplantation. See figure 4.16. The increases in vascular density between time 
points were statistically significant except between day 5 and 7, and day 14 and 
30.
4.5.3b Grid method
This pattern of vascular density change with the grid method was similar to the 
vessel branching method but the increase of vascular density after day 1 was 
more rapid- figure 4.16. This method calculated the vascular density to be 
1826(±73) vessels per mm2 in native islets which immediately fell post 
transplantation and reached a nadir on the first post transplant day. The density 
subsequently rose rapidly to achieve values above that found in native islets by 
day three post transplantation and continued to increase until day 5. After day 5, 
the vascular density did not change significantly. The sequential changes 
between time points were significant up to day 5 and subsequent changes were 
not significant.
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Figure 4.15: Quantitative changes in average islet area (pm2) and percentage of 
islet comprised of endothelium during engraftment. Values are measured in native 
islets, islets on the day of transplantation and day 1 ,3 ,5 ,7 ,1 4  and 28 post 
transplantation. Values are expressed as means plus standard error. The changes 
in values were compared to native islets and p values less than 0.01 are indicated on 
the graph by a *.
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Figure 4.16: Quantitative changes in islet vascular density during engraftment. 
Values are measured in native islets, islets on the day of transplantation and day 1, 
3 ,5 ,7 ,1 4  and 28 post transplantation. Values are expressed as means plus 
standard error. The changes in values were compared to native islets and p values 







4 0 0 0  
3 5 0 0
3 0 0 0  -^-----------
2 5 0 0  
2000
1 5 0 0
1000
5 0 0





□  Day 1
□  Day 3 
Day 5
□  Day 7 
Day 14
□  Day 28
B ran ch  cou nting  m eth o d G rid  m eth o d
164
4.5.4 Branching index
The branching index was used to quantify the relative branching of vessels within islets 
and whether a new glomerular type network was formed within the islet- figure 4.17.
The branching index fell from 0.77(±0.02) in native islets to achieved a nadir on day 
three before progressively increasing throughout revascularisation and achieving a 
maximal value on day 30 post transplantation. The branching index on the first day post 
transplantation was elevated when compared to native islets but did not fit with the 
changing trend seen within islets and was probably due to the small percentage of 
endothelium within islets on which the result was based.
Figure 4.17: Branching index in native and engrafting islets. Values are expressed 
as means plus standard error. The changes in values were compared to native islets 
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4.6 Discussion
The current model used for islet transplantation worked well with good resolution of 
clinical parameters post transplantation and easy histological retrieval of islets from 
recipient livers. The staining of islets within the pancreas and liver sections provided 
good delineation of P-cell cell mass with clear identification of endothelium within 
native and transplanted islets. The analysed images generated from qualitative 
histological analysis subsequently provided further quantitative evidence for the 
stepwise progression of islet revascularization. These observations and the implications 
relating to islet revascularization will now be considered.
4.6.1 Assessment of native islets
The native pancreatic islet architecture was well visualised with the dual staining 
technique and comprised of a central core of beta cells with a surrounding mantle of non 
beta cells, although this was less prominent in the smaller islets. The native islets 
appeared highly vascular with a network of blood vessels, similar to previous 
descriptions (Bonner-Weir and Orci 1982). The blood vessels appeared to traverse the 
islets and coalesce in a network of vessels surrounding the beta cell mass or outer mantle, 
depending on the islets size. The gross histological examination suggested that smaller 
islets did not have an extensive glomerular like network of blood vessels but vessels 
were more likely to be non-branching, purely traversing the islet core. Unfortunately, 
this observation was not reinforced by the branching index which did not show any 
difference between large and small native islets.
When considering the vascular architecture in different sized islets, the issue of 
sectioning has to be considered. Although islets were only analysed if they were greater 
than 1000pm2, the differences in islet size may have been due to the position of the 
section in relation to the islet being examined. If islets are considered to be almost 
spherical in shape and a large islet was sectioned at the very periphery of the sphere, the 
sectioned islet would appear to have the same area as a smaller islet that was sectioned 
through the centre of the sphere. This situation would confound analysis of the vascular 
architecture of different sized islets because it would be difficult to differentiate between
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small islets and the edge of large islets. Serial sections may have obviated this 
confounding factor but were not used for the analysis. The random orientation of islets 
within cut sections should have provided arbitrary samples through all parts of islets and, 
given the number of islets analysed, the sample size would have reduced the 
confounding factor of how islets were sectioned. The problem of sectioning through 
islets would only have affected the observation of small islets, as large areas could only 
have arisen from large islets. Lastly, the observation of different vascular anatomy in 
association with the size of native islets has been reported before by a number of 
different authors (Bonner-Weir and Orci 1982; Lifson, Lassa et al. 1985; Brunicardi, 
Stagner et al. 1996) and the observations reported here are in keeping with previous 
publications. The sectioning of islets may have been a confounding factor for examining 
the change in vascular architecture with size of islets and the model could have been 
further improved by the use of serial sections or thicker sections with the use of scanning 
confocal microscopy.
4.6.2 The change in islet area after transplantation
Islet area changed dramatically after transplantation with an immediate fall on the day of 
transplantation which was followed by a gradual rise to levels just below the area of 
native islets by day 14. Although some of the reduction in islet size may be explained by 
the loss of islet cell mass during isolation from the whole pancreas, the reduction in islet 
area of over 50% would be out of keeping with that observed in freshly isolated islets in 
culture. The force of embolising an islet into portal venules might have played a part in 
reducing the size of the islet, as free islets are pushed into ever decreasing sized vessels 
until forward motion is stopped by the occlusion of the vessel. Unfortunately, this effect 
is also minimal and the change in islet size after transplantation may be better explained 
by sectioning artifact. This situation would arise when a spherical islet is forced into a 
portal venule and made to take on the cylindrical shape of the vessel. Although islets 
were visualised within vessels in cross section (perpendicular to vessel direction) and 
along their long axis (within the same plane as the vessel direction), random sectioning 
is more likely to examine islets in short axis (cross section) than in long axis. This 
situation would have biased the measurement of early post transplant islets toward
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smaller cross sectional islets and therefore reduced the area of islets sampled at this time 
point. With time, the islets are integrated into the hepatic architecture and probably take 
on a more spherical shape which would reduce the variability of directional sectioning 
and may explain the increase in islet area over time. Despite the changes in islet area 
after transplantation, the percentage vasculature and vascular density are unlikely to be 
affected as both measurements are calculated per unit area and would not be affected by 
orientation of sectioning.
4.6.3 The revascularisation o f transplanted islets
The vascular architecture of islets changed markedly after transplantation in a stepwise 
and logical fashion which started with regression of native endothelium. On the day of 
transplantation endothelium was clearly seen within the centre of the islets although the 
staining appears sparser than in native islets. This observation is supported by the lower 
percentage vascular area and vascular density at this time point and suggests that even 
by the time of transplantation, and probably due to the isolation process, islets have 
already started to lose endothelium. On the first post transplant day, there is very little 
endothelium within the islet suggesting that further regression/differentiation of 
endothelium has occurred with no evidence o f revascularization. By day three, islets 
have a paucity of endothelium in the beta cell core but endothelial staining is increased 
at the periphery of the islets and there are discemable endothelial cords which appear as 
single, non branching vessels traversing outer parts of the islet. This observation 
corresponds to a low branching index found at day 3 and suggests that the first step of 
revascularization is the piercing o f the islet by single vessels which subsequently branch 
to form a network of vessels. The subsequent branching of these vessels corresponds to 
the gradual increase in branching index and vascular density found between day 3 and 
day 30.
By day five, endothelium is seen invading deeper into the islet and discrete vessels are 
starting to form. The vascular density, measured by the grid method, has increased from 
day 3 but further increases are small. These observations suggest that the network of 
endothelial cells has probably formed as early as day 5 and after this time point, the
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tubular formation o f vessels and branching to form a glomerular network occurs. By day 
seven, there are discemable vessels in the centre o f the islet. The percentage vasculature 
has increased only a small amount from day 5 and subsequent increases are not 
significant. There has been no change in vascular density but subsequent increases occur 
after this time point in association with increases in the branching index. Therefore, 
endothelium is laid down at an early stage and after day 5 post transplantation, the 
transformation into a vascular network take place. These observations correlate well 
with the previous in-vivo description of islet revascularization where one or two 
perforating afferent vessels enter the islet during the early stages of revascularization but 
the vascular density increase and flow of blood cells through vessels is only seen after 
day 6 (Vajkoczy and Menger 1995; Vajkoczy, Menger et al. 1995). This would suggest, 
as with other examples o f neovascularisation, that the initial endothelial structure is laid 
down early (up to day 5) and is followed by a quiescent phase of perivascular cell 
recruitment and tubularisation o f endothelium occurring between day 5 and day 7.
The measured parameters of vascular density and branching index changed very little 
from day 5 to day 7 but increased significantly between day 7 and 14 post 
transplantation with further significant changes of the branching index occurring out to 
day 30. Although formed vascular channels were visualized at day 7 post transplant, 
further remodeling of the vascular network appears to take place after this time point. It 
is therefore difficult to suggest exactly when the islet is fully revascularised as a 
rudimentary vascular network appears to be in place by day 7 post transplant but further 
changes are still occurring by day 30 and some authors have suggested that remodeling 
continues long after this time point (Rooth, Dawidson et al. 1989). These experiments 
were not continued after 30 days and it is therefore impossible to say whether further 
remodeling occurs after this time point.
When considering this model as a tool for assessing the effects of accelerating 
revascularization, the late remodeling changes are probably irrelevant and the important 
time point is probably between day three and seven after transplantation. This early time 
point is critical as maximal graft loss occurs around day 3 (Davalli, Scaglia et al. 1996)
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and early functional vessels are not seen until day 6 (Vajkoczy and Menger 1995; 
Vajkoczy, Menger et al. 1995). Therefore, any successful manipulation of 
revascularization would have to allow the beta cell mass to last longer or the 
revascularization to occur at an earlier point and reduce hypoxic cell death. The 
observation and quantification produced by this model changed at its fastest rate during 
this time period and would therefore be sensitive enough to detect any change in the 
time course of revascularization associated with islet manipulation. Therefore, 
observation and quantification o f islet vascularisation between days 3-5 should produce 
a robust model for assessing the manipulation of islet revascularization and engraftment.
4.7 Conclusions
These experiments have shown that the selective right branch intra-portal transplant 
model with subsequent dual BS-1 and insulin staining provides a robust model for the 
study of islet revascularization. The qualitative and quantitative analysis suggests that 
transplanted islets revascularise in a coordinated and sequential fashion which starts with 
an initial reduction in endothelial content and progress from invasion of new 
endothelium through to formation of a completely new vascular network. The 
revascularization process can be visualised as early as day 3 and is probably complete by 
day 7 but vascular remodeling continues long after revascularization is complete.
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Chapter 5 -  Results: 
In-vitro desferrioxamine treatment studies
5.1 Introduction
The experiments described in the previous chapter have shown that the revascularisation 
of transplanted islets is a complex and orderly process. The coordination of this intricate 
process requires the sequential expression of a number of growth factors (Vasir, Reitz et 
al. 2000) in order to achieve the angiogenic stimulus necessary for islet revascularisation. 
The manipulation of some of these growth factors has been shown to improve clinical 
outcomes in islet transplant models and may enhance the survival and function of islets 
(Nakano, Yasunami et al. 2000; Garcia-Ocana, Takane et al. 2003; Lopez-Talavera, 
Garcia-Ocana et al. 2004). Unfortunately, the techniques employed require either genetic 
modification of islets or local delivery of factor to provide their effect. The treatment of 
islets with desferrioxamine potentially obviates these complications and provides a 
simple technique for manipulating angiogenic growth factors which would be easily 
transferable to the clinical setting.
Desferrioxamine was originally discovered as a by product of antibiotic research and has 
been available for the treatment of iron overload since the early 1960s (Hershko, Konijn 
et al. 1998). The clinical benefit of desferrioxamine is achieved by chelation of 
intracellular iron and subsequent removal of iron from the body by urinary excretion. 
Most intracellular iron is bound to transferrin and only about 5% is freely available in 
the labile iron pool (Kakhlon and Cabantchik 2002). It is this pool of iron which is 
available for cellular functions and is chelated by desferrioxamine. The removal of iron 
from the labile pool has a number of effects and iron depletion with desferrioxamine has 
been shown to up regulate HIF-1, inhibit the enzyme ribonucleotide reductase (Cooper, 
Lynagh et al. 1996), precondition myocardium (Dendorfer, Heidbreder et al. 2005) and 
brain (Prass, Ruscher et al. 2002) to ischaemic damage and alter the expression of 
important cyclins necessary for cell cycling (Le and Richardson 2002). The 
concentration of DFO required to achieve these in-vitro effects is higher than those used
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clinically (~5pM) (Cooper, Lynagh et al. 1996) and most authors have used DFO 
concentrations of lOOpM (Ebert, Gleadle et al. 1996; Yamakawa, Liu et al. 2003) and 
130pM (Wang and Semenza 1993) to induce HIF-1. Desferrioxamine concentrations of 
25 - 300|iM (Cooper, Lynagh et al. 1996) have also been used to study the modulation 
of ribonucleotide reductase, with doses of lOOpM causing an 80% reduction in DNA 
synthesis (Zanninelli, Glickstein et al. 1997). The dose of DFO used here was based on 
the experience of these authors and lOOpM DFO was chosen as an experimental dose, 
with ten fold dilutions above and below for comparison of effect.
The initial in-vitro desferrioxamine treatment experiments were designed to explore 
whether DFO would up-regulate the expression of important angiogenic factors. The 
candidate growth factors were chosen either for their previously reported importance 
during islet revascularisation, VEGF, HGF and bFGF (Gorden, Mandriota et al. 1997; 
Vasir, Aiello et al. 1998; Vasir, Reitz et al. 2000; Vasir, Jonas et al. 2001), or their 
ability to improve post transplant outcomes when up regulated, VEGF and HGF (Garcia- 
Ocana, Takane et al. 2003; Lopez-Talavera, Garcia-Ocana et al. 2004; Lai, Schneider et 
al. 2005; Schultz, Fanburg et al. 2006). Angiopietin 1 was chosen for its ability to 
stabilise vasculature and work synergistically with VEGF (Davis, Aldrich et al. 1996; 
Thurston, Rudge et al. 2000). The expression of an important angiogenic inhibitor, 
endostatin (O'Reilly, Boehm et al. 1997), was also explored in order to see whether DFO 
treatment could suppress the expression of this inhibitory molecule and improve 
angiogenesis. Once the growth factor effects were determined, further in-vitro 
experiments were performed to investigate whether DFO altered islet viability and 
function, in view of the cell cycling modulation induced by iron chelation. This chapter 
will describe the results of these experiments and discuss the underlying mechanisms for 
the associated changes.
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5.2 Effect of desferrioxamine treatment on protein expression of growth factors
These experiments used in-vitro culture techniques to explore whether desferrioxamine 
would alter the protein expression of important angiogenic growth factors. The number 
of growth factors explored by this technique was limited by the availability and 
sensitivity of suitable ELISA kits and further growth factor analysis was performed 
using molecular techniques for analysis of growth factor messenger RNA.
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5.2.1 VEGF protein expression from desferrioxamine treated islets after overnight 
culture
Overnight incubation of islets with DFO produced a dose-dependent increase in mean 
supernatant VEGF protein concentration when compared to islets cultured in CMRL 
alone (figure 5.1): 30.6pg/ml control cultured, 35.3pg/ml DFO lOpM (p=0.14), 
53.5pg/ml DFOlOOpM (p< 0.001) and 181.5pg/ml DFO lOOOpM (p< 0.001). 
Supernatants from islets incubated in 1% oxygen did not have higher concentrations of 
VEGF when compared to control cultured supernatants: 29.9pg/ml hypoxic control 
(p=0.30). Supernatants from islets incubated in 95% oxygen had significantly lower 
concentrations of VEGF, compared to control cultured supernatants: 13.8pg/ml 
hyperoxic control (p=0.004).Ten sets of cultures were analysed in each group.
Figure 5.1: VEGF concentration in supernatants from islet cultures after overnight 
incubation in increasing concentrations of desferrioxamine (DFO 10 = 
desferrioxamine lOpM, DFO 100 = desferrioxamine lOOpM and DFO 1000 = 

























5.2.2 bFGF protein expression from desferrioxamine treated islets after overnight culture 
Unlike the VEGF experiments, there was no significant difference in bFGF protein 
expression after overnight culture with DFO when compared to control cultured islets 
(figure 5.2): 80.4pg/g control cultured, 93.4pg/g DFO 10 (p=0.30), 102.7pg/g DFO 100 
(p=0.23) and 90.40pg/g DFO 1000 (p=0.34). The expression of bFGF in fresh 
(105.2pg/g, p=0.17) and hyperoxic control islets (93.0pg/g, p=0.28) was not different 
from control cultured islets but islets cultured in 1% oxygen had a significantly higher 
expression of bFGF protein (181.4pg/g p=0.034), when compared to control cultured 
islets. Six sets of cultures were performed in each group.
Figure 5.2: Corrected bFGF concentration from 350 lysed islets after overnight 
culture in increasing concentrations of DFO or lysed fresh islets. Values are 
expressed as mean concentration of bFGF protein per g of total protein from cell 
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5:2.3 VEGF protein expression from desferrioxamine treated islets after culture in M l 99
The overnight incubation of islets with DFO produced a dose dependent increase in 
VEGF expression but it was unclear how long the increased expression would be 
sustained and whether VEGF expression would rapidly return to basal levels after 
transfer to an iron-containing environment. The time course of VEGF expression 
induced by DFO was examined by culturing islets overnight with DFO and subsequently 
transferring them to an iron containing media. This experiment was designed to simulate 
a transplant procedure where DFO cultured islets would be transplanted into the portal 
system and bathed in iron containing blood.
This experiment showed that VEGF protein levels remained significantly elevated in the 
supernatants of islets that were initially treated with DFOlOOOpM and DFOlOOpM for 
48 and 24 hours respectively after transfer into iron-containing media, when compared 
to supernatants from control cultured islets (figure 5.3). Six sets of cultures were 
performed in each group.
Figure 5.3: VEGF concentration in supernatants from extended islet cultures in 
M199 medium after overnight incubation in desferrioxamine. Values are means 
plus standard error. Statistical significance: p value of less than 0.01 is indicated by 
* and a value of less than 0.05 is indicated by +, when compared to control cultures.
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5.3 Effect of desferrioxamine treatm ent on gene expression of growth factors
One of the rationales for treating islets with desferrioxamine was to over express a 
number of angiogenic growth factors by a more physiological method than adenoviral 
gene transfection techniques. The previous experiments showed VEGF protein 
expression increased after treatment with DFO but ELISA protein assays were not 
available for a number of other rat specific factors. Therefore the expression of a number 
of important growth factors was explored using mRNA techniques.
The increase or reduction in expression was compared to fresh and control cultured islets, 
as outlined in figure 5.4 and figure 5.5 respectively. The experiments were performed on 
5 sets of islets with duplicate analysis of expression.
Figure 5.4: The effect of desferrioxamine treatm ent on the expression of angiogenic 
growth factor RNA expression, compared to fresh islets. The values are presented 
as average fold change plus standard error. Statistical significance: p value of less 
than 0.01 is indicated by * and a value of less than 0.05 is indicated by +, when 
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Figure 5.5: The effect of desferrioxamine treatm ent on the expression of angiogenic 
growth factor RNA expression, compared to control cultured islets. The values are 
presented as average fold change plus standard error. Statistical significance: p 
value of less than 0.01 is indicated by * and a value of less than 0.05 is indicated by 
+, when compared to control cultures.
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5.3.1 Change in expression of VEGF mRNA with desferrioxamine treatment 
Desferrioxamine treatment produced a significant, dose responsive increase in the 
expression of all isoforms of VEGF and VEGF 164, when compared to both fresh and 
control cultured islets. The increase in all isoforms of VEGF with DFO treatment was 
similar to that induced by hypoxic culture but DFO treatment increased VEGF 164 
expression to a greater extent than hypoxic culture, 2.37 fold (p=0.04) DFO 100 and 
4.14 fold (p=0.001) increase in VEGF 164 when compared to hypoxic controls. 
Hyperoxic culture significantly increased all VEGF isoform expression but suppressed 
VEGF 164 expression when compared to fresh and control cultured islets.
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5.3.2 Change in expression of HGF mRNA with desferrioxamine treatment 
Hepatocyte growth factor expression was significantly down regulated by DFO 
treatment when compared to both fresh and control cultured islets. The pattern was 
related to concentration of DFO with lOOOpM producing greater suppression than the 
lOOpM treatment. All controls produced a non significant reduction in HGF expression 
when compared to fresh islets, with no difference in the extent of suppression between 
the different control groups.
5.3.3 Change in expression of bFGF mRNA with desferrioxamine treatment
The expression of bFGF was down regulated by DFO treatment and in all control groups, 
when compared to fresh islets. The reduction in bFGF expression with DFO appeared to 
be dose related but only the DFO1000, hypoxic and hyperoxic controls reached 
statistical significance. When the changes were compared to control culture islets, there 
was no significant difference between any groups. The fresh islets had a non 
significantly higher expression of bFGF compared to cultured islets.
5.3.4 Change in expression of Angl mRNA with desferrioxamine treatment.
All control and DFO treated groups showed a significantly reduced expression of Angl, 
when compared to fresh islets. There were no significant changes in Ang 1 expression 
compared to control cultured islets, except for the fresh islet group.
5.3.5 Change in expression of endostatin mRNA with desferrioxamine treatment 
There were no significant changes in the expression of endostatin when compared to 
either fresh or control islets. In addition, there was no obvious pattern to the changes in 
expression.
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5.4 Effect of desferrioxamine treatment on islet viability
The initial experiments had shown that desferrioxamine treatment altered the expression 
of a number of growth factors and appeared to be a promising technique for up 
regulating the expression of VEGF. In addition to HPH, haem compounds and other 
important cellular enzymes require iron and depletion of iron from cells can lead to 
arrest of cell cycling through the inhibition of ribonucleotide reductase (Cooper, Lynagh 
et al. 1996). Therefore, it was important to ascertain that desferrioxamine treatment did 
not affect the viability of islets.
The viability of DFO treated and control islets was assessed by direct visualisation and 
flow cytometry, figure 5.6. The two different methods were used to assess any adverse 
effect of disrupting the islets before flow cytometry evaluation. Four sets of islets were 
assessed within each group. The flow cytometry measurements were analysed in 
triplicate and the direct visualisation was carried out on four sets of islets within a 
sample.
When analysed by direct visualisation, the viability of cells within islets was not 
significantly different in the DFO treated (95.1%- DFOIO, 93.5%- DFOIOO, 94.3%- 
DFO 1000), control cultured (93.7%) or hyperoxic control islets (90.5%) when 
compared to fresh islets (90.7%) but viability was significantly lower in the hypoxic 
control (70.3%, p=0.001) and hydrogen peroxide treated (67.6, p<0.001) islets (figure 
5.6). This pattern of viability was similar when analysed by flow cytometry, although 
the viability in the control culture group was also significantly lower than fresh islets: 
Fresh 74.3%, hyperoxic control- 70.3%, DFOIO- 74.0%, DFOIOO- 71.3%, DF01000- 
73.0%, control culture- 68.6% (p=0.011), hypoxic control- 59.9% (p=0.001), hydrogen 
peroxide treated-15.5% (p<0.001).
Within each group, the viability was significantly lower when analysed by the flow 
cytometry method compared to direct visualisation. This effect may be due to a loss of 
viability during the disruption process.
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Figure 5.6: Viability of cells within islets assessed by direct visualisation or 
dispersion and flow cytometry. Islets treated with hydrogen peroxide acted as 
positive control. Other groups were hypoxic controls, hyperoxic controls, freshly 
isolated, control cultured or desferrioxamine treated with DFO. Data are presented 
as mean percentage plus standard error. Statistical significance: p value of less 
than 0.01 is indicated by * and a value of less than 0.05 is indicated by +, when 
compared to fresh islets.
100
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5.5 Effect of desferrioxamine treatm ent on islet apoptosis
The islet viability experiments did not suggest any immediate and irreversible adverse 
effect of desferrioxamine treatment on the viability of islets. Unfortunately, viability is a 
crude test and non viable cells may be the endpoint of a more subtle process, such as 
apoptosis. If the desferrioxamine treatment of islets induced apoptosis, it is possible that 
this would not be appreciated by assessing viability and islets with early apoptosis would 
be transplanted, leading to subsequent loss. Given that desferrioxamine treatment up- 
regulates HIF, and HIF may induce pro-apoptotic and anti-apoptotic genes (Piret, Mottet 
et al. 2002), the assessment of apoptosis would be an important endpoint to measure.
Islet apoptosis was therefore assessed in disrupted islets with the Anexin/7AAD method. 
Desferrioxamine treated, fresh and control cultured islets were assessed from four 
different animals. The assays were performed in triplicate for each experiment and 
results are expressed graphically in figure 5.7.
Figure 5.7: Assessment of apoptotic and viable cells from dispersed islets. Values 
are expressed as means plus standard error.
□  Apoptotic cells 
■  Viable cells




The level of apoptosis in the control cultured and desferrioxamine treated islets was 
significantly lower than in the fresh islets (control fresh- 10.4%, control cultured- 6.1% 
(p<0.001), DFOIO- 6.5% (p<0.001), DFO 100- 6.9% (p<0.001), DFO 1000- 4.8% 
(p<0.001)). There was no significant difference in the percentage apoptosis between the 
control cultured and desferrioxamine treated groups.
The level of viable cells was much lower when assessed by 7AAD than when assessed 
by PI, as above. In addition, there was a difference in the percentage of viable cells 
between the different groups, with significantly better viability in the DFO 1000 group 
(table 5.1)
Table 5.1: Percentage viable cells in control and desferrioxamine treated groups 
when assessed by 7AAD in dispersed islets.






Control fresh 40.2 - -
Control culture 43.1 p= 0.185 -
DFO 10 38.6 p= 0.505 p= 0.068
DFO 100 46.9 p= 0.035 p= 0.193
DFO 1000 54.9 p< 0.001 p< 0.001
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5.6 Effect of desferrioxamine treatm ent on glucose stimulated insulin release
The experiments so far did not shown any adverse effect of desferrioxamine treatment 
on islet integrity. In view of the ability of HIF-1 to affect genes necessary for glucose 
uptake and metabolism (Wenger 2000), the metabolic response of DFO treated islets to 
glucose was explored. The glucose related insulin release and insulin content of control 
and desferrioxamine treated islets was assessed by glucose stimulation tests and 
measurement of islet insulin content.
5.6.1 Glucose stimulation tests
Glucose stimulation tests (figure 5.8) in each group were performed on eleven sets of 
islets isolated from Lewis rats (~31 Og).
The glucose stimulated insulin release was not adversely affected by desferrioxamine 
treatment but conversely, DFO 1000 islets had a significantly higher stimulation index 
than control fresh or control cultured islets (p=0.024 and p=0.020 respectively), table 5.2.
Figure 5.8: Insulin concentrations in supernatants from glucose stimulation tests 
performed on control and desferrioxam ine treated islets. Data are presented as 
mean concentration plus standard  error.
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Table 5.2: Stimulation indices from glucose stimulation tests performed on control 
and desferrioxamine treated islets. Data are presented as mean value + 1 standard 
deviation.
Islets Stimulation index
Control fresh 1.13 (+/- 0.52)
Control cultured 2.10 (+/- 1.40)
DFO 10 2.21 (-*7-0.86)
DFO 100 2.77 (+/- 2.05)
DFO 1000 4.52 (+/- 3.80)
5.6.2 Insulin content of islets
The data from the glucose stimulation tests showed an improved glucose related insulin 
release in islets treated with higher doses of DFO which would suggest that 
desferrioxamine treatment may enhance the function of islets. Although glucose 
stimulation tests can give an indication of the functional capacity of islets, there is no 
correlation between stimulation indices and outcome post transplantation (Migliavacca, 
Nano et al. 2004). Insulin content of islets does correlate with outcome, with higher 
insulin content correlating with an improved outcome post transplantation (Migliavacca, 
Nano et al. 2004). Therefore, insulin content of the islets from the above glucose 
stimulation tests (figure 5.9) was assessed in order to gauge whether the insulin content 
was similar in control and desferrioxamine treated islets.
The data were generated by lysing the eleven sets of islets used for the glucose 
stimulation tests above and assaying the resultant supernatant.
The results showed a lower content of insulin in the stimulated islets compared with 
basal islets, although none of the changes were significant. In addition, there was no 
difference in insulin content, either basal or stimulated islets, between control, fresh or 
desferrioxamine treated islets. The insulin content of DFO 1000 islets was lower than 
the other groups, although not significantly so.
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Figure 5.9: Mean insulin content per islet of control and desferrioxamine treated 
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5.7.1 Effect of desferrioxamine treatment on angiogenic growth factor expression 
Angiogenic growth factors, such as VEGF, have been shown to be important for the 
revascularization of transplanted islets (Vasir, Reitz et al. 2000). Up regulation of these 
important factors can improve islet engraftment (Nakano, Yasunami et al. 2000; Garcia- 
Ocana, Takane et al. 2003; Lopez-Talavera, Garcia-Ocana et al. 2004) but rely on local 
delivery or adenoviral techniques which would not be easy to transfer to the clinical 
setting. Desferrioxamine treatment of cells has been shown to increase the expression of 
HIF-1 (Wang and Semenza 1993; Wang, Jiang et al. 1995; Cooper, Lynagh et al. 1996; 
Gleadle and Ratcliffe 1997; Linden, Katschinski et al. 2003) and the down-stream 
hypoxia response elements that lead to angiogenesis (Yamakawa, Liu et al. 2003). 
Therefore, desferrioxamine treatment presents a novel and attractive method for up 
regulating angiogenic growth factors in islets that does not require genetic manipulation 
of islets or growth factor treatment of the recipient.
5.7.1a Expression of vascular endothelial growth factor
Vascular endothelial growth factor, or vascular permeability factor as it was originally 
known, was first isolated in 1983 (Senger, Galli et al. 1983) and belongs to a family of 
growth factors which include VEGF A-D and placental growth factor (Neufeld, Cohen 
et al. 1999). From this family of growth factors, VEGF A is the most studied and is 
commonly referred to as just VEGF. Therefore, all citations relating to vascular 
endothelial growth factor in this thesis will refer to VEGF A.
Vascular endothelial growth factor is a powerful endothelial mitogen which exerts its 
action through two endothelial receptor tyrosine kinases, VEGFR-1 (or Fit-1) and 
VEGF-2 (KDR) (Ferrara 2004). The main action of VEGF is to induce the growth of 
vascular endothelial cells and promote their survival but VEGF can also encourage 
vascular permeability (Dvorak, Brown et al. 1995) and may have some haemopoeitic 
effects (Broxmeyer, Cooper et al. 1995).
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The human VEGF gene is encoded by 8 exons (Tischer, Mitchell et al. 1991) which are 
alternatively spliced to form five different isoforms that are denoted by their amino acid 
length (VEGF1 2 1 , VEGF1 4 5 , VEGF1 6 5 , VEGF189 and VEGF2 0 6 ). The rat gene similarly 
has 8 exons (Tober, Cannon et al. 1998) which results in a 90% amino acid homology to 
the human VEGFs but the rat VEGFs lack an amino acid at the N terminal portion 
(Breier, Albrecht et al. 1992), therefore leading to isoforms VEGF1 2 0 , VEGF1 4 4 ,
VEGF164, VEGFigg and VEGF2 0 5 . The VEGFi6 4 isoform is the most predominant in rats 
(Bacic, Edwards et al. 1995) and is increased in the early stages of islet engraftment 
(Vasir, Jonas et al. 2001). Further to this observation, a number of authors have up 
regulated the expression of VEGF 1 64 in transplanted islets and have reported a variety of 
improved outcomes (Zhang, Richter et al. 2004; Chae, Lee et al. 2005; Lai, Schneider et 
al. 2005). Therefore, the effect of DFO on the expression of VEGF was explored.
Desferrioxamine up regulated the expression of VEGF protein in a predictable dose 
dependent manner. In addition, the higher doses of desferrioxamine (DFOlOOpM and 
DFOlOOOpM) induced a sustained increase in VEGF protein production after transfer to 
an iron-containing medium, suggesting that VEGF over expression may continue after 
transplantation into the iron rich environment of the portal vein. This pattern of 
expression is unlikely to be due to low iron availability within the culture medium as M- 
199 contains free iron and the medium was supplemented with FCS, which contains free 
and bound iron. The explanation for the sustained VEGF production is most likely to be 
due to the hydrophilic property of DFO reducing its exit from cells (Richardson, Ponka 
et al. 1994; Cooper, Lynagh et al. 1996) and prolonging the chelation of labile iron pools. 
This property of DFO provides a unique method for prolonging the increased expression 
of VEGF after transplantation that will eventually wash out after a few days. Conversely, 
the hydrophilic property that causes retention of DFO within cells also requires time for 
the ingression of DFO into cells (Cooper, Lynagh et al. 1996). Therefore, islets would 
need to be exposed to higher concentrations of DFO (lOOpM or more) for at least 4 
hours in culture (Cooper, Lynagh et al. 1996).
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The increase in VEGF protein expression with DFO was mirrored by the changes in the 
VEGF mRNA expression, with a dose dependent increase in both all isoforms of VEGF 
and VEGF 164. The benefit of analysing mRNA expression is the comparison with 
different controls, such as fresh islets, which would not be possible with protein 
expression. Although the changes with DFO were predictable, the changes with hypoxia 
and hyperoxia require further explanation.
Hypoxia increased the expression of all isoforms of VEGF to a similar extent as 
treatment with DFO lOOpM but the VEGFim isoform was up regulated to a lesser 
degree and was not significantly higher than in the control cultured islets. This result 
was reinforced by the VEGF protein data and reflects the fact that the R&D systems 
ELISA is specific for the 164 and 120 isoforms. Differential expression of the VEGF 
isoforms in response to oxygen tensions has been reported before and in an in-vivo rat 
pup model of retinal vascularisation, the VEGF120 and VEGFjgo isoforms were up 
regulated to a greater extent than VEGF 16 4 in response to a hypoxic stimulus (McColm, 
Geisen et al. 2004). The study also showed a greater reduction in the expression of 
V E G F^to  hyperoxia (50% O2 ) than the VEGF 120 and VEGFjgo isoforms (McColm, 
Geisen et al. 2004). This observation is mirrored in these results where VEGFi6 4  
expression was reduced by hyperoxia but other isoforms were not. The reason for this 
difference in isoform expression is not clear but may be because VEGF is not only 
regulated by transcriptional induction (Neufeld, Cohen et al. 1999; Ferrara 2004) but its 
expression can be induced by changes in mRNA stability (Levy, Levy et al. 1995; Levy, 
Levy et al. 1996). Therefore, the differences in mRNA structure between isoforms may 
account for differences in stability or induction under different conditions.
Despite the differences between VEGF isoforms, the change in VEGF 164 expression 
induced by hypoxia (exposure to 1 % oxygen mix) was less than expected. The cause of 
this poor up regulation is probably multifactorial. Firstly, the hypoxic stimulus of 1% 
ambient oxygen (7.5mmHg) may not have been sufficient to maximally induce VEGFi6 4 - 
The in-vitro 50% maximal induction of VEGF165 in human cervical cancer cell lines has 
been estimated to be between 13 and 27mmHg, depending on the cell line, with maximal
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induction occurring at 0 to 6.3 mmHg (Chiarotto and Hill 1999). Our model did not 
directly measure the partial pressure of oxygen within media and despite the 20 minute 
gassing of modular chambers, it is possible that either the gas did not fully equalize or 
there was additional oxygen dissolved within the media. For this reason, it may have 
been better to use a lower oxygen concentration for induction of VEGF, such as 0.5%, 
0.1% or 0% oxygen, as described by other authors (Pham, Uchida et al. 2002; Turner, 
Crew et al. 2002; Nilsson, Shibuya et al. 2004) or a longer incubation time. However, 
this was not the experience of Vasir et al. who showed a 3.8 and 2.6 fold induction of 
VEGFjm in rat islets exposed to 24 hours of 1% oxygen, when compared to fresh and 
normoxic cultured islets respectively (Vasir, Aiello et al. 1998). In addition, the culture 
of islets exposed to 1% oxygen has been shown to up regulate H IF-la protein 
expression after only 1 hour, which suggests that 1% ambient oxygen should be a 
sufficient stimulus to the induction of hypoxia response elements such as VEGF (Moritz, 
Meier et al. 2002).
Secondly, the fold change in mRNA expression is a relative change and fresh and 
control cultured islets were used as the reference for gene expression. Both of these 
reference points require isolation and manipulation of islets which may affect the 
expression of growth factor mRNA. In cultured cells, the effect of stirring (Chiarotto and 
Hill 1999) or changing cellular architecture (Milsom and Rak 2005) can increase the 
expression of VEGF and other angiogenic growth factors. Therefore, the manipulation 
required to isolate islets may have altered baseline gene expression in control islets and 
reduced the effect of increased expression in the experimental islets. A better control 
may have been fresh whole pancreas, although this control may influence gene 
expression patterns as the sample would contain exocrine tissue.
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5.7.1b Expression of Hepatocvte growth factor
Hepatocyte growth factor, or scatter factor, is a heterodimeric molecule consisting of an 
alpha and beta subunit (Funakoshi and Nakamura 2003). HGF is secreted as an inactive 
form but is activated by serine proteases and exerts its actions through the c-MET 
receptor (Funakoshi and Nakamura 2003). The active molecule is a potent mitogen to 
primary cultured hepatocytes and has an important role in organogenesis of the liver and 
other organs, with embryonic lethality in knockout animals (Uehara, Minowa et al. 1995; 
Uehara, Mori et al. 2000). Hepatocyte growth factor has also been shown to reduce 
endothelial cell death due to hypoxia (Hayashi, Morishita et al. 1999), protect from 
ischaemia induced apoptosis (Funakoshi and Nakamura 2003) and promote angiogenesis 
(Hayashi, Morishita et al. 1999; Taniyama, Morishita et al. 2001).
The pro angiogenic and anti-apoptotic properties have made HGF an attractive target for 
improving the survival and revascularization of transplanted islets and a number of 
authors have looked at this issue by either adenoviral transfection (Garcia-Ocana,
Takane et al. 2003; Lopez-Talavera, Garcia-Ocana et al. 2004) or increased local 
delivery techniques (Nakano, Yasunami et al. 2000). The increased expression of HGF 
either locally or in transplanted islets has been shown to improve glucose normalisation 
and histological endpoints in marginal islet transplant models (Nakano, Yasunami et al. 
2000; Garcia-Ocana, Takane et al. 2003; Lopez-Talavera, Garcia-Ocana et al. 2004). In 
view of these studies and the fact that co administration of HGF with VEGF enhances 
angiogenesis in-vivo and vitro over the single molecules alone (Xin, Yang et al. 2001), it 
was hoped that DFO would also up regulate HGF.
Hepatocyte growth factor was significantly and dose dependently down regulated by 
DFO. This finding was further supported by a four fold trend toward reduced expression 
of HGF in response to hypoxia. Although HGF does have angiogenic effects, its 
expression has been shown to be down regulated by hypoxia both in-vitro (Hayashi, 
Morishita et al. 1999; Corpechot, Barbu et al. 2002) and in-vivo (Morishita, Nakamura 
et al. 1999).
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The expression of HGF was also down regulated, although not significantly, in control 
cultured and hyperoxic treated islets when compared to fresh islets. This suggests that 
hypoxia is not the only determinant of HGF expression and that the culture of islets may 
have a negative impact on HGF expression. If HGF is truly necessary for islet 
engraftment (Nakano, Yasunami et al. 2000), the impact of culture on its expression may 
explain the impaired vascular density and normalisation of hyperglycaemia post 
transplant of cultured islets when compared to fresh islets (Olsson and Carlsson 2005).
5.7.1c Expression of basic fibroblast growth factor
The fibroblast growth factors consists of 22 members, of which basic fibroblast growth 
factor, also known as FGF-2, is a single member (Omitz and Itoh 2001). The basic 
fibroblast growth factor gene extends over 36kb and consists of 3 exons with large 3' 
and 5' untranslated regions (UTR), suggesting its regulation may be transcriptional 
(Okada-Ban, Thiery et al. 2000). The transcription of the gene is bidirectional, giving 
rise to a 1.5kb antisense transcript complementary to the 3' UTR which has been 
implicated in the transcriptional and post transcriptional regulation of bFGF expression 
(Knee and Murphy 1997).
The translation of the gene is further complicated by multiple non-classical CUG start 
codons 5' to the classical AUG start codon which results in 5 protein isoforms of 18, 22, 
22.5, 24 and 34kDa (Florkiewicz and Sommer 1989; Prats, Kaghad et al. 1989; Delrieu 
2000). The classical AUG start codon gives rise to the smaller 18kDa isoform and 
translation starting at the other non classical CUG start codons leads to formation of the 
larger molecular weight isoforms. The expression of the different bFGF isoforms is 
complex and although the 18kDa isoform may be up regulated at the transcriptional 
level, the larger CUG initiated isoforms are differentially regulated at the translational 
level, independent of mRNA expression (Vagner, Touriol et al. 1996). This has been 
shown in an in-vitro model where oxidative stress and heat shock up regulated the large 
molecular weight isoforms but not the 18kDa isoform (Vagner, Touriol et al. 1996).
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The small 18kDa isoform is mainly cytosolic but the larger isoforms contain a nuclear 
localising sequence which directs the protein to the nucleus (Okada-Ban, Thiery et al. 
2000). The larger isoforms tend to have nuclear targets but the 18kDa isoform can be 
secreted into the extracellular medium and may have autocrine or paracrine effects 
through FGF receptors (Okada-Ban, Thiery et al. 2000). The smaller isoform was 
initially shown to be mitogenic to fibroblast cells but other actions include endothelial 
morphogenesis and proliferation leading to angiogenesis, and protection of neural cells 
from apoptosis (Okada-Ban, Thiery et al. 2000). The angiogenic properties of bFGF 
have interested researchers in the filed of islet revascularisation and early studies 
suggested that a local increase of bFGF protein could enhance normalisation of 
glycaemia (Hayek, Lopez et al. 1990) and improve vascular density within transplanted 
islets (Hayek, Lopez et al. 1990). In addition, bFGF has been shown to augment the 
vascular smooth muscle (Schultz, Fanburg et al. 2006) and endothelial cell proliferation 
(Calvani, Rapisarda et al. 2005) in response to HIF and hypoxia. Therefore, it was 
hypothesised that DFO might up regulate both bFGF and HIF-1.
The investigation of bFGF in islets produced different results depending on whether 
mRNA or protein expression was analysed. The mRNA results suggested that cultured 
islets had a lower expression of bFGF compared to fresh islets but there was no 
difference in mRNA expression between any of the groups when control cultured islets 
were used as the reference point. When bFGF protein was analysed, there was no 
significant difference between any of the groups except for the hypoxic islets, where 
bFGF protein was significantly increased. Therefore, hypoxic treatment of islets 
increases bFGF protein but not mRNA expression while DFO treatment does not affect 
either bFGF protein or mRNA levels. Although the specificity of the ELISA for bFGF 
isoforms is not listed, I have assumed that the ELISA measures all protein isoforms. If 
so, these results would suggest that hypoxia induces bFGF protein expression by 
translational modification that is independent of hypoxia inducible factor. A mechanism 
for this pattern of expression could be hypothesised through the complex 
transcriptional/translational regulation of bFGF expression. Other authors have also 
shown a similar response of protein up regulation without changes in mRNA expression
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in response to hypoxia (Ishibashi, Shiratuchi et al. 2001). A further study by Brogi et al. 
using a human vascular smooth muscle cell culture model found that hypoxia up 
regulated VEGF mRNA expression but not bFGF mRNA expression and also postulated 
that HIF-1 may have no affect on bFGF mRNA expression (Brogi, Wu et al. 1994). 
Contrary to this finding, a further study using human umbilical vein endothelial cells has 
shown that 1% oxygen up regulates both bFGF protein and mRNA expression which 
could be blocked by the use of HIF 1-a siRNA, therefore suggesting that both protein 
and message are regulated by hypoxia inducible factor (Calvani, Rapisarda et al. 2005). 
Therefore, it remains to be determined whether these results are reproducible and 
whether HIF-1 controls bFGF expression.
These results suggest that neither culture nor DFO treatment significantly affect bFGF 
expression although the trend was toward a reduction in expression when compared to 
fresh islets. Once again, this suggests a further hypothesis as to why cultured islets seem 
to do worse than fresh after transplantation.
5.7.Id Expression of angiopoietin 1
The angiopoietins are unusual angiogenic factors which contain three separate domains. 
The first is an N terminal section which has no known structural homology. The N 
terminal domain is followed by a coiled-coil domain and a final C terminal domain that 
has close homology to fibrinogen (Davis, Aldrich et al. 1996). The angiopoietin family 
consists of four members A ngl-4, of which Ang-3 is found only in mice and Ang-4 is its 
human counterpart (Valenzuela, Griffiths et al. 1999). Ang-1 is an agonist for the Tie-2 
receptor and, unlike a number of angiogenic factors, was discovered after its receptor 
(Davis, Aldrich et al. 1996). Ang-1 appears to orchestrate the normal interaction 
between endothelial cells and supporting cells which leads to improved vascular stability 
(Thurston, Rudge et al. 2000; Loughna and Sato 2001). This property of Ang-1 was 
highlighted by a study that used a transgenic mouse which over expressed Ang-1. The 
over expression of Ang-1 in a model of increased VEGF expression caused reduced 
capillary leakage induced by the over expression of VEGF. Ang-1 is not a strong 
endothelial mitogen (Davis, Aldrich et al. 1996) but probably works in conjunction with
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VEGF to promote vascular remodeling and endothelial sprouting (Maisonpierre, Suri et 
al. 1997). Ang-2 is a natural antagonist of the Tie-2 receptor and probably works by 
balancing the effect of Ang-1.
The Tie (tyrosine kinase with immunoglobulin and epidermal growth factor homology 
domains) receptors were found to be predominantly endothelial based. Their function 
was initially investigated using knock out mice and Tie 1 null mice embryos have 
subcutaneous oedema and hemorrhaging leading to late embryonic death (Sato, Tozawa 
et al. 1995), suggesting that Tie-1 is important for vascular integrity. The Tie-2 null mice 
had extensive malformations of early vasculature with early embryonic death (Sato, 
Tozawa et al. 1995) which suggests that Tie-2 is involved in network formation and 
maintenance during angiogenesis.
Increased VEGF expression has been shown to improve outcomes after transplantation 
but there was no evidence about the effect of VEGF up regulation on vascular integrity 
or supporting cells within transplanted islets. Given that Ang-1 can improve the poor 
vascular integrity associated with VEGF up regulation (Thurston, Suri et al. 1999), I was 
interested to see whether DFO would be able to regulate both angiogenic molecules 
together.
All the cultured groups showed a significant down regulation of Ang-1 when compared 
to fresh islets, with no difference between DFO treated, hypoxic or hyperoxic controls 
when compared to control cultured. While this result was initially disappointing, it is 
possible to postulate the mechanism for the reduced expression. Our in-vivo data had 
already shown regression of endothelium after the first day of transplantation and the 
reduced Ang-1 expression in cultured islets would be consistent with endothelial 
dissolution. In addition, hypoxia and HIF-1 are known to up regulate the expression of 
Ang-2 and Ang-4 while inducing tube formation of endothelium (Yamakawa, Liu et al.
2003). Hypoxia in-vivo has also been shown to down regulate Tie-2 and Ang-1 mRNA 
expression in a variety of tissues (Abdulmalek, Ashur et al. 2001). This balance would 
suggest that in the early stages of angiogenesis, Ang-1 and the effect of Tie-2 is
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probably down regulated in order to increase the flexibility of new vessel formation. 
Therefore, it may be more informative to look at levels of Ang-2 which have been 
shown to be increased with VEGF during angiogenesis and may potentiate VEGF- 
induced neovascularisation (Hackett, Ozaki et al. 2000).
The expression of Ang-1 during islet revascularization has not been elucidated so far but 
our results suggest that culture reduces the expression of Ang-1 when compared to fresh 
islets. In view of the necessity of Tie-2 action for coordinated vasculogenesis (Sato, 
Tozawa et al. 1995) and Ang-1 expression for developing leakage resistant vessels 
induced by VEGF (Thurston, Suri et al. 1999), the down regulation of Ang-1 during 
culture may be an additional reason for poor revascularization of cultured islets (Olsson 
and Carlsson 2005).
5.7. le Expression of endostatin
Endostatin is a compact globular protein that is proteolytically cleaved from the C 
terminal end of collagen XVIII (Sim, MacDonald et al. 2000; Abdollahi, Hlatky et al. 
2005). Endostatin has been shown to reduce expression of VEGF (Hajitou, Grignet et al. 
2002), inhibit VEGF induced tubularisation of endothelium (Ergun, Kilic et al. 2001) 
and promote endothelial apoptosis (Dhanabal, Ramchandran et al. 1999). The anti- 
angiogenic effect of endostatin has been investigated in a mouse tumour model where 
exogenous endostatin reduced the vascularity and size of experimentally induced 
haemangioblastomas (O'Reilly, Boehm et al. 1997).
The mechanism for regulation of endostatin is unclear and although it has been 
suggested that endostatin down regulation does not induce angiogenesis by changes in 
HIF-1 (Macpherson, Ng et al. 2003), it is not known whether HIF-1 expression alters 
endostatin expression. Hypoxia has been reported to down regulate endostatin protein 
expression in human endothelial cells, pericytes and endometrial cells (Wu, Yonekura et 
al. 2001; Nasu, Nishida et al. 2004) but chronic hypoxia has been shown to up regulate 
endostatin protein in a number of murine tissues (Paddenberg, Faulhammer et al. 2006).
I was unable to show a change in endostatin mRNA expression in response to hypoxia,
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hyperoxia or DFO treatment. This lack of mRNA expression change with hypoxia has 
been reported before and when combined with changes in endostatin protein, has lead 
the authors to conclude that endostatin regulation is post translational (Wu, Yonekura et 
al. 2001; Nasu, Nishida et al. 2004). Further experiments could therefore examine 
protein expression of endostatin rather than mRNA levels.
5.7. I f  Angiogenic factor expression and effect
These experiments have shown that DFO can alter the expression of angiogenic factors 
in islets in a similar but with more exaggerated pattern than moderate hypoxia. This 
pattern of expression provides a useful insight into the effect of DFO on islets but does 
not provide the whole picture of its end organ effects. A number of the angiogenic 
growth factor receptors are also modulated by hypoxia (Neufeld, Cohen et al. 1999;
Vasir, Reitz et al. 2000; Yamakawa, Liu et al. 2003) which leads to a change in the end 
organ effect of the angiogenic factor. I have not examined the effect of DFO and culture 
on receptor expression but this would be an important endpoint for evaluating the full 
effect of these treatments.
Isolated islets produce growth factors in culture and in response to hypoxic signal. These 
experiments have examined the expression of growth factor protein and mRNA but have 
not looked at where the growth factors originate from or the change in their time course 
after transplantation. Although the growth factor sequences were obtained, amplified 
and sequenced using IMAGE clones, I was unable to develop the in-situ hybridization 
technique for analysing RNA expression in tissue sections. The analysis of isolated and 
transplanted islets will provide further data on the origin of growth factor expression and, 
although not quantifiable, could provide insight into the post transplant time course of 
their expression.
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5.7.2 Effect of desferrioxamine treatment on islet viability 
Iron is an important cofactor in a number of cellular enzymes and the effects of 
desferrioxamine treatment may affect cellular functioning and viability. In addition, 
HIF-1 may exert both pro-apoptotic and anti-apoptotic effects with the apoptotic effects 
becoming more evident after prolonged hypoxia (Piret, Mottet et al. 2002). It is possible 
that the effects of desferrioxamine treatment and HIF-1 over-expression may have had 
negative effects on the islets by either inhibiting proliferation or increasing apoptosis in 
the grafts.
The viability assessment techniques deployed here worked well with good correlation 
between both methods. Despite the good correlation, the viability assessed by flow 
cytometry was numerically lower than the direct visualisation group. This observation 
has been recorded by other authors using flow cytometry (73.2% viability) versus 
confocal microscopy (86.3% viability) (Boffa, Waka et al. 2005) and is probably due to 
the disruption of islets prior to assessment. Despite the use of a non trypsin based 
technique, the disassociation of adherent cells probably leads to the reduced viability 
seen between these techniques but when each individual technique was used (flow 
cytometry or direct visualisation), the results allowed comparison between different 
experimental groups.
The viability assessment of iron depleted islets showed that DFO treatment did not 
significantly reduce viability when compared to fresh islets. When the viability was 
compared to the hypoxic control islets, there was a significantly higher viability in the 
both DFO treated groups using either technique. This pattern of viability suggests that 
although DFO can mimic the growth factor profile of hypoxia, it does not have the 
associated reduction in viability. Although the viability within islets in the control 
cultured group was lower than in fresh islets, when assessed by flow cytometry, there 
was no significant difference between control cultured and DFO treated groups. 
Therefore, it is impossible to say whether DFO may have protected against any loss of 
viability in culture.
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If DFO does have a hypoxia preconditioning effect, further experiments should assess 
the viability of control cultured islets and DFO treated islets after both groups had been 
exposed to a further 24 hours of hypoxic culture. This experimental design would 
simulate control cultured and DFO treated islets being transplanted into the hypoxic 
environment of the liver and may help examine whether DFO could hypoxia 
precondition islets prior to transplantation.
5.7.3 Effect of desferrioxamine treatment on islet apontosis
The islet viability experiments suggested that desferrioxamine treatment did not have a 
negative impact on the early survival of cells within islets but it is not clear whether 
desferrioxamine treatment may initiate apoptosis. The increased expression of HIF-1 a  in 
islets exposed to hypoxic culture conditions has been shown to induce apoptosis (Moritz, 
Meier et al. 2002) and it would be important to examine whether the induction of HIF-1 
by treatment with DFO had the same affect. The initiation of apoptosis would not be 
revealed by the use of cell exclusion dyes and cells within islets may then progress to 
late apoptosis at the time of transplantation, with subsequent loss of graft mass.
The assessment of apoptosis presented here suggests that desferrioxamine treatment has 
no affect on islet apoptosis but the results have to be interpreted in light of the technique 
used. Our modification of the Cattan technique (Cattan, Bemey et al. 2001) still required 
the use of islet disruption which may have increased the rate of islet apoptosis or 
necrosis within islets. This hypothesis is further backed up by the difference in cell 
viability between disrupted and non disrupted islets (in above section) and suggests that 
disruption and flow cytometry can negatively affect viability. Despite the need for 
disruption, the assessment presented here suggested lower values of apoptosis when 
compared to the description of the original technique (Cattan, Bemey et al. 2001) but 
should be interpreted in light of value presented by other authors. The values generated 
for annexin positive cells presented here are similar to the values presented by Boffa et 
al (6.4%) in their assessment of apoptosis in islets (Boffa, Waka et al. 2005). 
Unfortunately, their assessment of apoptosis was different and it is unclear why the 
authors have selected annexin positive/propidium iodide negative incorporated with
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annexin positive/propidium iodide positive cells for the assessment of apoptosis because 
the annexin positive/propidium iodide positive cells should denote necrosis, as outlined 
in the original description of the technique (Vermes, Haanen et al. 1995). The values for 
apoptosis in islets presented by Boffa and here differ greatly from the original 
description of the annexin V and propidium iodide technique (21.1%) by Cattan (Cattan, 
Bemey et al. 2001), the 7AAD and TMRE technique (40-50% of viable cells) presented 
by the same group in Miami (Ichii, Inverardi et al. 2005) or the TUNEL technique (1.5%) 
presented in Cattan’s paper (Cattan, Bemey et al. 2001). A further paper using acridine 
orange and direct visualisation suggested that islet apoptosis is closer to 1%
(Hadjivassiliou, Green et al. 1998). This immense variability highlights the difficulty of 
assessing apoptosis in islets and suggests that once a technique is established, the 
relative differences between treatment groups are more important than the absolute 
values.
Despite the inadequacies of this technique, the results suggested that DFO treatment did 
not increase the rate of apoptosis within cultured islets. Conversely, the results did not 
suggest a reduction of apoptosis either. Apoptosis was higher in the fresh islets (10.4%) 
compared with the cultured islets (~6%) and this may be a result of apoptosis induced by 
islet isolation. Conversely, the result could represent selection bias where healthy (non 
apoptotic) islets may have been hand picked from culture dishes after overnight culture 
compared with all fresh islets being non selectively used for analysis. A further analysis 
using hypoxic cultured islets would have been a useful positive control for this assay, as 
culture of islets exposed to 1% ambient oxygen has been shown to induce apoptosis 
(Moritz, Meier et al. 2002).
The percentage of necrotic cells using the 7 AAD/Annexin technique were much higher 
than when PI alone was used and are higher than previously reported (Cattan, Bemey et 
al. 2001; Boffa, Waka et al. 2005; Ichii, Inverardi et al. 2005). The reason for this was 
unclear and was originally thought to be due to differences between 7AAD and PI but 
7AAD has been used before on islets without such high levels of necrosis (Ichii,
Inverardi et al. 2005). The reason for the higher percentage may be due to flow
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cytometry set up, overlap of signal and changes with compensation or may have been 
the higher concentration of 7AAD used in order to generate a clear signal.
Despite the difficulties of the technique, there does not appear to be any detrimental 
effect of DFO on islet apoptosis.
5.7.4 Effect of desferrioxamine treatment on insulin secretion 
Viability is a useful test for assessing islets but does not correlate with post transplant 
outcomes (Migliavacca, Nano et al. 2004). The secretory function of islets may effect 
their engraftment post transplantation and any procedure which modifies or manipulates 
islets, in order to improve their engraftment, should not reduce their functional capacity. 
Insulin secretion in response to a glucose challenge (glucose stimulation tests) gives 
some indication of the function capacity of islets in-vitro, although the results do not 
necessarily correlate with clinical outcomes after transplantation (Migliavacca, Nano et 
al. 2004).
The glucose stimulation data suggested that desferrioxamine treatment does not impair 
the functional capacity of islets and, in higher doses, desferrioxamine treatment may 
improve the glucose-induced insulin response. The cause for this increased insulin 
response is unclear but may be related to an up regulation of glucose transporters by 
HIF-1 (Gleadle and Ratcliffe 1997) leading to an increased sensitivity of islets to 
glucose. This hypothesis is supported by the insulin content data which suggests that the 
insulin content of DFO 1000 islets subjected to high levels of glucose tends to be lower 
than that of the other groups.
When interpreting the glucose stimulation data, the results need to be compared to 
ranges achieved by other authors. De Haan et al (de Haan, Faas et al. 2004) used a 
similar method for the assessment of glucose stimulation and found an insulin secretion 
of around 20-25ng/ml.l0 islets; a value 4-5 fold higher than those reported here. In 
addition, the stimulation indices of fresh and cultured islets reported here are lower than 
might be expected. The cause for the reduced insulin secretion is complex but donor
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weight, donor strain, culture conditions and source of protein for processing are all 
factors which may influence the stimulation index in rodent islets (de Haan, Faas et al. 
2004). The rats chosen for the in-vitro experiments were of slightly higher body mass 
than the rats used for transplantation and this may have negatively impacted on their 
stimulation indices (Davalli, Scaglia et al. 1996; Biames, Montolio et al. 2002). When 
all the individual factors are considered, the stimulation indices presented here may be 
explained by the different subjects used for these experiments (de Haan, Faas et al.
2004). The important fact remains that all islets were exposed to the same experimental 
conditions and the values attained are reproducible. Therefore, desferrioxamine 
treatment does not appear to have a negative impact on the secretory function of islets 
in-vitro and in higher doses, may enhance their response
5.7.4 Effect of desferrioxamine treatment on islet insulin content
Dynamic islet tests, such as glucose stimulation, provide some information about islet
health and function but, as mentioned above, do not correlate with clinical outcome after
transplantation (Bertuzzi, Secchi et al. 2004). Insulin content of islets provide a better
indicator of outcome after transplantation and were therefore performed on the in-vitro
islets.
The islets exposed to higher concentrations of glucose had lower insulin content than 
basal islets and would be consistent with the secretion of stored insulin in response to a 
glucose challenge. The reduction of insulin content was lowest in the fresh islets and 
represents the low stimulation index seen in this group of islets. When all the groups are 
compared, there was no significant difference in insulin content between control and 
DFO treated islets, suggesting that DFO did not affect insulin content. Although the 
change did not quite reach statistical significance, the insulin content for stimulated and 
basal islets exposed to DFOlOOOpM was lower than the other groups. This observation 
is in agreement with a possible increased sensitivity to glucose caused by HIF-1 up 
regulation but may also lead to a poorer outcome post transplantation, if insulin content 
correlates with glucose normalisation after treatment with DFO
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5.8 Conclusions
These experiments have shown that the desferrioxamine treatment of islets in-vitro can 
induce a similar but more exaggerated pattern of angiogenic growth factor response to 
that seen in hypoxia. In particular, desferrioxamine treatment can produce a prolonged 
over expression of VEGF and does not adversely affect islet viability or apoptosis and 
may improve islet insulin response to a glucose challenge.
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Chapter 6 -  Results: 
In-vivo desferrioxamine treatment studies
6.1 Introduction
The analysis of transplanted islet revascularisation (chapter 4) showed that islet 
engraftment is a complex process which follows a coordinated sequence of events. The 
coordination of these events is probably due to the expression of local growth factors 
which drive angiogenesis and lead to the formation of a new vascular network (Menger, 
Yamauchi et al. 2001). Although a number of candidate growth factors have been 
suggested to control revascularisation, VEGF is probably the most important factor 
(Menger, Yamauchi et al. 2001) and is known to be expressed early during the 
revascularisation process (Vasir, Jonas et al. 2001). The manipulation of VEGF 
expression is therefore a prime target for improving the revascularisation of islets and its 
up regulation has been shown to improve the insulin responsiveness and glucose 
normalisation post transplant in addition to increasing insulin staining and vascular 
density within islet grafts (Zhang, Richter et al. 2004). Despite these positive results, 
VEGF may not be the entire answer to islet revascularisation and experimental islet 
transplantation in the presence of VEGF receptor blocking antibodies has shown that 
islets revascularise normally when compared to controls (Schramm, Yamauchi et al. 
2003). This suggests that the manipulation of multiple factors is probably required to 
improve revascularisation. Therefore, increasing VEGF expression by targeting the 
hypoxia signalling cascade with DFO may present a method for improving the 
engraftment of islets post transplantation.
The in-vitro results suggested that desferrioxamine treatment of islets produced a 
sustained increase in VEGF expression which persisted after the return to an iron 
containing environment. In addition, the treatment with desferrioxamine did not affect 
the viability or function of islets and in higher doses, may have improved glucose 
stimulated insulin release. It was therefore postulated that desferrioxamine treatment
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could precondition islets to over express VEGF during the peri transplant and immediate 
post transplant period. The increased expression of VEGF would therefore bring forward 
the time of peak endothelial mitogen expression to the day of transplantation, rather than 
at day 3 (as suggested by (Vasir, Jonas et al. 2001)), and hopefully improve transplant 
outcome. In addition, it is possible that the hypoxia preconditioning effect of 
desferrioxamine seen in neuronal cells (Prass, Ruscher et al. 2002) could be replicated in 
islets prior to transplantation and hence reduce hypoxic cell death after transplantation. 
Therefore, the next experiments were designed to determine whether the in-vitro data 
could be transferred to the in-vivo setting and desferrioxamine treated islets could 
improve the outcome of experimental islet transplantation.
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6.2 Effect of desferrioxamine treatment on ultra-marginal (350 islet) svngeneic islet
transplants
The initial experiments with the right branch transplant model suggested that this 
technique may reverse streptozotocin induced diabetes with a lower dose of transplanted 
islets. Therefore, the initial experiments were carried out using a single donor to 
recipient model with a dose of 350 islets.
6.2.1 Change in blood glucose after 350 islet transplant
Three diabetic animals were transplanted in each group (fresh islets, islets cultured 
overnight in CMRL alone and islets treated overnight in either DFO lOOpM or DFO 
lOOOpM). There was no significant difference in mean weight or mean blood sugar 
between each group at the time of transplant, table 6.1. All transplanted animals 
survived surgery and had a moderate fall in blood glucose and rise in body weight from 
pre transplant baseline. One animal in the control culture group died unexpectedly 6 
weeks after transplant. The cause of death was not obvious at post-mortem examination.
There was a fall in blood glucose in all groups from pre transplant levels to the day of 
harvest, although this was only significant in the fresh islet group. None of the animals 
were rendered normoglycaemic. The fall in blood glucose did not appear to be different 
between the groups graphically (figure 6.1) but when the overall changes in blood 
glucose was analysed by repeated measures ANOVA, all the cultured groups (control 
and desferrioxamine treated) were significantly different from the control fresh group 
(table 6.2). There was no difference between any of the desferrioxamine treated or 
control cultured groups (table 6.2). This observation was further backed up by the area 
under the curve analysis for blood glucose over time between the different groups 
(Control fresh- 1767.0mmol/l.d, control culture- 1926.4 mmol/l.d, DFO- 100 1934.0 
mmol/l.d and DFO 1000- 1905.6 mmol/l.d), which suggested a lower overall blood 
glucose in the control fresh group compared with the other groups.
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Table 6.1: Change in body weights and blood sugar concentrations of diabetic rats 
on the day of transplant and day of harvest (11 weeks post transplantation) after 
350 islet transplants. Data is displayed as mean ± 1 standard error. Significance is 
calculated by paired t test.











Fresh 249.3(3.8) 32.5(0.37) 298.7(2.4) 25.7(1.8) 0.003 0.021
Control
Culture
254 (8.1) 28.8(4.2) 304.5(11.0) 23.0(0.1) 0.044 0.365
DFO
100
243 (9.1) 30.1(2.2) 276(10.2) 27.6(3.1) 0.073 0.541
DFO
1000
243 (17.0) 26.1(3.5) 287(22.6) 21.3(3.2) 0.017 0.366
207
Figure 6.1: Change in mean non-fasting blood glucose over time in diabetic 
recipients of 350 desferrioxamine treated islets. The islets were either transplanted: 
fresh, overnight culture in CMRL alone (control cultured), or desferrioxamine 
treated (DFO 100) and (DFO 1000). Three animals were transplanted in each
group.
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Table 6.2: Significances for the difference between transplanted groups in the 
change of blood glucose after transplantation, when analysed by repeated measures
ANOVA.
Fresh Control culture DFO 100
DFO 1000 0.007 0.884 0.65
DFO 100 0.019 0.745
Control Culture 0.006
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6.2.2 Change in body weight after 350 islet transplant
All groups showed an increase in body weight from pre transplant to the day of sacrifice, 
table 6.1. The increase was significant in all groups, except the DFO 100 group. There 
was no difference in the change in body weight between any of the different groups 
(figure 6.2) and this was confirmed when the data was analysed by repeated measures 
ANOVA.
Figure 6.2: Change in mean body weight over time in diabetic recipients of 350 
desferrioxamine treated islets. The body weights were recorded prior to 
streptozotocin injection (day -14), at time of transplantation and weekly thereafter. 
The islets were either transplanted fresh (control fresh), after overnight culture in 
CMRL alone (control cultured), or desferrioxamine treated, (DFO 100) and (DFO 
1000).
-•-Control cultured 
-■ -D FO  1000 
DFO100 
Fresh
-21 -1 4  -7  0  7  1 4  21 2 8  3 5  4 2  4 9  5 6  6 3  7 0  7 7  8 4
Time post transplant (days)
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6.3 Effect of desferrioxamine treatment on marginal (500 islet) syngeneic islet 
transplants
The 350 islet transplant experiments did not show any clinical advantage of using 
desferrioxamine treated islets over fresh or cultured islets.Other than non efficacy of the 
original hypothesis, one explanation could be the low dose of islets transplanted which is 
supported by the observation that no animals were rendered normoglycaemic in the fresh 
group. Therefore, the experiments were repeated with a higher marginal dose of islets in 
order to try to exclude the low graft mass for the lack of efficacy.
6.3.1 Change in blood glucose after 550 islet transplants
Three animals were rendered diabetic and transplanted in each group (fresh islets, islets 
cultured overnight in CMRL alone and islets treated overnight in either lOOpM or 
lOOOpM DFO). There was no significant difference in mean weight or mean blood sugar 
between each group at the time of transplant and animals were followed up for 8 weeks, 
table 6.3.
The blood glucose did not fall significantly over the 8 weeks post transplant in any of 
the groups. None of the animals were rendered normoglycaemic and the fall in blood 
glucose did not appear to be different between the groups graphically (figure 6.3). When 
the overall changes in blood glucose was analysed by repeated measures ANOVA, there 
was no significant difference between any of the groups.
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Table 6.3: Change in body weights and blood sugar concentrations of diabetic rats 
on the day of transplant and day of harvest after transplantation with 550
desferrioxamine treated islets. Data is displayed as mean ± 1 standard error.











Fresh 236.7(3.8) 29.6 (3.0) 268.8 (7.0) 27.6(3.2) 0.020 0.11
Control
Culture
261.3 (9.7) 31.6 (0.8) 260.9(28.6) 28.2(3.8) 0.497 0.31
DFO
100
272.7 (6.2) 30.6(1.8) 306.1 (2.1) 26.9(2.3) 0.018 0.13
DFO
1000
241.3(10.1) 27.1 (3.9) 269.9 (9.4) 25.7(2.5) 0.002 0.11
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Figure 6.3: Change in mean non-fasting blood glucose over time in diabetic 
recipients of 550 desferrioxamine treated islets. The islets were either transplanted: 
fresh, overnight culture in CMRL alone (control cultured), or desferrioxamine 
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6.3.2 Change in body weight after 550 islet transplant
All groups, except the control culture group, showed a significant increase in body 
weight from pre transplant to the day of sacrifice, table 6.3. When the changes in body 
weight between groups were analysed, there were no obvious differences (figure 6.4) 
and this observation was confirmed by ANOVA.
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Figure 6.4: Change in mean body weight over time in diabetic recipients of 550 
desferrioxamine treated islets. The body weights were recorded prior to 
streptozotocin injection (day -14), at time of transplantation and weekly thereafter. 
The islets were either transplanted fresh (control fresh), after overnight culture in 
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6.4 Histological analysis of desferrioxamine treated and control islets post ultra­
marginal (350 islet) transplants.
The changes in blood sugar and weight post transplant with desferrioxamine treated 
islets were disappointing, as it was expected to see improvement in outcomes with DFO 
treated islets. The principle behind the improved outcome was enhancement of islet 
engraftment by up-regulating the expression of key angiogenic growth factors and 
hypoxia preconditioning islets. The question remained whether the desferrioxamine 
treated islets had engrafted better but the crude endpoints of blood sugar and weight 
changes were not sufficiently sensitive to reveal the benefits of improved engraftment. 
Therefore, the islets were examined histologically to visualise any improvement in 
engraftment. This section will discuss the histological evaluation of islets from the 350 
islet transplant recipients. Unfortunately, the livers were not available from the 550 islet 
transplant experiments due to storage mismanagement.
6.4.1 Gross histological appearance of transplanted control and desferrioxamine treated 
islets
The livers were harvested, fixed, embedded, sectioned and stained as previously 
described. All islets stained with the dual endothelial and insulin staining technique. The 
islets were easily identified within the hepatic architecture with one pole close to a portal 
triad. The islets from each experimental group had similar gross morphological 
appearances, vascular architecture and surrounding hepatic vaccuolation, although there 
were some minor differences between the groups.
The fresh transplanted and DFO 1000 islets were often larger and easier to distinguish 
from surrounding liver, with better migration into the hepatic tissue and occasionally 
spanning from the portal triad to hepatic vein. Although the density of insulin staining is 
a poor endpoint for engraftment, there was a more homogeneous insulin staining pattern 
in the fresh and DFO 1000 islets compared with the very poor insulin staining in the 
control cultured islets. Representative images of the different groups can be seen in 
figures 6.5 to figure 6.8.
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Figure 6.5: Dual 
stained islets from 
recipients of 350 
fresh islets. Image a 
and b are of the same 
islet at 200x and 
400x respectively. 
Image c and d are of 
additional islets at 
400x magnification.
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Figure 6.6: Dual 
stained islets from 
recipients of 350 
control cultured 
islets. Image a and b 
are of the same islet 
at 200x and 400x 
respectively. Image c 
and d are of 
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Figure 6.7: Dual 
stained islets from 
recipients of 350 
DFO 100 islets.
Image a and b are of 
the same islet at 200x 
and 400x
respectively. Image c 
and d are of 
additional islets at 
400x magnification.
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Figure 6.8: Dual 
stained islets from 
recipients of 350 
DFO 1000 islets. 
Image a and b are of 
the same islet at 200x 
and 400x
respectively. Image c 
and d are of 
additional islets at 
400x magnification.
6.4.2 Quantitative histological analysis of desferrioxamine treated and control islets 
The islet images were analysed as described in materials and methods. The islet area, 
vascular area and vascular density were calculated for all islet images. A total of 28 
control fresh islets, 19 control culture islets , 32 DFO 100 islets and 40 DFO 1000 islets 
were suitable for analysis (of sufficient size with clear vascular network).
6.4.2a Analysis of islet area
The area of engrafted islets differed between all the groups, with the lowest islet 
area in the control cultured group and the highest islet area in the control fresh 
group (figure 6.9). The two desferrioxamine treated groups had lower islet areas 
than the freshly transplanted group, although not significantly so. There was 
significantly higher islet area in the desferrioxamine treated groups when 
compared to the control cultured group, suggesting that islet engraftment may be 
better in fresh and desferrioxamine treated islets compared to control culture 
islets.
Figure 6.9: Average islet area of control and desferrioxamine treated groups. The 
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6.4.2b Analysis o f percentage vascular area and vascular density 
All islets had roughly a quarter o f their area dedicated to endothelium, with no 
significant difference between any o f the groups and (Fresh- 23.2(±2.6)%, 
control culture- 21.9(±3.0)%, DFO 100- 24.8(±2.4)% and DFO 1000- 
22.5(2.0)%)- see figure 6.10.
The vascular density was measured by both the number of vessel branches per 
islet area and the grid method. There was no significant difference in the vascular 
densities between the control fresh islets and the desferrioxamine treated islets. 
When the control cultured islets were compared to the other groups, there was a 
significantly lower vascular density in the fresh and desferrioxamine treated 
islets- see figure 6.10 (Vessel counting method: control cultured 2279 
vessels/mm2, fresh 1838 vessels/mm2 (p=0.053), DFO 100 1674 vessels/mm2 
(p=0.003), DFO 1000 1645 vessels/mm2 (p<0.001). Grid method: control 
cultured 3448 vessels/mm2, fresh 2229 vessels/mm2 (p<0.001), DFO 100 2468 
vessels/mm2 (p<0.001), DFO 1000 2411 vessels/mm2 (p<0.001).
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6.4.2b Analysis of percentage vascular area and vascular density 
All islets had roughly a quarter of their area dedicated to endothelium, with no 
significant difference between any of the groups and (Fresh- 23.2(±2.6)%, 
control culture- 21.9(±3.0)%, DFO 100- 24.8(±2.4)% and DFO 1000- 
22.5(2.0)%)- see figure 6.10.
The vascular density was measured by both the number of vessel branches per 
islet area and the grid method. There was no significant difference in the vascular 
densities between the control fresh islets and the desferrioxamine treated islets. 
When the control cultured islets were compared to the other groups, there was a 
significantly lower vascular density in the fresh and desferrioxamine treated 
islets- see figure 6.10 (Vessel counting method: control cultured 2279 
vessels/mm2, fresh 1838 vessels/mm2 (p=0.053), DFO 100 1674 vessels/mm2 
(p=0.003), DFO 1000 1645 vessels/mm2 (p<0.001). Grid method: control 
cultured 3448 vessels/mm2, fresh 2229 vessels/mm2 (p<0.001), DFO 100 2468 
vessels/mm2 (p<0.001), DFO 1000 2411 vessels/mm2 (p<0.001).
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Figure 6.10: Vascular densities (vessels per mm2) and percentage vascular area of 
transplanted control and desferrioxamine treated islets. Values are presented as 
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6.4.2c Analysis of branching index
The vascular density estimation for the control cultured islets was different from 
the other groups. When this data is combined with a non significant difference in 
the percentage islet area dedicated to endothelium, it suggested that the 
architecture of the vascular networks formed may be different. Therefore, the 
branching index was analysed to estimate whether there were any differences in 
vascular architecture.
There was no significant difference in branching index between the groups, 
although the index in the fresh and DFO 1000 group was higher than that in the 
DFO 100 and control culture group: fresh- 0.77(0.03), DFO 1000- 0.76(0.03), 
DFO 100- 0.69 (±0.03) and control cultured- 0.69(±0.06).
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6.4.2d Analysis of transplanted islet vessel size
The vascular density results were surprising, as it was expected that the control 
islets would have a lower vascular density than the desferrioxamine treated islets. 
In addition, the percentage vascular area within the islet was not different 
between groups suggesting that there was a difference in the size of the formed 
vessels. Therefore, the size of the vessels within the islets was measured.
The average vessel width in the fresh islets was 4.69(±0.09) pm and decreased to 
4.33(±0.09)|im (p=0.007) in DFO 1000 islets, 4.22(±0.10)pm (p<0.001) in DFO 100 
islets and 3.83(±0.12)pm (p<0.001) in control cultured islets. When control cultured 
islets were compared to desferrioxamine treated islets, the differences were still 




The in-vitro experiments showed that desferrioxamine treatment of islets induced a 
prolonged over-expression of VEGF and it was postulated that the over-expression 
would lead to a faster normalisation of blood glucose with an associated improvement in 
islet engraftment. Unfortunately, the transfer of desferrioxamine treated islets to an in- 
vivo model did not obviously improve the rate of normalisation of blood glucose, the 
change in body weight or the achievement of insulin independence. Although the blood 
glucose data for the ultra-marginal dose transplants did suggest that there may be some 
benefit to transplanting islets fresh, the data was not reproduced in the marginal dose 
animals. Despite the two doses of islets used, none of the groups achieved insulin 
independence and the first issue to consider is whether the model was suitable for 
examining the hypothesis. This section will consider the suitability of the transplant 
model and the significance of the histological evaluation. The failure of the original 
hypothesis as a cause for the lack of difference between the groups will be considered in 
chapter 8.
6.5.1 Suitability of transplant model
The transplant model used should be a robust and reproducible experimental tool in 
order to examine any subtle changes in experimental conditions. Within each model 
there are a number of variables which may limit the accuracy of a particular 
investigation. The islet transplant model relies on the resolution of diabetes as the 
primary outcome and requires the induction of diabetes, measurement of blood glucose 
and transplant of sufficient (3-cell mass to reverse the diabetes. Each of these processes 
are open to variability and this section will consider the different steps.
6.5.1a Induction of diabetes
Diabetes induction with streptozotocin is used as a gold standard for the study of islet 
transplantation. Streptozotocin is a nitrosurea derivative with broad spectrum antibiotic 
and antineoplastic activity which can induce diabetes at high doses (Rees and Alcolado
2005). Although STZ has a number of effects, including interference with glucose
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transport, alkylation, induction of DNA strand breaks and alteration of glucokinase 
function, the induction of diabetes is probably a direct toxic effect on islets (Rees and 
Alcolado 2005). The single large dose administration of STZ in rodents induces a type 1 
diabetic model but repeated low dose administration or in combination with high fat diet 
can induce a situation more like type 2 diabetes (Chen and Wang 2005).
In the present study, diabetes was induced prior to islet transplantation with the 
intraperitoneal injection of streptozotocin. Although most animals became diabetic 
within three days, some animals did not achieve the criteria for diabetes and some 
animals, mostly females induced with higher doses of STZ, became too unwell to 
transplant. This variability in diabetes induction could have led to a difference in the 
severity of diabetes and the dose of islets required to achieve normoglycaemia, thus 
increasing the intra-experiment variability. The reason for this variability is probably 
due to the route of administration of STZ and the nutritional status of the rat. The intra 
peritoneal administration of drugs is known to be more variable than the intravenous 
route (Sarangarajan and Cacini 1996) and it may have been more sensible to use 
intravenous administration of STZ. Secondly, the nutritional status and dose of STZ can 
effect the severity and type of diabetes (Chen and Wang 2005) and overnight starvation 
of rats prior to STZ can induce a more severe but more predictable diabetes model. 
Therefore, a lower dose of intravenous STZ could be administered after over night fast, 
in order to improve reproducibility further.
The use of spontaneously diabetic animals (Rees and Alcolado 2005) could have been 
considered but would have required a more complex model and a move away from 
syngeneic transplantation. Diabetic NOD-Scid mice have been used to receive islet 
transplants from humans (Sabek, Fraga et al. 2005) but the model requires kidney 
subcapsular transplantation and selective intra-portal transplantation would have been 
too difficult. The last option for diabetes induction would have been pancreatectomy but 
this technique is harder in rats, due to the diffuse nature of rodent pancreases, and would 
require two major procedures.
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The model of diabetes induction used for these experiments was variable but other 
models would have been too technically demanding or not clinically relevant. It may 
have been possible to reduce the variability of diabetes by altering the route and 
conditions of STZ administration, therefore reducing experimental variability.
6.5.1b Measurement of blood glucose
The use of blood or plasma glucose as an endpoint for monitoring islets engraftment is 
widely accepted, as the reduction of blood glucose is a rough indicator of insulin 
secretion. Unfortunately, the upper range of blood glucose does not correlate well with 
the severity of induced diabetes and elevated blood glucose can correlate with a wide 
range of (3-cell mass, depending on the size and nutritional status of an animal. Therefore, 
it is possible that there was a large variability of surviving (3-cells at the time of 
transplantation despite the similarity of blood glucose estimations between animals. The 
survival of native (3-cell mass has been shown to influence the outcome of experimental 
islet transplantation and animals with more surviving p-cells have better outcomes than 
animals with less P-cell survival (Hughes, Powis et al. 2001). Therefore, the variability 
of diabetes severity could have further influenced the reproducibility of the experiments.
The measurement of blood glucose is highly variable and will differ with the feeding 
patterns of the animals. Rodents tend to be nocturnal (or dark cycle) eaters (Strubbe and 
Woods 2004) and blood glucose measurement were performed at 1 lam each day in 
order to improve reproducibility. Nevertheless, animals showed daily variation in their 
blood glucose estimations which was particularly noticeable within the first two post 
operative weeks when the eating pattern of animals tends to be most disrupted (Sharp, 
Zammit et al. 2003). The first two weeks are the most crucial for islet transplantation as 
the islets engraft during this period and any difference in revascularisation caused by 
islet manipulation is hoped to be seen during this time. The variability of weekly blood 
glucose measurement was reduced by repeated measurements but there was still 
considerable variation which may have hidden any subtle changes in insulin 
responsiveness. These issues are difficult to overcome and while daily blood glucose
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measurements may have reduced variation, it is difficult to justify starving the rats each 
evening and changing their feeding patterns in order to improve reproducibility.
Despite the difficulties with blood glucose monitoring, body weight is a sensitive 
indicator of animal well being. The average weights between the different groups were 
not significantly different and this confirms the fact that there was probably no 
difference between the experimental groups.
The most widely used method for reducing variability is to increase the number of 
experimental subjects. Only three transplants were performed in each group and while a 
higher number may have improved the statistical analysis, the large number of rodents 
required could probably not be justified given the lack of any difference when the initial 
experiments were analysed.
6.5.1c Islet dose
The marginal islet transplant model relies on a dose of islets which partially cures 
induced diabetes and achieves a situation where small changes in islet survival or 
engraftment lead to either persistent diabetes or normoglycaemia. If too small a dose is 
chosen, all animals will remain diabetic but too large a dose will render all recipients 
normoglycaemic with no discrimination between groups. The original experiments by 
Hughes et al within our laboratory showed that a dose of 500-700 non-selective intra- 
portally transplanted islets in 280-300g recipients was sufficiently marginal to allow 
differentiation between experimental groups (Hughes, Davies et al. 2003). Our early 
experience with the selective right branch transplant technique suggested that the dose of 
islets required to induce insulin independence was less than that required for main 
branch transplantation. For this reason, the dose of 350 islets was initially chosen for 
transplantation.
After the first set of DFO experiments, it became clear that 350 islets were not sufficient 
to provide a marginal dose and all recipients remained significantly hyperglycaemic 
after transplantation. The dose of islets was increased further to 550 but there was still
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no resolution of diabetes or discrimination between groups. On review of these results it 
became clear that the right branch transplant technique was not better at reversing 
diabetes and although 500 islets had proven to be a marginal dose in 200g female rats 
(Figure 3.2), this was not the case in 240-260g male recipients. Therefore, a larger dose 
of islets may be required for marginal transplantation in these recipients. Unfortunately, 
because none of the animals were rendered normoglycaemic, these results have neither 
proven nor disproven the hypothesis of whether DFO treatment improves the resolution 
of diabetes by a marginal dose transplant.
6.5.2 Histological outcomes
The clinical outcome data did not show any robust evidence for improved engraftment 
after DFO treatment. Therefore, islets were analysed histologically to examine whether 
DFO treatment and subsequent up regulation of VEGF had any effect on the 
morphology or vascular architecture of transplanted islets.
The islets analysed for histology were from the ultra-marginal (350 islet) transplants, as 
the marginal (550 islet) transplant livers were not available for analysis. The low dose of 
islets transplanted into the liver made their histological retrieval difficult and only small 
numbers of islets were analysed. The small number of islets analysed makes firm 
conclusions difficult but there were some striking qualitative and quantitative 
differences between the two groups.
The general appearance of fresh and DFO 1000 islets was much better defined than the 
control cultured islets, with brighter insulin staining in the fresh and DFO treated groups. 
Although this is a relatively soft indicator of engraftment, the quantitative analysis also 
showed a significant difference in the islet area between the groups; with the highest 
area in the fresh islets and progressively lower average area in DFO 1000, DFO 100 and 
control cultured islets. This data suggested that the fresh islets had engrafted best and 
were followed by DFO 1000, DFO 100 and finally control cultured islets. These 
observations are in keeping with other studies which have examined increasing VEGF 
expression in transplanted islets, where VEGF up regulation has been shown to improve
227
the insulin staining (Zhang, Richter et al. 2004) and reduce islet mass loss after 
transplantation (Stagner, Mokshagundam et al. 2004; Chae, Lee et al. 2005; Lai, 
Schneider et al. 2005). The exact cause for these changes has not been fully examined 
but has been suggested to be due to an improved vascular supply caused by VEGF up 
regulation.
Unfortunately, this hypothesis does not explain why fresh islets engrafted better than the 
DFO treated islets, as the fresh islets would have had a lower VEGF expression at the 
time of transplantation. Other investigators have also shown improved engraftment in 
fresh islets compared to cultured islets (Olsson and Carlsson 2005) but could not 
correlate their findings with VEGF, as levels were higher in the cultured islets rather 
than the fresh islets. These findings suggest less of a role for VEGF and the authors 
postulated that the reduced engraftment in cultured islets may be due to loss of donor 
monocytes and endothelial cells during culture.
Vascular density has been used as a marker of islet engraftment with higher density 
suggesting better engraftment (Carlsson and Mattsson 1993; Carlsson, Palm et al. 2002; 
Mattsson, Jansson et al. 2002; Mattsson, Jansson et al. 2003; Olsson and Carlsson 2005). 
The increased expression of VEGF within islets has been shown to increase the relative 
vascular density and staining of endothelial markers in islets exposed to higher 
concentrations of VEGF (Zhang, Richter et al. 2004; Chae, Lee et al. 2005; Lai, 
Schneider et al. 2005). The data presented here is in contrast to these observations and 
suggests that the vascular density in control cultured islets is higher than that in fresh 
islets, with smaller vessels and no difference in the percentage vasculature. This result 
was unexpected as VEGF up regulation was predicted to increase endothelial migration 
and therefore increase vascular density.
One explanation for the higher vascular density in the control cultured group may be the 
time point of histological sampling. Most studies have investigated islet vasculature after 
2-5 weeks but the recipients in this study were sacrificed after 11 weeks. Under these 
circumstances the differences seen between groups may have less to do with initial
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engraftment and more to do with vascular remodeling. We know from our own and other 
author’s data that remodeling continues long after the initial period of revascularization 
(Rooth, Dawidson et al. 1989). If cultured islets revascularise poorly and have lower 
oxygen tensions (Olsson and Carlsson 2005) they may continue to express angiogenic 
growth factors during the period of remodeling. The increased angiogenic growth factor 
expression would occur long after the well engrafted islets have stopped expressing 
these factors and therefore, the continuing hypoxia in cultured islets may stimulate 
further angiogenesis during remodeling and increase the vascular density in poorly 
engrafted islets. This situation may explain why the vascular density in our control islets 
is higher compared to the fresh or DFO treated.
The original rationale for treating islets with DFO was to speed up revascularization and 
improve reversal of diabetes with a marginal mass transplant. The simultaneous 
measurement of these two endpoints is difficult because the period of revascularisation 
is short (within the first week or two) and blood glucose does not tend to normalize for a 
few weeks. The time point of 11 weeks was chosen in order to allow the animals 
sufficient time to achieve normoglycaemia with the marginal mass transplants. This 
prolonged time point would have led to islets being examined well after 
revascularisation and during the remodeling phase of islet vascular architecture. 
Therefore, a better time point for examination of islets may be after 4 weeks to try to 
examine both endpoints or after 5 days to see whether desferrioxamine treatment 
accelerated revascularisation.
The engraftment and revascularization of islets is a complex process which requires the 
interaction of numerous growth factors, either previously defined or undiscovered. We 
have only looked at a small number of these growth factors which have been shown to 
be responsible for engraftment. Despite the changes in these factors with DFO treatment, 
the histological analysis suggests that DFO treated islets are more similar to the better 
engraftment seen in the fresh islets. This observation would suggest that the fresh islets 
probably engraft best but that DFO treatment may reverse some of the adverse effects of 
culture. If the adverse affects of culture are due to loss of endothelium, it is possible that
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DFO may cause persistence of endothelium in culture by inducing cellular arrest 
(Hodges, Reese et al. 2005). Therefore, DFO treatment may have reduced the loss of 
islet endothelium associated with culture and may explain why the vascular architecture 
of desferrioxamine treated islets was more similar to fresh islets than that of control 
cultured islets. This observation would also suggest that islet revascularization has less 
to do with the effects of VEGF but may be influenced more by the persistence of donor 
endothelium.
The beneficial effects of DFO treatment are not purely limited to the up regulation of 
angiogenic factors and hypoxia preconditioning. Desferrioxamine has also been shown 
to modulate immune response and in-vivo, DFO can reduce the expression of MCP-1 
(Bosco, Puppo et al. 2004) and VCAM-1 (Koo, Casper et al. 2003). Although this has 
less relevance to a syngeneic model, the immune modulation may be important for islet 
transplantation in an allergenic situation. Therefore, treatment of islets with DFO prior 
to allogeneic islet transplantation may provide some benefit and investigation of this 
clinically important model would be warranted.
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6.7 Conclusions
These experiments were designed to bridge the gap between in-vitro experimentation 
and transfer to an in-vivo model of islet transplantation. Unfortunately, there was no 
obvious improvement in clinical outcomes when DFO treated islets were transplanted 
into syngeneic recipients. The lack of diabetes resolution in the control group suggests 
that the model may have weakened the conclusions drawn from the experiments and 
when combined with improvement of histological endpoints in DFO treated islets, 
suggests that further experiments are required to prove or disprove the hypothesis.
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Chapter 7- Results: 
Clinical islet transplantation
7.1 Introduction
Despite the early progress in non vascularised pancreas transplantation and the claim to 
the first xenogenic (Williams 1894) and allogenic transplants (Pybus 1924), the United 
Kingdom has lagged behind the rest of the world in the provision of clinical islet 
transplantation. Prior to the publication of the Edmonton protocol the UK had only 
performed 12 human allogenic islet transplants and none of the recipients had achieved 
insulin independence. The advances described in the publication from Edmonton 
encouraged Diabetes UK to form the UK islet transplant consortium and in early 2001, 
the head of research at Diabetes UK predicted that there would be 10 islet transplants 
performed in the UK by the end of the year. Sadly this prediction was not to come true 
and by March 2006, only eight Edmonton protocol transplants have been performed in 
the United Kingdom. This slow progress highlights the difficulties involved in 
transferring a successful technique to the practices and infrastructure of another country 
and the steep learning curved involved in isolating and transplanting pancreatic islets.
The advances of the Edmonton protocol have revolutionised the transplantation of 
pancreatic islets and rekindled the international interest in this valuable clinical tool. 
Despite these important advances, the transplantation of pancreatic islets requires further 
refinement before it is widely accepted as the treatment of choice for the difficult 
secondary complications of type 1 diabetes. Both whole pancreas and islet 
transplantation can improve metabolic control and abolish hypoglycaemia but islet 
transplantation currently requires a large number of donor organs to induce insulin 
independence (Shapiro, Lakey et al. 2000) and the long term graft survival rates are poor 
(Ryan, Paty et al. 2005). The issues surrounding these problems are multifactorial but 
are mainly reflected in the variability of islet yield and function after isolation (Lakey, 
Wamock et al. 1996; Goto, Johansson et al. 2005; Nano, Clissi et al. 2005). The number 
of pancreas preparations suitable for transplantation is often low and over 60% of
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processed pancreases are not suitable for transplantation (Nano, Clissi et al. 2005).If islet 
transplantation is to be established as an accepted technique, the issue of variable islet 
yield needs to be addressed and the isolation technique optimised to achieve consistent 
improvements in islet yield.
After islets have been isolated from the whole pancreas they are transplanted into the 
portal vein of diabetic recipients. The common route of transplantation is percutaneous 
puncture of the liver with intra-portal catheterisation. Despite the improvements in 
radiological techniques, there is still a significant risk of portal thrombosis and 
haemorrhage from the liver (Shapiro, Lakey et al. 2000; Ryan, Paty et al. 2005). This 
significant peri transplant risk is combined with the long term adverse effects of 
immunosuppression and will require further improvements to reduce the negative impact 
of islet transplantation.
The establishment of new islet transplant programmes throughout the world have a dual 
role in providing clinical care to diabetic recipients. The first and most important role is 
to establish a functioning clinical programme with repetition of the Edmonton 
experience. This usually requires duplication of the original protocols in order to avoid 
changing any key procedures of unknown significance which may impact on final 
outcome. Once a programme is established, the protocols should be further refined to 
optimise islet transplantation and provide an improved clinical procedure.
As part of my PhD studies I contributed to the clinical islet transplant programme at the 
Royal Free hospital and extended my experience of transplantation into the field of 
clinical islet transplantation. This provided a natural link from the basic science work 
through to the end result and challenge of clinical islet transplantation. I was heavily 
involved in the isolation, culture and transplantation of human islets as well as taking a 
major role in the work up, peri- and post transplant care of islet transplant recipients. 
This chapter documents some of the challenges and successes of establishing a clinical 
islet transplant programme within the United Kingdom and emphasises areas in which 
we have optimised the original protocol.
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7.2 History of the Roval Free clinical islet transplant programme
The clinical islet transplant programme at the Royal Free hospital was established in late 
2000 and started to receive human pancreases for islet isolation from February 2001. 
After mastering the basics of islet isolation and purification, the isolation process was 
transferred to an MHRA accredited laboratory in April 2003. Ethical permission for 
transplantation was granted in October 2003 (see Appendix 3 for ethics submission) and 
the isolation process was further refined and validated to product release criteria over the 
next two years. In March 2005, the first patient underwent islet transplantation and 
subsequently received a second infusion of islets in July 2005. In addition, a second 
patient was transplanted in May 2005 and a third in August 2005.
7.3 Donor pancreases for islet isolation
From February 2001 until the end of August 2005, 76 pancreases were offered to the 
programme at the Royal Free hospital (figure 7.1). Initially, the number of offers 
received was low (0.3 pancreas offers per month in 2001) but after a number of meetings 
and information sharing sessions with donor coordinators, the number of offers started to 
increase (1.8 offers/month in 2002, 1.3 offers/month in 2003, and 1.5 offers/ month in 
2004). Despite the increase in offers, the supply of donor organs was still slow and it 
was not until after our first transplant that the number of offers started to increase further 
(2.3 offers/ month in 2005 and 3.25offers/ month since the first transplant). The 
increased number of offers received subsequently highlighted the logistical problems of 
lab turnaround time and restocking. On the contrary, the increased supply allowed 
selection of donors for transplantation and acceptance of only good pancreases which 
resulted in a total of 15 pancreas offers being refused (figure 7.2).
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Figure 7.1: Average num ber of pancreas offers per month to the Royal Free islet 
isolation unit between November 2000 and August 2005. The black line represents 
the trend in the number of offers per month.
Date
Figure 7.2: Reasons for refusal of pancreas offers to the Royal Free islet isolation 
unit.
■  Lab not ready
■  Islets in culture
□  No staff
□  Donor unsuitable
■  Wrong blood group
□  NHBD
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7.4 Pancreatic islet isolation
Islets were isolated using a modified version of the automated technique (Ricordi, Lacy 
et al. 1988) which incorporated some improvements from the Edmonton protocol 
(Shapiro, Lakey et al. 2000) and modifications from our own observations. The main 
modifications we instituted were to use a collagenase and neutral protease mixture 
(Serva, Germany), rather than using Liberase HI (Roche Pharma, Germany) and run the 
digest temperature slightly lower with a second coil to cool the digest before harvesting. 
A number of other small changes were made within the process which included 
automated perfusion rather than syringe loading and DNAse washing, and are too 
numerous to describe in detail.
7.4.1 Islet yield from processed pancreases
A total of sixty three pancreases were accepted and processed between February 2001 
and August 2005. A number of pancreases, roughly five, were received but not suitable 
for processing due to damage to the organ (the exact figure was not recorded). A mean 
of 378,049(±38,796) IEQ were isolated from the 63 pancreases and a mean of 
200,105(±39,030) IEQ were purified from 29 of these preparations suitable for Cobe 
purification.
The initial isolations were poor and there was a steep learning curve for the technique of 
islet isolation, see figure 7.3. The purification of islets using the Cobe 2991 was a further 
hurdle but with time, the percentage of islets purified from the original digest increased 
and two purification runs were used per preparation in order not to overload the gradient.
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Figure 7.3: Islet equivalent yield from pancreas preparations over time. The red 
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7.4.2 Cooling of the Cobe 2991 centrifuge
The Cobe 2991 centrifuge, used to purify islets from the pancreatic digest, was designed 
20 years ago and was not originally intended to be refrigerated. The purification process 
is lengthy, roughly 20-25 minutes, and involves the use of non physiological density 
gradients with high osmolarity. During this process, islets are re-warmed and have an 
increased risk of enzymatic digestion from the proteolytic enzymes released from the 
exocrine fraction of the pancreas. The perceived benefit of cooling the digest during 
purification is a reduction in the proteolytic digestion of islets by exocrine enzymes and 
a reduced metabolism of islets while they are surrounded by the harsh environment of 
the ficoll density gradient. Therefore, cooling of the digest may help reduce the damage 
and cellular compromise during density purification and therefore improve islet health 
and viability.
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Professional refrigeration modifications are not only expensive (between US $5,000 -  
20,000) but may exceed the specifications of a class 1 cell separation unit. Therefore, a 
method was developed for cooling the Cobe 2991 using dry ice, which is relatively 
inexpensive and obviates the problems caused by a large air conditioning unit in a cell 
processing laboratory.
Initial inspection of the Cobe 2991 revealed a flow of air from the bottom of the 
machine, up through the bowl surrounding the rotor head and out via the gap between 
the top of the machine and the Perspex covers to the centrifuge bowl. It is this air flow 
that warms the machine during operation, as the air is drawn in from outside the 
machine over the hot centrifuge motor and subsequently into the centrifuge bowl. This 
flow of air is created by the centrifugal force generated by the spinning rotor head and 
initial modifications aimed at limiting the flow of air, in order to reduce warming of the 
centrifuge head (figure 7.4). The upwards flow of air was limited by placing a pre cut 
piece of polystyrene in between the rotor shaft and the bottom edge of the bowl.
Cold air was generated by passing air over carbon dioxide ice placed on a metal mesh 
within a piece of four inch plastic ducting. The mesh and tubing was attached to a hole 
in the Cobe lid above the centrifuge rotor head and the air flow was assisted by the use 
of a toilet extractor fan. The Cobe lid was further adapted by drilling a hole in the top 
and inserting a temperature probe into the centrifuge bowl, in order to monitor the air 
temperature within the centrifuge bowl.
The initial prototypes worked well but the temperature only reached 10-15°C and the 
carbon dioxide ice sublimed rapidly. The prototype was then modified further by sealing 
the gap between the lid and body of the centrifuge, to limit loss of cold air, and adding a 
second large hole to the centrifuge lid in order to recirculate the cold air and maintain 
the low air temperature. The two holes in the lid were placed at different distances from 
the rotational axis of the centrifuge head in order to benefit from the flow of air 
generated by the centrifugal force of the rotating centrifuge head (the inflow hole was 
close to the rotating axis and outflow hole was further from the rotational axis).
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These modifications improved the cooling device further and experiments, using saline 
loads onto the Cobe, proved that an air temperature of 0°C within the centrifuge bowl 
could be achieved, with fluid offloading temperatures of 10-12 °C. The device was 
further modified with a fan rheostat added to adjust the airflow across the dry ice and 
control the air temperature within the centrifuge bowl -  figure 7.5.
Experiments were subsequently performed on human islet preparations with pre-cooling 
of the centrifuge, followed by gradient and digest loading. Measurements were recorded 
of the air temperature within the centrifuge bowl, the temperature of the digest at loading, 
the temperature of the digest at offloading and the temperature of the bag after the 
purification run. Four runs with and four runs without the device were used- figure 7.6.
The room temperatures were not significantly different between the non cooling and 
cooling runs, 24.03°C vs. 23.97 °C (p=0.26) respectively. In the non cooling run, the 
Cobe air temperature during operation was slightly but not significantly higher than the 
room temperature, 24.02 °C vs. 26.44 °C (p=0.38) respectively. In the cooling runs, the 
Cobe air temperature during operation was significantly lower than room temperature, 
23.97 °C vs. 0 °C (p<0.001). The digest loading temperatures were not significantly 
different between the non cooling and cooling runs, 13.28 °C vs. 12.93 °C (p=0.213) 
respectively. In the non cooling runs, the digest temperature increased significantly 
during purification from 13.28 °C to 28.76 °C (p<0.001), which was also significantly 
higher than the Cobe air temperature (p>0.001). In the cooling runs, the digest 
temperature fell significantly during purification from 12.93 °C to 10.4 °C (p=0.033).
This data suggests that during the purification process, the temperature of the Cobe 2991 
machine increases without cooling. This increase in temperature, probably due to the 
heat generated by the by the motor and directly transferred up the shaft to the rotor head, 
increases the temperature of the digest during purification to a level above room 
temperature (28.76 °C). At this temperature, it is possible for exocrine enzymes to be 
activated and damage the islets within the preparation. The addition of the cooling
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device not only stopped this warming effect but reduced the temperature of the digest 
during purification. Unfortunately, viability and islet function is not available and the 
number of runs was too small to tease out any difference in yield during purification. In 
addition, concentrations of carbon dioxide in the islet isolation facility were not 
measured during the purification process.







■  Polystyrene - to stop flow of air past rotor shaft 
□  Draft excluder - to stop flow of air betw een lid and bowl
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Figure 7.5: Final prototype of the cooling device used for refrigerating the Cobe 
2991 centrifuge. The tubing is constructed from 4 inch ducting with the addition of 
a toilet extractor fan. Toilet flanges have been added to aid the removal of the top 
“u-bend” connector. The down pipe, containing dry ice, has been insulated by 
using a surrounding piece of 6 inch drainage pipe and cavity filler. The fan rheostat 
was added to control the flow of air across the dry ice and a temperature probe was 
added to measure the air temperature within the centrifuge bowl. The draught 
excluder can be seen under the Perspex lid.
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Figure 7.6: Temperatures achieved in the digest and centrifuge bowl with and 
without the cooling device. Values are presented as mean ± standard error.
45 ■ Room temperature
■ Cobe air temperature
□ Digest loading temperature
□ Digest offloading temperature
Cobe bag temperature
cooling With cooling device
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7.5 Clinical islet transplantation
Three patients underwent clinical islet transplantation, in the period until January 2006. 
All three patients were transplanted for hypoglycaemic unawareness and progressive 
secondary diabetic complications. They all received an islet alone transplant and all had 
normal renal function. The next section will describe the transplant and clinical course 
of the patients.
7.5.1 Islet recipient number 1
The first islet recipient was a 39 year old female who had diabetes since the age of seven 
She had poor control of her diabetes throughout the teenage and early adult life and had 
suffered with recurrent episodes of hypoglycaemic unawareness over the last 3 years, to 
the point that she was unable to go to the shops unaccompanied. This had great impact 
on her life and as a single mother, compromised her relationship with her two children. 
Her only other medical history was of hypothyroidism on thyroxine replacement.
On the third of March 2005, she underwent intra-portal islet transplantation and received
660,000 IEQ (12,200IEQ/Kg) of 88% viability. Portal puncture was uncomplicated and 
portal pressure rose to a maximum of 9mmHg. The initial post transplant course was 
unremarkable and she was discharged 4 days after the procedure. Her blood glucose 
concentrations did not drop rapidly but after two to three weeks her glycaemic 
variability started to reduce. Interestingly, she started to regain sensation of 
hypoglycaemic episodes within the first week and, although the symptoms were not 
similar to her previous hypoglycaemic warning, she was able to recognise 
hypoglycaemia again. Subsequently, her episodes of hypoglycaemia became much less 
frequent and she did not require any outside assistance.
Within two to three days of her transplant she developed abdominal discomfort which 
consisted of abdominal fullness and dull ache in her epigastric region. The discomfort 
was associated with a rise in liver enzymes which peaked at an ALP of 130U/1, AST of 
308U/1 and ALT of 222U/1. The clotting and other markers of synthetic function were 
not affected. The pain and abnormal liver function tests resolved by the second week
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post transplant. By day 5 post transplant the white blood cell count started to fall and 
septrin was stopped. The white blood cell count fell to 3.53 x l09/l after two weeks post 
transplant and slowly rose after that time.
Oral ulceration was a significant side effect in this recipient (figure 7.7) and she started 
to have difficult oral ulcers from one month post transplantation. The ulcers were 
initially treated with antiseptic and anaesthetic mouthwashes but this did not improve 
her symptoms. Advice was sought from the otorhinolaryngologists who suggested 
doxycycline mouth washes, as used for difficult recurrent aphthous ulceration in 
unimmunosuppressed patients. Not only did this not relieve her symptoms but she 
swallowed the mouthwash which led to inhibition of the metabolism of her 
immunosuppressants and subsequent high trough levels of the drugs. She was then 
switched to regular, three plus times per day, tooth brushing and topical steroid 
application. This settled her symptoms but she still had further ulcers. Swabs of the ulcer 
resulted in the isolation of herpes simplex virus 1 (HSV1) and she was subsequently 
treated with oral valacyclovir. At the same time, we stopped her atorvastatin, as there 
were reports that this drug exacerbated oral ulceration. The ulcers disappeared within 
one day but after the course of valacyclovir was finished, she was again troubled with 
oral ulcers. This culminated in an episode of oral ulceration with subsequent presumed 
bacterial sepsis, where the only identified portal of entry for infection was the ulcer 
(figure 7.7B).
The patient also developed further infections in her chest and ear. The ear infection was 
a particularly severe form of otitis externa (malignant otitis externa) which was caused 
by a Pseudomonas Aeruginosa infection and required inpatient stay and intra-venous 
antibiotics. During this time, her immunosuppression was stopped due to life threatening 
infection but was restarted on resolution of infection and after discussion with the patient.
The metabolic control improved but not dramatically. Her blood finger prick tests 
improved to readings of 8-9mmol/l from pre-transplant levels in double figures and 
glycated haemoglobin fell from 12.2% to 7.8%. Despite these improvements, her insulin
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dose was relatively unchanged and basal C peptide levels were only just recordable at 
98pmol/l and 128pmol/l. Despite the recurrent infections, the patient felt her life had 
been revolutionised and wished to continue immunosuppression. In view of the marginal 
results from her islet graft, she was re-listed for transplantation.
Figure 7.7: Oral ulceration in islet recipient 1. Image A) shows an aphthous ulcer 
on the base of the mouth under the tongue and closely associated with the 
submandibular salivary duct. Image B) shows an ulcer on the left lateral aspect of 
the tongue with a green discoloured base which is probably secondarily infected.
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On the 26th of July 2005, she underwent a second islet transplant carried out at the 
Churchill hospital in Oxford. The transplant was carried out in Oxford as the unit is part 
of a combined network with the Royal Free (FROX network). She received 280,000IEQ 
(5200IEQ/Kg) of 95% viability. The transplant was associated with difficult access to 
the portal vein but there was no significant procedural complication. Her blood sugar 
estimations improved almost immediately and improved to 5-7mmol/l within days of the 
transplantation and she had no further episodes of hypoglycaemia. Initial insulin doses 
were unchanged but gradually reduced to almost half her pre-transplant dose within 2 
months of her transplant.
Her subsequent course has been relatively uncomplicated although she has had further 
trouble with aphthous ulceration, acneform eruptions and an infected boil on her face.
She also suffered a single episode of graft dysfunction in association with low levels of 
immunosuppressants which responded to increased doses of insulin and tacrolimus. As 
of January 2006, she has well controlled blood sugars between 5-8 mmol/1, with a 
glycated haemoglobin of 7.4% and basal C peptide of 362pmol/l. Some of her 
biochemical parameters are outlined in figure 7.8.
The impact of the transplant was not only observed in the biochemical parameters and 
hypoglycaemic episodes. Due to her severe symptoms prior to the transplant, the 
recipient had formed a carer/dependent relationship with her partner. This was not 
obvious prior to the transplant but her partner would supervise her glycaemic control and 
check she was not hypoglycaemic during trips out of the house. As the patient was 
unable to go to the shops for fear of hypoglycaemia, the supervision was continuous and 
the patient relied heavily on her partner. After the transplant, the patient was able to 
pursue a normal life and started to socialise with her friends without the need for her 
partner to supervise her diabetes. This lead to her partner loosing his carer role and his 
attempts at supervision were deemed interfering. This situation led to the breakdown of 
the relationship and highlights the social and psychological impact of transplantation.
246
Figure 7.8: Selected parameters from recipient 1. The graph shows values for 
random blood glucose, glycated haemoglobin and insulin dose per day over time 
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7.5.2 Islet recipient number 2
The second recipient was a 52 year old female who had diabetes since the age of 18. Her 
control had been very erratic during her early twenties and she had subsequently 
developed background diabetic retinopathy and diabetic gastropathy. The variable 
emptying of her stomach and diarrhoea had made sugar absorption erratic which further 
complicated the timing of her insulin injections. Over the five years prior to her 
transplant she had reducing awareness of her hypoglycaemic episodes which eventually 
culminated in full blown hypoglycaemic unawareness.
On the 20th of May 2005, she received a single islet infusion of 360,000IEQ 
(6200IEQ/Kg) of 90% viability. The digest had an estimated purity of 40% and volume
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of 9ml. The transplant was performed under radiographic guidance and portal pressure 
rose from 4.5mmHg to 16mmHg. The procedure was uncomplicated and the patient was 
discharged after 4 days.
The second patient experienced abdominal fullness and nausea which was associated 
with a liver enzyme rise to at ALP of 264U/1, AST of 627U/1 and ALT of 476U/1. Once 
again, the total white cell count fell after the first week and bottomed out at 2.3x109/l 
after 11 days. This time, the white cell count took 5 months to return to normal, despite 
stopping septrin within the first week. With the lessons learnt from our first patient and 
the HSV1 isolated from the mouth swabs, the patient was given valacyclovir 500mg per 
day and mouthwashes as prophylaxis for mouth ulcers. She suffered with a single small 
ulcer 4 weeks after her transplant which healed quickly with topical steroid cream and 
has not had any further oral ulceration.
The control of her diabetes improved almost immediately and her hypoglycaemic 
awareness returned within 7 days of transplantation. Her blood sugar estimations were 
between 5-8mmol/l within 4 weeks of transplantation. Her insulin doses were reduced 
after two weeks and she stopped all soluble insulin two months after transplantation. As 
of January 2006, she takes 4 units of glargine per day and on occasions has forgotten to 
take the insulin but has achieved normal glucose estimations for the following days. The 
long acting insulin has not been stopped as it is hoped that the basal insulin will reduce 
the metabolic stress/glucose toxicity to the islets and hopefully prolong the life of the 
graft. The basal C peptide was positive within one month of transplantation at 333pmol/l 
and has maintained around 300pmol/l on further sampling. Some of the metabolic 
parameters are outlined in figure 7.9.
In addition to the single mouth ulcer and leucopoenia, the second recipient has two 
episodes of cellulitis following trauma, one after an iron bum and one after a cut to the 
leg. The only other potentially more serious complication relates to her renal function.
At the time of transplantation the patient had a creatinine of 85pmol/l (correlating to an 
estimated GFR by Cockcroft and Gault formula of 60ml/min) and a normal albumin
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creatinine ratio of 0.54g/mmol. After her transplant, her creatinine has risen to an 
average of 95-100pmol/l, despite reducing the tacrolimus dose to achieve trough levels 
~3ng/ml. The rise in creatinine was also associated with an increase in the albumin 
creatinine ratio which has been between 8.6 and 11.4g/mmol. It is unclear whether this 
effect is due to her immunosuppression but recent publications have suggested that 
sirolimus may be the cause (Senior, Paty et al. 2005). At present she is being observed 
with a view to renal biopsy or switch to mycophenolate mofetil if the situation 
deteriorates.
Figure 7.9: Selected parameters from recipient 2. The graph shows values for 
random blood glucose, glycated haemoglobin and insulin dose per day over time 
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7.5.3 Islet recipient number 3
The third recipient was a 49 year old female who had developed diabetes at the age of 16. 
Her control was generally good but she suffered with diabetic retinopathy which 
required laser treatment and autonomic neuropathy which manifested itself with postural 
hypotension (ECG at the time of work up showed no R-R variation with forced 
respiration). She also suffered with hypoglycaemic unawareness which limited her daily 
activities and subsequent metabolic control was poor due to fear of hypoglycaemia. 
Independent of her diabetes, she suffered with recurrent oral and genital herpes and had 
a hysterectomy in 1988 for CIN I and menorrhagia.
On the 24th of August 2005, she received an islet infusion of 700,000IEQ 
(11,900IEQ/Kg) of 97% viability. The portal vein cannulation was difficult and 
associated with pain. The patient also received a higher dose of heparin due to intra­
cannula heparin being given with heparin in the bag with the islet transplant. These 
occurrences culminated in a large intra-abdominal haemorrhage of 2-3 units which was 
associated with profound (80/40) hypotension, in the absence of reflex tachycardia 
caused by her autonomic neuropathy. Her bleeding resolved spontaneously and 
subsequent radiological imaging did not show any evidence of hepatic bleeding. She had 
a 2 unit transfusion after her haemoglobin fell to 8.4g/dl and luckily, subsequent 
Luminex analysis has not shown any indication of sensitisation.
The third recipient also experienced epigastric pain and fullness for 10 days after the 
transplant which was associated with a rise in liver enzymes to an ALP of 156U/1, AST 
of 128U/1 and ALT of 187U/1. The white blood cell count fell to 2.53xl09/l by 2 weeks 
after the transplant but has slowly risen back toward normal with no change in therapy 
and without stopping the prophylactic agents. Due to her history of previous oral and 
genital herpes and the experience with the first patient, the third recipient also received 
HSV prophylaxis with valacyclovir. For three months after her transplant, she did not 
have any evidence of genital or oral ulceration but has had one or two small oral ulcers 
since.
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Despite the large dose of islets infused, her glycaemic control has only improved 
marginally and she still has episodes of hypoglycaemia, although less severe than before 
her transplant. Her basal C peptide remains undetectable and it is unclear whether her 
graft is functioning at all. She has not been sensitised by the transplant and does not have 
detectable islet antibodies post transplant; either by screening luminex or PRA analysis. 
Therefore, it is presumed that her graft was irreversibly damaged at the time of 
transplantation due to her episode of hypotension and poor hepatic perfusion. Some of 
her metabolic parameters are highlighted in figure 7.10.
Four months after her transplant, she developed some oral ulceration and has more 
recently developed an acneform eruption on her hands and face. Both of these 
occurrences are recognised side effects of Sirolimus treatment and, as of January 2006, 
her Sirolimus was discontinued because she had side effects of immunosuppression 
without the benefits of a functioning graft. The Tacrolimus therapy has been retained in 
order to reduce the risk of alio sensitisation and as of February 2006, she is still awaiting 
a further transplant.
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Figure 7.10: Selected parameters from recipient 3. The graph shows values for 
random blood glucose, glycated haemoglobin and insulin dose per day over time 
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Despite the successes of the Edmonton protocol, the UK has lagged behind the rest of 
the world and, as of March 2006, only 20 islet transplants have ever been performed in 
the UK. Our data has shown that islet transplantation can be established in the UK and 
the successes of the Edmonton protocol can be transferred to other units. The 
development of our programme has involved a steep learning curve for the isolation of 
islets which has required centre specific alterations to the protocol. The change in 
enzyme blend, circuit design, DNAse addition, temperature control, purification and 
pancreas handling have all lead to a gradual increase in islet yields which have 
culminated in successful islet transplants. Despite our own and world wide successes, 
islet transplantation is still an imperfect clinical tool and work is still required to 
improve the yield of islets from whole pancreases, reduce post transplant p-cell loss, 
improve long term immunosuppression regimes and prolong graft survival.
7.6.2 Clinical islet transplantation
The first step in establishing a clinical islet transplant programme is to achieve a 
minimal standard of success through reduplication of the Edmonton experience. Our 
three patients had a full range of experience from probable primary non function through 
to the first single donor to recipient success in the UK. Our first two recipients achieved 
dramatic reductions in their insulin doses which was associated with initial sensing of 
hypoglycaemia and, as their insulin dose was reduced, abolition of hypoglycaemia. The 
life altering impact of these achievements can not be underestimated and this is reflected 
in a reduction of fear of hypoglycaemia scores (data not presented) and improvements in 
quality of life. Our first recipient has been transformed from a patient who was 
housebound from her diabetic complications to an unrestricted individual who is able to 
enjoy boundless social interaction, unfortunately to the detriment of her obvious carer 
patient relationship. Islet transplantation should therefore not be viewed purely as a tool 
for improving diabetic control but as a method for improving quality of life in patients 
with the severe secondary complications of their type 1 diabetes.
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The post transplant outcome for our patients was variable but probably reflects the 
worldwide experience of replicating the Edmonton protocol. A certain level of success 
and failure is to be expected when transferring an established technique to another unit 
and comparison with other islet transplant centres is required. The interim data from the 
Immune Tolerance Network trial (presented by James Shapiro at the American 
Transplant Congress in 2004) provides a bench mark for the level of success to expect 
when the protocol is adopted world wide. The data for the first 36 recipients in the trial 
has shown that 53% of patients achieve insulin independence after one to three islet 
grafts and a further 19% have abolition of hypoglycaemia and improved metabolic 
control on reduced doses of insulin. Technical and transplant related failure rate can be 
expected and the trial reported a 17% primary non function rate with an additional 11% 
of patients withdrawing from transplantation due to side effects (Shapiro, Ricordi et al. 
2004).
Our transplant protocol was modified from the original Edmonton publication and most 
of the changes were made to the isolation process. One important change was the use of 
islet culture prior to transplantation which may have affected the clinical outcomes of 
islet recipients. The original Edmonton protocol attempted to transplant islets as fresh as 
possible (Shapiro, Lakey et al. 2000) but subsequent publications suggested that a period 
of static culture may improve islet purity (Froud, Ricordi et al. 2005; Wamock, Meloche 
et al. 2005). Our protocol incorporated a period of culture in order to improve islet purity, 
allow detailed microbiological assessment of the preparation and enable the transplant 
procedure to be performed during daytime working hours. Although a period of islet 
culture may have resolved logistical issues related to transplantation, it is possible that 
this may have adversely affected the outcome in our transplant recipients and subsequent 
publications (King, Lock et al. 2005; Olsson and Carlsson 2005) have shown that culture 
prior to transplantation may negatively affect glucose resolution in experimental 
transplant models. Therefore, subsequent islet transplants should probably be performed 
as fresh as possible and only incorporate a very brief period of culture long enough for 
rapid assessment of the graft and organisation of transplant logistics.
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7.6.3 Complications of islet transplantation
Islet transplantation is a relatively safe procedure when compared to other transplant 
techniques. The main procedural complications are related to bleeding and portal vein 
thrombosis (Shapiro, Lakey et al. 2000; Ryan, Paty et al. 2005) and a fine balance exists 
between thrombosis and the risk of anti-coagulant induced haemorrhage. One of our 
recipients suffered an intra peritoneal haemorrhage which probably contributed to the 
loss of her islets. This complication was possibly related to the dose of anti-coagulant 
she received and we have subsequently modified our protocol. The intra-peritoneal 
haemorrhage also raised the issue of cardiovascular disease and screening in our patient 
work up. All patients were initially required to have a formal stress echo cardiogram and 
subsequent evaluation of coronary arteries, if necessary. With the delay of stress echo 
appointments and the first two uncomplicated transplants, this policy was reconsidered. 
Our third recipient had a normal myocardial perfusion on stress testing. When she bled, 
her diabetic autonomic neuropathy meant she did not mount a tachycardia with her 
hypovolaemia and her bleeding was only diagnosed when her blood pressure dropped 
precipitously. This situation highlights the hazards involved with transplanting high risk 
patients and the necessity for full cardiovascular work up in patients who may have 
silent cardiac ischaemia. If this patient had had significant undiagnosed coronary 
vascular disease at the time of her transplant and bleed, she may have suffered a stress 
induced myocardial infarct which could have had significant impact on her survival and 
the progression of our programme. In view of this patient’s complication, the policy of 
full cardiovascular evaluation is currently maintained prior to transplantation.
The greatest risk from islet transplantation relates to the use of long term 
immunosuppression and all patients should be fully informed of the risks. The main 
complications we encountered were related to the side effects of sirolimus. All patients 
developed mouth ulcers post transplant and one recipient required hospitalisation from a 
secondarily infected ulcer. The ulceration was so severe in one case that the first 
recipient was unable to eat for two to three days. Mouth ulceration is a common side 
effect of sirolimus use (van Gelder, ter Meulen et al. 2003) and occurs in up to 20% of 
kidney recipients taking 5mg of sirolimus per day (MacDonald 2001) and 89% of
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patients on the Edmonton protocol (Ryan, Paty et al. 2005). There is an association 
between sirolimus use and the frequency of herpes infections (Kahan 2000) although not 
all ulcers were proven positive for herpes on culture or biopsy (MacDonald 2001). Our 
first patient responded well to anti-viral therapy after a positive HSV swab and 
subsequent patients had limited ulceration on valacyclovir prophylaxis, suggesting a 
possible causative link with HSV.
The other side effects encountered with sirolimus were ankle oedema, anaemia, 
lymphopenia, acneform rash requiring discontinuation of the drug and microalbuminuria. 
The microalbuminuria and proteinuria is a serious complication of sirolimus use and is 
worse if patients have underlying urinary protein abnormalities prior to sirolimus 
initiation (Senior, Paty et al. 2005). Although the urinary protein abnormalities reverse 
on withdrawal of the drug (Senior, Paty et al. 2005), there is an associated reduction of 
renal function that does not appear to be reversible.
The increasing list o f side effects and the anti-angiogenic properties of sirolimus (Guba, 
von Breitenbuch et al. 2002) have thrown doubt over whether it is the right agent for 
islet transplantation. The drug was successful in achieving a steroid free 
immunosuppression protocol and a number of transplant centres initially moved to copy 
the Edmonton experience. The time has probably come to look at other 
immunosuppression agents and mycophenolate mofetil or campathl-H may be the 
solution to the side effects of sirolimus.
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7.7 Conclusions
Our experience with islet transplantation has confirmed that islet transplantation can be 
established in the UK using the Edmonton protocol. The protocol still requires further 
optimization in order to successfully achieve insulin independence in a recipient from a 
single donor pancreas and reduce the short and long term side effects of transplantation. 
The long term resource issues need to be addressed and central funding is required for 
this clinically important technique to survive in the UK.
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Chapter 8 — Discussion
8.1 Background and aims
Diabetes is a common disease which has important implications for healthcare providers 
around the world. The increasing incidence of both type 1 and type 2 diabetes will have 
a major financial and social impact on the global population (King, Aubert et al. 1998; 
Onkamo, Vaananen et al. 1999) which will probably be due to the effect of the 
secondary complications and disability caused by diabetes, rather than the direct effects 
of diabetes treatment (ADA 2003).
The secondary complications of diabetes are associated with poor glycaemic control and 
improving control can reduce their incidence (DCCT 1993). Unfortunately, achieving 
this goal is difficult and is associated with life threatening episodes of hypoglycaemia. 
Transplantation of islets, either in association with a whole pancreas or as islets alone, 
provides a method for achieving excellent metabolic control without the associated risk 
of hypoglycaemia (Robertson, Sutherland et al. 1996; Shapiro, Lakey et al. 2000). Islet 
transplantation is now an established treatment for type 1 diabetic patients with severe 
secondary complications (Shapiro, Lakey et al. 2000) but is limited by the large quantity 
of islets needed to induce insulin independence and the poor long term graft survival; 
under 10% insulin independent at five years (Ryan, Paty et al. 2005). These two 
interrelated issues remain the stumbling blocks of islet transplantation and their 
resolution should ensure a more widespread uptake of this important clinical tool.
The short and long term insulin independence rates are probably dependant on the early 
survival of islets within the peri- and immediate post transplant period. The high level of 
graft loss immediately post transplant (Biames, Montolio et al. 2002) is probably related 
to a lack of functional vasculature, the time taken to reform a new network of blood 
vessels (Vajkoczy, Menger et al. 1995) and the low partial pressure of oxygen achieved 
within the islets (Carlsson, Palm et al. 2002). If the revascularisation process could be 
targeted in order to accelerate the revascularisation process and improve oxygen delivery
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to the islet, it may be possible to reduce the immediate loss of islets post transplantation 
and improve long term outcomes.
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8.2 The revascularisation of intra-portal transplanted islets
8.2.1 Introduction
Islet revascularisation is an essential step in the engraftment of transplanted islets.
During this important process, a high percentage of transplanted islets are lost and 
successful revascularisation probably holds the key to initial and long term outcomes. A 
better understanding of revascularisation is required to improve engraftment and 
hopefully improve clinical outcomes so that more patients can be transplanted with the 
small number of donated pancreases available.
8.2.2 Models of transplanted islet revascularisation
The investigation of transplanted islet revascularisation depends on a good model of islet 
transplantation that provides both parallel conditions to clinical methods and allows the 
evaluation of scientifically important parameters. The different models used have their 
own individual strengths and weaknesses which guide the investigator to choose the 
model most relevant to their individual research.
Kidney subcapsular methods of islet transplantation provide a well vascularised site of 
engraftment for islets with easy retrieval o f the entire graft. The kidney subcapsular 
model has proved popular for the assessment of mRNA (Vasir, Jonas et al. 2001), 
oxygen tensions (Carlsson, Palm et al. 2000) and vascular density (Carlsson, Palm et al. 
2002) within transplanted islets and has been used for the assessment of human islets 
transplanted into immunodeficient mice (Carlsson, Palm et al. 2002). Dorsal skin fold 
models of islet transplantation provide a further site for transplantation which allows 
easy retrieval of the entire graft and also presents a useful tool for direct in-vivo 
visualisation of graft revascularisation in real time (Vajkoczy and Menger 1995).
The limitation of these transplant models lies in the lack of clinical relevance, as most 
clinical islet transplants are performed intraportally, and the clumping of cells after 
transplantation rather than wide dispersal throughout a vascularised organ. The clumping 
of transplanted islets increases the diffusion distances for molecules and may alter the
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conditions relevant to islet engraftment. Although intra-portal transplant models obviate 
these problems, they are limited by the lack of full retrieval of the graft and the wide 
dispersal of islets which makes histological analysis of transplanted islets difficult. The 
right branch transplant model, as developed within our laboratory (Juszczak M 2003), 
has improved the density and histological recovery of transplanted islets within liver 
sections and we have been able to visualise an average of 4.5 islets per liver section.
This model was further extended by the use of dual BS-1 and insulin staining to allow 
both qualitative and quantitative analysis of islet vascular architecture and track the 
revascularisation of transplanted islets within the liver. Therefore, the current model 
enables better sampling and analysis of islets within the more clinically relevant 
transplant intra-portal transplant site.
8.2.3 Revascularisation of intra-portal transplanted islets
The complex vascular network of native islets is disrupted during isolation from the 
whole pancreas and islets reform a new blood supply from the surrounding tissue 
(Andersson, Korsgren et al. 1989; Vajkoczy and Menger 1995). Passenger endothelium 
within the islet starts to disappear during the first few days post transplant (Furuya, 
Kimura et al. 2003) and new vessels invade the islet to form a new network of vessels. 
Revascularization is initiated by capillary sprouting between day 2 to 4, which results in 
fusion of vascular channels by day 6 post transplantation and eventual formation of a 
glomerulus like network of blood vessels (Vajkoczy, Menger et al. 1995). Complete 
revascularization of islets has been estimated to occur by day 10-11 post transplantation, 
irrespective of whether the islets are transplanted into the liver (Griffith, Scharp et al. 
1977) or the dorsal skin fold (Vajkoczy, Menger et al. 1995).
The initial stage of islet revascularisation is a reduction in islet endothelium which is 
followed by the formation of a new vascular network. The initial reduction of 
endothelial staining has been observed by a number of authors (Griffith, Scharp et al. 
1977; Furuya, Kimura et al. 2003; Nyqvist, Kohler et al. 2005) and is demonstrated here 
by the fall in percentage of islet comprised of endothelium and reduction in vascular 
density over the first few days post transplant. The revascularisation of transplanted
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islets was initially shown to arise from cells of host origin (Vajkoczy and Menger 1995) 
and it was assumed that donor endothelium, within islets at the time of transplantation, 
was lost early after transplantation and did not play any role in the new vascular network. 
Subsequent work has shown that isolated islets suspended in fibrin gel can form 
endothelial sprouts from the islet core without the need for host tissue and suggests that 
donor islet endothelium does not necessary disappear after isolation (Linn, Schneider et 
al. 2003). The same publication described the use of a transgenic mouse with a Tie2- 
LacZ reporter construct which enabled visualization of donor endothelium in islet grafts 
up to 3 weeks after transplantation (Linn, Schneider et al. 2003) and lead the authors to 
conclude that the endothelium was not lost but may have dedifferentiated after isolation 
and subsequently redifferentiated to participate in the revascularization process. This 
theory was further substantiated by the use of a Tie-2 gfp (green fluorescent protein) 
mouse which is characterized by endothelial expression of gfp. Cultured islets from this 
animal show a reduction in islet endothelium, as indicated by the loss of CD31 
expression, over time but culture encouraged the appearance of a population of CD31 
negative/gfp positive cells, suggesting that the islet endothelium may have 
dedifferentiated and lost its CD31 cell surface marker (Nyqvist, Kohler et al. 2005). The 
islets from this transgenic mouse were then transplanted into athymic nude mice and 
were found to have islet endothelium expressing gfp after revascularization, suggesting 
that the donor endothelium survives after transplantation to participate in the new islet 
vascular architecture (Nyqvist, Kohler et al. 2005). These experiments imply that islet 
endothelium may dedifferentiate during the early stages of engraftment and loose its cell 
surface markers before redifferentiating during revascularization, in order to contribute 
to the new islet vasculature. Therefore, the early reduction in BS-1 staining after 
transplantation may not represent loss of endothelium but may be due to the loss of 
endothelial carbohydrates specific for the binding of BS-1, caused by endothelial 
dedifferentiation. Unfortunately, the Y chromosome FISH was not suitably robust to use 
for analysis of islet endothelial origin and it is not possible to speculate whether these 
cells subsequently redifferentiate to take part in revascularisation.
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The assessment o f islet revascularisation, presented here, agrees with previous 
descriptions but suggests that islets are revascularised at an earlier time point and may 
already be revascularised as early as day 5 post transplantation. The period between day 
five and fourteen are probably associated with a consolidation of vascular architecture, 
as seen by the rise in vascular density and branching index, and is most likely to 
represent a period of formation of the multibranching glomerular network.
The changes in vascular architecture continue up to 30 days post transplant and suggest 
that vascular remodelling is still ongoing at this time point. The experiments were not 
continued beyond 30 days post transplant and it is therefore impossible to say whether 
further remodeling occurs after this time point. If the fresh group from the 350 islet 
desferrioxamine treatment experiments are taken into account, the results would suggest 
that although the size of islets are not significantly different, the vascular density and 
branching index of freshly transplanted islets after 11 weeks is significantly less than at 
day 30; grid density after 11 weeks- 2328vessels per mm2 vs. 3172 vessels per mm2 at 
30 days (p>0.01) and 0.76 vs. 0.87(p>0.01) respectively. Interestingly, when the fresh 
islets from the 350 islet experiments are compared to native islets, the vascular density is 
higher in the transplanted islets but the branching index is the same; grid density after 11 
weeks- 2328 vessels per mm2 vs. 1826 vessels per mm2 in native islets (p>0.01) and 
0.76 vs. 0.77 (p=0.94) respectively. These comparisons would suggest that further 
remodeling does occur with time and the vascular architecture changes back toward that 
found in native islets.
One note of caution for this extrapolation is that the dose of islets in the control culture 
group from the desferrioxamine treatment experiments was much smaller than that used 
for the revascularisation experiments; 350 islets in the DFO experiments compared with 
an average of 752 islets in the revascularization experiments. This factor may have 
affected engraftment and revascularization, as it has been proven that engraftment may 
be effected by early glycaemic control (Biames, Montolio et al. 2002), although other 
authors suggest have suggested that early glycaemic control does not effect vascular 
density (Mattsson, Jansson et al. 2003).
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8.2.4 Methods for assessing vascular density
The experimental comparison of islet engraftment requires a quantitative method for 
analysing vascular architecture between different experimental groups. Vascular density 
is frequently used to assess the engraftment of islets after transplantation and higher 
values have been suggested to denote improved islet engraftment. The measurement of 
this parameter is not standardized and the vascular density of transplanted islets has been 
assessed using a number of different methods. The two main methods either assess the 
total length of vessels per islet area (Vajkoczy and Menger 1995; Beger, Cirulli et al.
1998) or the number of vessels per area. These two methods produce different numerical 
results which can not be directly compared but within each method they provide 
comparative data to explore the effect of different experimental conditions.
The question remains whether one or other technique is more reproducible between 
different groups and which is less likely to be subject to operator bias. This situation has 
been investigated within malignant tumors (Weidner, Semple et al. 1991; Goddard, 
Sutton et al. 2001; Vermeulen, Gasparini et al. 2002; Sharma, Sharma et al. 2005) and 
the consensus amongst pathologists suggests that most use a modified system based on 
the original description by Weidner (Weidner, Semple et al. 1991). Weidner described a 
method for identifying a “hotspot” (area of increased vascular density within a tumour) 
and counting the number of vessels within a 200x field which were stained for factor 
VIII. The microvascular density was subsequently found to have positive correlation to 
metastatic spread of breast tumours (Weidner, Semple et al. 1991). A modification of 
this system, using the islet as the hotspot area, has been used here and by other authors 
(Carlsson and Mattsson 1993; Mattsson, Jansson et al. 2002). The problem with this 
system relates to observer bias when counting vessels and whether two adjacent stained 
structures represent the reflection of a single vessel or two separate vessels. One 
suggested method for overcoming this bias is to use a grid, where the density is 
calculated by counting grid hits (stained vessels crossing a part of the grid) per area.
This system has been suggested to reduce bias and has been positively correlated with 
outcome in breast cancer (Fox, Leek et al. 1995). A modification of this system was also
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used here for the assessment of vascular density and gave a different perspective to the 
examination of islets vascular architecture.
The vessel count method indicates the number of vessel branches per area but non 
branching vessels score low using this system. The grid method will calculate a higher 
score for the same islet with non branching vessels but an islet with small branching 
vessels, as seen in a glomerular like network, will score more equally with the two 
systems. This observation allowed the analysis of the islet vascular network by 
comparing the two methods and calculating the branching index, with higher values 
suggesting a greater degree of branching. The result generated by the branching index 
shows a good correlation with the gross morphology of islet vascular architecture and 
changes in an expected and progressive way during engraftment. This would suggest 
that the branching index, in addition to vascular density, provides useful information for 
assessing islet vascular architecture during engraftment.
The current evaluation of transplanted islet revascularisation relies on the assessment of 
gross islet morphology and vascular density but it is unclear whether these techniques 
are the most appropriate methods to assess revascularization. The field of islet 
revascularization could learn a great deal from the oncology pathologists who, like islet 
researchers, study the vascularisation of metastatic tissue. The question remains whether 
the state of differentiation or composition may be a better indication of vasculogenesis 
than purely measuring the number of blood vessels per area (Vermeulen, Gasparini et al. 
2002). Therefore, the analysis of different cell surface markers or surrounding 
supportive cells may give a better indication to how well an islet has revascularised 
rather than purely assessing vascular density.
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8.2.5 Vascular density in native and transplanted islets
Islet engraftment is a complex process and requires the formation of a new vascular 
network. When the islets have fully engrafted, the new vascular supply is poor when 
compared to that found in native islets and oxygen tensions within transplanted islets are 
lower than those found in native islets (Carlsson, Palm et al. 2000; Carlsson, Palm et al.
2002). In addition, the vascular density of transplanted islets has been reported to be 
lower than in native islets (Carlsson, Palm et al. 2002; Mattsson, Jansson et al. 2002; 
Mattsson, Jansson et al. 2003), suggesting poor revascularization of transplanted islets. 
These observations are in contrast to the data presented here which suggests that 
although the vascular density falls immediately after transplantation, it returns to normal 
and subsequently overshoots to a level above that found in native islets.
The numerical and gross observation of intra portal transplanted islets presented here 
does not suggest that islet vascular density is reduced after revascularization has 
occurred. Before considering the reasons for this discrepancy with reported literature, 
the methodology should be examined to exclude errors in assessment. Firstly, the 
staining of transplanted islet endothelium is difficult (Mattsson, Carlsson et al. 2002) 
and any differences in staining between transplanted and native islet endothelium could 
lead to a discrepancy. This cause for error would seem unlikely as endothelial staining 
within native islets was bright and there were no obvious unstained areas which could 
have correlated with endothelium. In addition, the numerical data presented for native 
islets (1358 vessels per mm2 in native islets) is similar to the values from other authors 
using a similar methodology (-1300 vessels per mm2) (Mattsson, Jansson et al. 2002) 
and it is unlikely that either the staining or density assessment methodology is the cause 
of the discrepancy between native and revascularised transplanted islets.
If the methodology for assessing vascular density is not the cause for the difference, why 
is there a discrepancy? One possible explanation for the discrepancy is the model of 
revascularization used to investigate islet transplantation. Most of the studies have been 
performed using kidney subcapsular models of islet transplantation (Carlsson, Palm et al. 
2002; Mattsson, Jansson et al. 2003). This model involves clumping the entire graft
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together under the kidney capsule and does not distribute the tissue widely throughout 
the organ. It is possible that this clumping not only leads to increased diffusion distances 
for important molecules but also reduces contact with the host tissue and local growth 
factors which are vital for new vessel formation. This situation is highlighted by the 
connective tissue seen around islets implanted beneath the kidney capsule which is not 
seen when islets are transplanted into the liver (Mattsson, Jansson et al. 2002). The 
contact of cells with endothelium is important for angiogenesis and in a model of cancer 
metastases, it has been shown that the contact of tumor cells with endothelium is 
important for metastasis proliferation, migration and early vessel formation (Barrett, 
Mangold et al. 2005). In addition, endothelial I-CAM 2 has been shown to regulate 
angiogenesis (Huang, Mason et al. 2005) and it may be that islet-endothelial interaction 
is important for engraftment and subsequent revascularization. Islet endothelium 
interaction is not present in islets that have been transplanted under the kidney capsule 
and may give a false indication of revascularization when compared to islets 
transplanted into the liver.
The reduced contact of endothelium with transplanted tissue does not explain the lower 
vascular density found in intra portal transplanted mouse islets, compared to native 
mouse islets, in the paper by Mattson and his colleagues (Mattsson, Jansson et al. 2002). 
The reason for this is unclear as dual insulin and BS-1 immunohistochemistry staining 
was used on consecutive sections, in order to localize islets within the liver. 
Unfortunately, the example shown in the paper does not show any endothelial staining 
within the intra-portal transplanted islet and it is difficult to judge the pattern of 
revascularization in their model. The other important factor may have been the use of 3- 
4 days islet culture prior to transplantation, which has subsequently been shown to 
reduce vascular density after transplantation when compared to non cultured islets 
(Olsson and Carlsson 2005).
The question of whether intraportally transplanted islets do have a lower vascular 
density requires further clarification with additional studies. If the observations here are 
reproducible, the next issue is why the vascular density of transplanted islets is higher
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than that found in native islets. This probably relies on how islets revascularise and how 
endothelium knows where to proliferate before forming new vessels. The imaging of 
islets early during revascularization suggested there may be spaces left between the beta 
cell mass by endothelium which had regressed or dedifferentiated. As the islets 
revascularise, it may be that new endothelium grows back along the old vascular 
channels, possibly on remnant basement membranes from the native vasculature. If this 
were the case, the number of vessels within the islet would remain the same but the area 
of the islet would be reduced due to loss of beta cell mass during engraftment, therefore 
leading to an increase in measured vascular density in transplanted islets when compared 
to native islets. However, this does not explain the doubling of vascular density from 
1358 vessels per mm2 in native islets to 2715 vessels per mm2 in day 30 islets, as the 
loss in islet area between these time points is only 18%. Even when the differences 
between three dimensional structures and two dimensional sampling are taken into 
account, this theory does not explain the increase in vascular density.
All measured indices of islet vascular anatomy were different between native and day 30 
transplanted islets which suggest that transplanted islet vascular architecture is 
completely different from native islet architecture. In this case, it is probable that 
endothelium does not regrow down the predetermined channels left when the native islet 
endothelium regressed but the intense hypoxic signal within islets causes extensive 
random endothelial ingression into the islet. This intense revascularisation may account 
for the increased percentage islet endothelium and vascular density seen within 
transplanted islets but the size of islets and locality to blood supply would be unlikely to 
induce such an intense hypoxic response. If a parallel with malignant tumour growth is 
examined, the average islet of 150pm diameter is well below the 1mm diameter of 
maximal avascular tumour growth (Gimbrone, Leapman et al. 1972) and the 100pm 
diffusible distance for oxygen (Helmlinger, Yuan et al. 1997). Nevertheless, small 
tumours of 100-200pm still induce angiogenesis from host vasculature when implanted 
into well vascularised sites, with vascular densities similar to that of the surrounding 
tissue (Vajkoczy, Farhadi et al. 2002). Interestingly, when Vajkoczy used the same nude 
mouse model for studying the revascularisation of islets (Vajkoczy, Menger et al. 1995),
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the functional capillary density within islets (650-700cm1) was twice that found on the 
striated muscle (300cm1) in the tumour revascularisation paper suggesting that islets 
may have a greater angiogenic capacity when implanted into foreign tissues. 
Unfortunately, the islet transplant paper (Vajkoczy, Menger et al. 1995) did not describe 
any analysis of or comparison to the functional capillary density of the underlying 
muscle bed and it is impossible to fully validate this conclusion.
The environment into which tumours are implanted has an influence on their growth and 
outcome (Radinsky and Ellis 1996) with different implantation sites directly affecting 
vascular architecture (Fukumura, Yuan et al. 1997; Bemsen, Rijken et al. 1999). The 
vascular architecture of the liver is complex and blood from portal venules and hepatic 
arterioles drains through the hepatic sinusoids into the hepatic venules (Oda, Yokomori 
et al. 2003). The factors controlling and maintaining the development of this complex 
vascular architecture have not been fully elucidated but probably require the balance of 
local growth factors such as VEGF and pigment epithelium derived factor (Gouysse, 
Couvelard et al. 2002; Sawant, Aparicio et al. 2004). It is possible that the liver specific 
balance of these local growth factors may also regulate the vascular architecture of non 
malignant implanted tissue and may explain why the islet architecture changes after 
transplantation into the liver.
The liver is highly vascular and receives 30% of cardiac output from its dual blood 
supply but the oxygen tension within the main portal vein of air breathing rats is low 
(~38mmHg) (Hughes, Yang et al. 2004) and subsequent hepatic parenchymal oxygen 
levels have been reported to be even lower at 4 - 16 mmHg (Mucke, Richter et al. 2000; 
Carlsson, Palm et al. 2001). Therefore, the oxygen tension within the normal liver 
parenchyma is close to the 10-15mmHg necessary for 50% maximal induction of HIF-1 
found in HeLa cells (Jiang, Semenza et al. 1996) and the 9mmHg necessary for the 50% 
maximal induction of VEGF, measured within the same cell line (Chiarotto and Hill
1999). The low oxygen tension within the liver (4mmHg) contrasts with values of 
13mmHg and 30mmHg reported in the same paper for the renal cortex and exocrine 
pancreas, respectively (Carlsson, Palm et al. 2001). Although the values for tissue
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oxygen tension reported in the paper by Carlsson are lower than those reported by other 
authors (Schurek, Jost et al. 1990; Mucke, Richter et al. 2000), the important comparison 
is the constant half to two thirds lower oxygen concentration in the liver compared to the 
kidney. The lower oxygen concentrations within the liver may suggest why there is a 
greater hypoxic drive to revascularisation when islets are transplanted into the liver 
when compared to the more commonly used renal subcapsular model.
8.2.6 Conclusions
Transplanted islet revascularisation is a complex process which occurs in a stepwise 
fashion from initial reduction in endothelium through to reformation of a new and 
increased vascular network. This process is quantifiable and the novel methods 
described here can be used for the assessment and comparison of islet revascularisation 
under different experimental conditions. The final vascular density reported here is 
higher than that found in native islets and this contrasts to previous reports. This 
difference in vascular density can probably be explained by the differences in models 
and manipulation of islets prior to transplantation. Although a higher vascular density in 
transplanted islets is unusual, this may be explained by the implantation of islet tissue 
into a different and more hypoxic tissue than its native environment.
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8.3 Desferrioxamine treatment of islets
8.3.1 Effect of desferrioxamine treatment on isolated islets
Desferrioxamine has been successfully used for the treatment of transfusion dependent 
iron overload since the early 1960s (Hershko, Konijn et al. 1998) with proven reduction 
in patient mortality (Gabutti and Borgna-Pignatti 1994). Although DFO is widely used 
for iron overload, its hydrophilic nature results in poor penetration of cell membranes 
(Zanninelli, Glickstein et al. 1997). This characteristic of DFO not only requires higher 
concentrations and longer exposure of the cells to the drug, when compared to other 
lipophilic iron chelators, but DFO also requires a longer time to exit the cell (Richardson, 
Ponka et al. 1994) and chelated complexes of DFO are still detectable in the cell after 20 
hours post exposure (Cooper, Lynagh et al. 1996). On the other hand, this property 
means that DFO does not enter the mitochondria and does not affect mitochondrial 
function (Richardson, Mouralian et al. 2001).
The properties of desferrioxamine suggested that it would be a good compound for 
exploring the effect of iron depletion in islets. The treatment of islets was carried out in 
overnight culture and the length of time required for DFO to enter the cells was not an 
issue. Conversely, the hydrophilic nature of DFO and slow cellular washout was an 
important property and allowed the sustained effect of DFO after the islets were 
transferred into an iron containing environment. The higher concentrations of DFO 
produced a greater effect on VEGF expression and enabled a more prolonged expression 
than seen in lower doses but did not affect important cellular functions; probably as a 
result of DFO’s inability to enter the mitochondria.
The treatment of islets with DFO produced a dose dependent increase in the expression 
of VEGF but did not increase the expression of the other growth factors important for 
the engraftment of islets (Vasir, Reitz et al. 2000; Menger, Yamauchi et al. 2001). This 
finding was disappointing as earlier publications in islets had suggested that hypoxia up 
regulated HGF (Vasir, Reitz et al. 2000) and that HGF was an important factor for the 
engraftment of islets (Nakano, Yasunami et al. 2000; Garcia-Ocana, Takane et al. 2003;
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Lopez-Talavera, Garcia-Ocana et al. 2004). In addition to the down regulation of HGF, 
desferrioxamine treatment and overnight culture was associated with a reduction in the 
expression of bFGF and Angl. These two growth factors are probably important for islet 
engraftment as bFGF has an important angiogenic capacity (Okada-Ban, Thiery et al.
2000) and Angl is known to stabilise endothelium (Sato, Tozawa et al. 1995; Thurston, 
Rudge et al. 2000). Therefore, the reduced expression of these growth factors associated 
with culture may lead to a reduced angiogenic capacity and regression of donor 
endothelium within cultured islets. If so, cultured islets would be expected to engraft 
worse than fresh islets and this change in growth factor expression may explain the 
poorer outcome in cultured islets found by Olsson and colleagues (Olsson and Carlsson 
2005).
Despite the negative changes in growth factor expression, desferrioxamine treatment up 
regulated the expression of VEGF and increased VEGF expression has been shown to 
improve engraftment and clinical outcomes in experimental islet transplantation (Stagner, 
Mokshagundam et al. 2004; Zhang, Richter et al. 2004; Lai, Schneider et al. 2005). In 
addition, the treatment of islets with desferrioxamine did not reduce viability or function 
of isolated islets and may enhance the glucose stimulated insulin release. These 
important observations suggested that desferrioxamine treatment of islets was a 
promising technique for improving transplanted islet engraftment and should improve 
the outcomes after transplantation. The next step was to see whether the in-vitro data 
could be translated into improved outcomes in a marginal islet transplant model, using 
both clinical and histological endpoints to examine the effect of DFO treatment.
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8.3.2 Effect of desferrioxamine on transplanted islets
The hypothesis for improved outcomes is that DFO up regulates the expression of VEGF 
prior to transplantation and reduces the lag time to peak production of this important 
growth factor after transplantation. It was hoped that the earlier peak of VEGF 
expression would reduce the time necessary for revascularisation, leading to a reduction 
in hypoxia and therefore increased survival of beta cell mass. In addition, hypoxia pre­
conditioning with desferrioxamine should reduce the susceptibility to hypoxia induced 
cell death and when combined with improvements in revascularisation, lead to better 
early and long term transplant outcome. Unfortunately, the clinical outcomes did not 
shown any improvement in either the reversal of diabetes or the rate of glucose 
reduction post transplantation. The cause for this failure is unclear and the issues 
pertaining to the experimental model have been considered in chapter 6. The following 
section will consider whether the hypothesis may have been flawed.
8.3.2a Action of desferrioxamine and availability of iron
The premise for treating islets with DFO prior to transplantation is to induce prolonged 
over expression of VEGF and precondition islets to withstand hypoxia induced cell 
death. The in-vitro experiments confirmed a prolonged over expression of VEGF with 
DFO but it is plausible that these experiments did not sufficiently mimic the real life 
situation. The in-vitro desferrioxamine experiments were carried out in CMRL (iron-free) 
medium supplemented with foetal calf serum (FCS), with subsequent transfer into Ml 99 
(iron-containing) medium supplemented with FCS. It was hoped that these experimental 
conditions would simulate the transfer of DFO treated islets into the iron concentrations 
found in serum after transplantation.
Although Ml 99 contains similar concentrations of free iron to normal plasma and FCS 
contains ferritin, it is possible that these culture conditions do not mimic the availability 
of iron after transplantation into the liver. Therefore, the islets may have remained iron 
depleted after transfer to M 199 and the prolonged secretion of VEGF may have been 
related to poor iron repletion rather than any prolonged effect of DFO treatment. When 
the islets were transplanted into the rat recipients they would have been embolised into
273
liver and bathed in surrounding blood. Both of these media contain high concentrations 
of free iron and islets may have become iron replete shortly after transplantation. If this 
was the case, the islets would not have over expressed VEGF for a prolonged period and 
would not have augmented engraftment.
8.3.2b Administration of desferrioxamine
The preconditioning of islets with DFO was expected to reduce the hypoxia related cell 
death associated with transplantation. Islets are known to be hypoxic after 
transplantation (Carlsson and Mattsson 1993) but it is unclear whether this is the greatest 
hypoxic insult the islets suffer. The isolation of pancreatic islets is a prolonged 
procedure (4 hours in rodents and 10 hours in humans) which is preceded by the warm 
and cold ischaemic phases of pancreas retrieval. Although the percentage of islet 
apoptosis and necrosis presented here is low, other authors have published apoptosis 
rates of 20-50% after isolation (Cattan, Bemey et al. 2001; Ichii, Inverardi et al. 2005), 
suggesting that the hypoxic insult may occur during pancreas retrieval and isolation and 
before transplantation. If so, the point at which islets were treated with DFO would be 
too late to protect islets from maximal hypoxic insult and a better time to administer the 
DFO may be at the time of retrieval. Therefore, islets would be preconditioned before 
the insult of pancreas retrieval and islet isolation. Further experiments are probably 
required to explore this hypothesis.
8.3.2c The importance of VEGF to islet engraftment
Vascular endothelial growth factor is known to be important for angiogenesis (Ferrara 
2004) and is expressed during the early stages of islet revascularisation (Vasir, Jonas et 
al. 2001). The up regulation of VEGF in experimental models has been shown to 
improve islet engraftment (Stagner, Mokshagundam et al. 2004; Zhang, Richter et al. 
2004; Lai, Schneider et al. 2005) but it remains to be proven whether VEGF is truly 
pivotal in the revascularisation of islets. Two further studies have provided some insight 
into this issue and have looked at VEGF expression in cultured islets and the effect of 
VEGF receptor blockade on islet engraftment.
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Vascular endothelial growth factor expression is known to be up regulated in islets 
during culture (Gorden, Mandriota et al. 1997; Vasir, Aiello et al. 1998; Vasir, Jonas et 
al. 2001; Olsson and Carlsson 2005) but when cultured islets are transplanted, their 
outcomes are worse than fresh islets which have a lower VEGF expression (Olsson and 
Carlsson 2005). In addition, islets transplanted into recipients treated with VEGF 
receptor blockade have similar outcome and vascular density when compared to islets 
transplanted into control recipients, suggesting that signalling through the VEGF 
receptor plays less of a role in islet engraftment. These observations suggest that VEGF 
and its downstream effects are not a prerequisite for islet engraftment and other factors 
probably play an equally important role. Therefore, the use of desferrioxamine to up 
regulate VEGF alone may not be the answer to improving islet engraftment.
8.3.3 Conclusions
The treatment of islets with DFO has been shown to cause a sustained increase in the 
expression of VEGF without adversely affecting viability and may improve islet glucose 
responsiveness. Unfortunately, DFO treatment did not improve the change in weight or 
reversal of diabetes post transplantation but has improved some of the histological 
parameters of islet engraftment and may reverse some of the adverse effects of islet 
culture. Further experiments are required to examine whether the timing or route of 
administration of desferrioxamine may improve islet engraftment.
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8.4 Clinical islet transplantation
8.4.1 Introduction
Clinical islet transplantation has come a long way since the first recorded non 
vascularised pancreas transplants in 1893. Despite the initial enthusiasm for non 
vascularised pancreas transplantation, the progress in this area of medicine has been 
slow when compared to the transplantation of other organs. Isolated islet transplantation 
remained unproven as a clinical technique for many years and it was not until the 
experience of Najarian and his colleagues in 1977 that islet transplantation was shown to 
be of any clinical benefit (Najarian, Sutherland et al. 1977).The subsequent advances in 
islet isolation from the whole pancreas (Ricordi, Lacy et al. 1988) improved transplant 
outcomes but insulin independence rates remained poor and it was not until the 
publication of the Edmonton protocol that islet transplantation was realised as a valuable 
treatment option for patients with type 1 diabetes (Shapiro, Lakey et al. 2000).
8.4.2 Islet transplantation in the UK
Our data has shown that islet transplantation can be established in the UK and the 
successes of the Edmonton protocol can be transferred to other units. The success of the 
programme will hopefully be continued for the transplantation of further recipients but, 
as with all programmes, will be limited by the supply of pancreases and funding for staff 
costs and consumables. The number of pancreases for isolation has already been 
addressed by the Diabetes UK Expolink but the additional expense of pancreas retrieval 
(i.e. UW and duodenal stapler) has not been covered. This situation is further 
compounded by the lack of funding for isolation and transplant costs which are currently 
part funded by Diabetes UK. Unfortunately, this funding will only cover the next 7 
transplant recipients and further funding from governmental bodies, such as NSC AG, is 
currently being sought. If this funding is not forthcoming, the future of islet 
transplantation in the UK will remain uncertain.
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8.4.3 The place o f islet transplantation in management o f diabetic patients
If islet transplantation is to be endorsed and funded by the NHS, it should be cost 
effective and provide a valid and necessary treatment option for patients with diabetes. 
At present, islets are transplanted for hypoglycaemic unawareness, severe progressive 
secondary complications despite best management and improving the metabolic control 
of patients who are already immunosuppressed for another solid organ transplant. If islet 
transplantation were not available, the current options would be to remain on insulin 
therapy or receive a whole pancreas transplant. The benefit of islet transplantation over 
insulin therapy is the abolition of hypoglycaemia and improved metabolic control 
(Shapiro, Lakey et al. 2000), although not all authors have shown significantly better 
control over best medical therapy in short term studies (Wamock, Meloche et al. 2005). 
The risk of transplantation is mainly from long term immunosuppression and when 
pancreas transplantation is considered, the morbidity and mortality associated with a 
major abdominal operation. The benefit of pancreas transplantation over islet 
transplantation is long term immaculate diabetic control which islet transplantation can 
not currently provide. The question still remains where islet transplantation should be 
considered in the treatment of diabetic patients.
The first treatment choice for type 1 diabetic patients is insulin which should be 
delivered under best care guidelines (DCCT 1993; Wamock, Meloche et al. 2005). 
Patients should only be considered for transplantation when best care has failed and all 
other treatments have been exhausted, unless they are already receiving 
immunosuppression for another organ. Under these circumstances, patients should be 
considered for either islet or whole organ transplantation.
Patients who require beta cell replacement alone are generally quite rare (0.5 -  1% of 
type 1 diabetics) and indications are usually restricted to severe hypoglycaemic 
unawareness or severe progressive secondary complications. The risk to benefit ratio of 
pancreas transplant alone is marginal, if not against whole organ transplantation 
(Gruessner, Sutherland et al. 2004). In this small group of patients, islet transplantation 
can stop episodes of hypoglycaemia and improve diabetic control and is probably the
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best alternative. If the indication for beta cell replacement is the complications of 
neuropathy, pancreas transplantation is probably more advisable due to the need for long 
term immaculate control for stabilisation and possible reversal of neuropathy (Navarro, 
Kennedy et al. 1996; Allen, Al-Harbi et al. 1997; Navarro, Sutherland et al. 1997).
Type 1 diabetic patients who already have another solid organ transplant or are receiving 
a transplant already have the risk of immunosuppression and should be considered for (3- 
cell replacement. Most of the literature relating to this group of patients arises from renal 
transplantation, where diabetes is the leading cause of end stage renal disease. In patients 
who are awaiting a renal transplant there is a significant long term mortality benefit to 
undertaking a combined kidney/pancreas transplant when compared to wait listed 
patients (La Rocca, Fiorina et al. 2000; Gruessner, Sutherland et al. 2004) or cadaveric 
kidney transplant alone (La Rocca, Fiorina et al. 2000; Reddy, Stablein et al. 2003). 
When cadaveric kidney alone is compared to simultaneous pancreas kidney 
transplantation (SPK) there is little difference in initial survival but after 18 months to 
two years, the survival curves diverge and SPK patients do better in the long term (La 
Rocca, Fiorina et al. 2000; Reddy, Stablein et al. 2003). This benefit is probably due to 
improved glycaemic control which is reflected in lower rates of cardiovascular death (La 
Rocca, Fiorina et al. 2000). The transplantation of a kidney from a living donor initially 
improves survival over kidney alone or SPK but with time, the SPK and live donor 
survival curves start to converge and meet after about seven years (Reddy, Stablein et al.
2003). This pattern of survival is probably due to the high initial mortality associated 
with SPK but reduced mortality from cardiovascular disease in the long term, due to 
immaculate glycaemic control.
The patient and graft survival rates for SPK are continually improving (IPTR data) and 
all suitable type 1 patients with end stage renal failure should be considered for SPK 
transplantation unless a good live donor is available, where this option may be 
preferable. A further treatment for patients with end stage renal disease secondary to 
type 1 diabetes would be a live donor transplant, to benefit from a good kidney and low 
early mortality, followed by an islet transplant which would allow immaculate diabetic
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control and probable reduction in cardiovascular death. At present it is unclear how this 
option would fit into treatment strategies for type 1 diabetes patients with renal disease 
and whether this may be the optimal therapy.
Type 1 diabetic patients who already have a functioning renal allograft can benefit from 
the improved metabolic control associated with transplantation of beta cell mass. The 
alternatives here are islet after kidney (IAK) or pancreas after kidney (PAK). This is a 
difficult group to draw a definitive conclusion about because the benefit of PAK is 
probably equivocal (Gruessner, Sutherland et al. 2004) and IAK may have a slightly 
higher morbidity than islet alone transplantation (Bemey, Bucher et al. 2004). The 
benefit of IAK would be the lower procedural mortality and long term improvement in 
glycaemic control (Bemey, Bucher et al. 2004; Gonzalez Molina, Alonso et al. 2005) but, 
if patients survive the post operative period with a functioning pancreas, the outcome is 
likely to be better long term.
Cardiovascular disease is a common secondary complication of diabetes and some 
patients are deemed not suitable for whole organ transplantation due to cardiovascular 
risk. The cardiovascular risk associated with islet transplantation is less than whole 
organ transplantation and a number of these patients with lesser degrees of 
cardiovascular disease may be suitable for islet transplantation.
In conclusion, islet transplantation is a valuable treatment modality that should be 
considered along side whole organ transplantation. It is unlikely that islet transplantation 
will be able to offer the long term glycaemic control and insulin independence of whole 
pancreas transplantation but there are some circumstances where islet transplantation is 
preferable.
8.4.5 The requirement for insulin independence
The Edmonton protocol achieved initial insulin independence rates that were 
comparable to whole organ pancreas transplantation (Shapiro, Lakey et al. 2000; Ryan,
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Lakey et al. 2002) but with time, there has been a rapid decline in insulin independence 
(Ryan, Paty et al. 2005) and pancreas transplantation is currently a better modality for 
long term insulin independence (IPTR registry, Minneapolis). Despite the poor insulin 
independence rates achieved, islet transplantation abolishes hypoglycaemia (Shapiro, 
Lakey et al. 2000) and improves diabetic control (Ryan, Lakey et al. 2002; Ryan, Paty et 
al. 2005). Therefore, when considered within the initial indications of treating 
hypoglycaemic unawareness and improving metabolic control, islet transplantation 
achieves its goals successfully. This leads to the question of whether insulin 
independence should be the overall goal of islet transplantation. Even with the first 
transplant, and before insulin independence is achieved, metabolic control is improved 
(Shapiro, Lakey et al. 2000), hypoglycaemia is abolished (Shapiro, Lakey et al. 2000) 
and patients often regain a sensation of low blood glucose. The poor long term insulin 
independence rate remains the perceived problem of islet transplantation but we should 
consider whether insulin independence is the best end point to aim for or whether 
normalised metabolic control is a better target.
Before considering the reasons for changing targets, we should explore the cause for the 
high rate of attrition of insulin independence. The human pancreas contains roughly one 
million islets and islet isolation with collagenase digestion only yields about half to one 
third of the total islet mass (Lakey, Wamock et al. 1996; Shapiro, Lakey et al. 2000). 
After islets have been transplanted, only about 40% of the transplanted mass survives to 
engraft (Biames, Montolio et al. 2002). This poor rate of islet isolation and survival 
means that after one transplant, the recipient has only received between 10-30% of the 
normal human islet mass. The transplanted mass is often insufficient to cover the total 
insulin requirements of the recipient and therefore a second transplant is often needed. 
After the second transplant, the engrafted mass of islets is usually sufficient to cover the 
recipient’s insulin requirements but will only just meet these requirements under a great 
deal of metabolic stress. This situation is further exacerbated by diabetogenic 
immunosuppression, as tacrolimus causes direct islet toxicity and sirolimus can lead to 
insulin resistance (Lopez-Talavera, Garcia-Ocana et al. 2004). Therefore, the 
engraftment of a marginal mass of islets with withdrawal of exogenous insulin may
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precipitate beta cell exhaustion and lead to chronic glucose toxicity, which causes 
further exacerbation of beta cell exhaustion. Thus, it may be that trying to achieve 
insulin independence is one of the main reasons for the high rate of attrition of islet 
grafts. Therefore, reduction of exogenous insulin after transplantation should probably 
be limited, in order to abolish hypoglycaemia, and then the transplanted islets should be 
left to smooth glycaemic control where the exogenous insulin release does not match the 
variable pattern of glucose metabolism (figure 8.1).
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Figure 8.1: Schematic insulin profiles in normal individuals, exogenous insulin 
administration and after islet transplantation. Panel A shows the insulin profile of a 
normal individual with 3 biphasic peaks of insulin secretion, related to regular 
meals. Panel B shows the insulin profile of a type 1 diabetic maintained on a 
standard 4 times a day insulin delivery. The profile is superimposed on a normal 
insulin profile. Panel C is the insulin secretion (red area) required from an islet 
graft in a patient independent of insulin after islet transplantation. Panel D shows 
the reduced insulin secretion (red area) required from an islet graft post 
transplantation, if the patient is maintained on small doses of exogenous insulin.
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This regime would reduce the glucose toxicity and high rate of insulin production 
enforced on transplanted islets after the withdrawal of insulin and hopefully lead to a 
longer islet graft survival while maintaining immaculate glycaemic control. After all, it 
is immaculate glycaemic control which delays the onset of complications (DCCT 1993) 
and may reverse secondary complications (Navarro, Sutherland et al. 1997; Fioretto, 
Steffes et al. 1998). Therefore, the aim of islet transplantation should probably be long 
term and lasting tight glycaemic control, irrelevant of administered exogenous insulin, 
rather than measuring success by insulin independence.
8.4.6 Conclusions
We have shown that human islet isolation and transplantation can be established de- 
novo and that good short term clinical transplant results can be achieved. The process of 
islet isolation and transplantation is not fully optimised but requires further modification 
to achieve better insulin independence rates with a lower incidence of complications.
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8.5 Overall conclusions
Islet transplantation offers a promising treatment for patients with the severe 
complications of type 1 diabetes but is currently limited by the number of pancreases 
required for successful transplantation and the poor long term insulin independence rates. 
Islet engraftment probably holds the key to solving the problems associated with islet 
transplantation and hopefully, the ability to achieve success rates comparable to whole 
organ transplantation. Revascularisation is the first step in islet engraftment and I have 
developed a robust model for observing and quantifying this complex process which can 
be applied to strategies for improving islet engraftment. Desferrioxamine is a simple 
technique for preconditioning islets to over express the important angiogenic growth 
factor VEGF for prolonged periods without detrimentally affecting the viability or 
function of islets. Although I was unable to show positive benefit when DFO treatment 
was transferred to an in-vivo model, it remains a promising technique for hypoxia 
preconditioning which could be applied to islets and other organs for transplantation. 
Clinical islet transplantation is achievable within the United Kingdom but requires 
extensive training and has massive implications for resources and funding. The transfer 
of the Edmonton protocol to other units is achievable but once established, further 
optimisation of isolation and transplant protocols are required to improve outcome. The 
greatest hurdle facing islet transplantation in the UK is likely to be funding and the 
rationalisation of resources.
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Appendix 1: Commonly used solutions
Unless stated, all chemicals were sourced from Sigma Aldrich, UK.
Collagenase
15 mg/ml collagenase P (Roche Diagnostics, Germany) in HBSS supplemented
with 5.5mM calcium chloride solution
Made immediately prior to use and stored on ice
CMRL
CMRL culture medium (Gibco BRL) supplemented with 
100 units/ml penicillin 
0.1 mg/ml streptomycin g 
50mM HEPES (pH 7.4)
1.4mM L glutamine 
10% foetal calf serum
Citrate buffer pH 6.0




25mM Tris/HCl pH7.5 
lOmM EDTA pH8.0
HBSS
Made from premixed powder in 1 litre aliquots 
Stored at 4°C for up to 2 weeks
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HBSS /BSA









20mM Hepes (pH 7.4)
2mg/ml BSA
Make up to a final volume of 130ml with deionised water
LB Media
1 % bacto-trypone 
0.5% bacto-yeast extract 
171mM NaCl
Adjust to pH 7.0 with 5N NaOH 
Sterilise by autoclaving
Lowry solution A
188mM Na2C 0 3 
lOOmM NaOH 





Lvsis buffer (for bacterial lvsis)
0.2M NaOH 
1% SDS
Lvsis buffer #11 (for protein extraction)








Supplemented with Complete Protease Inhibitor cocktail (Roche Applied 
Science, UK)
Ml 99
500ml of Ml 99 culture media (Gibco BRL) supplemented with 
100 units/ml penicillin 
0.1 mg/ml streptomycin g 
50mM HEPES (pH 7.4)
1.4mM L-glutamine 
10% (v/v) foetal calf serum
Neuraminidase V
Stock solution of 1 U/ml neuramidase in 





0.45M Boric acid 







10 mM Tris HC1 (pH 7.4)
ImM EDTA (pH 8.0)




pH to 9 with NaOH
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Appendix 2:
NICE guidance on pancreatic islet transplantation
N H S
Pancreatic islet cell transplantation
Issue date: October 2003
1 Guidance
1.1 Current evidence on the safety and efficacy of pancreatic islet cell transplantation does not 
appear adequate to support the use of this procedure without special arrangements for consent 
and for audit or research. Clinicians wishing to undertake pancreatic islet cell transplantation 
should inform the clinical governance leads in their trusts. They should ensure that patients 
offered it understand the uncertainty about the procedure’s safety and efficacy and should 
provide them with clear written information. Use of the Institute’s Information for the Public is 
recommended. Clinicians should ensure that appropriate arrangements are in place for audit or 
research. Publication of safety and efficacy outcomes will be useful in reducing the current 
uncertainty. NICE is not undertaking further investigation at present.
1.2 All cases should be registered with the International Islet Transplant Registry, which is based 
in Germany and run by Mathias D Brendel, Third Medical Department, University Hospital 
Giessen, D-35385 Giessen, Germany (www.med.uni-giessen.de/itr/).
2 The procedure
2.1 Indications
2.1.1 Pancreatic islet cell transplantation is used to treat type 1 diabetes mellitus and diabetes 
mellitus secondary to surgical removal of the pancreas for chronic pancreatitis. Type 1 diabetes 
mellitus is a condition, usually developing in childhood or early adulthood, in which the islet cells 
of the pancreas do not produce enough insulin, requiring the person to inject insulin. Chronic 
pancreatitis is a less common condition which often causes severe chronic abdominal pain. 
Sometimes pancreatitis is treated by removal of the pancreas (pancreatectomy). After a 
pancreatectomy, people are unable to produce insulin and injections are required.
2.2 Outline o f the procedure
2.2.1 An alternative to insulin injection is pancreatic islet cell transplantation. This involves 
replacing a person’s islet cells with either autologous islet cells (the person’s own cells) or 
allogeneic islet cells (from a donor). The islet cells are usually placed in the liver.
2.2.2 Normal islet cells are able to produce naturally the correct amount of insulin. Pancreatic 
islet cell transplantation may, therefore, provide better continuous control of blood sugar than is 
achieved by insulin injections, which may in turn reduce diabetic complications. However, 
immunosuppressive drug treatment is needed to prevent rejection of transplanted allogeneic 
islet cells.
2.2.3 Other possible treatments for people suitable for pancreatic islet cell transplant include 
continuous insulin infusion using an automatic pump implanted under the skin, and total 
pancreatic transplantation.
2.3 Efficacy
2.3.1 Most of the evidence available was related to pancreatectomy. The rates of independence 
from injected insulin following the procedure were not always well reported. One study reported 
that 20 of 39 patients were insulin-independent at 1 month (51%).
2.3.2 The Specialist Advisors stated that if people were able to establish normal glucose control 
without insulin after transplantation then the potential benefits were likely to be great. However, 
the identified studies did not compare blood sugar control or risks of diabetic complications for
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the treatment options (injected insulin versus pancreatic islet cell transplantation). There was 
also a lack of long-term follow-up data.
2.4 Safety
2.4.1 In one UK case series of 24 patients, complications were reported in three patients; these 
included partial portal vein and splenic thrombosis.
2.4.2 All of the Specialist Advisors reported that there was a potential risk of thrombosis of the 
portal vein, as well as of bleeding from the liver at the time of transplantation. They were also 
concerned about the side effects from the immunosuppressive drugs required after allogeneic 
transplantation, including malignancy.
2.5 Other com m ents





3.1 NICE will review the guidance on pancreatic islet cell transplantation in December 2004, 
when research evidence is expected to be available.
Information for the Public
NICE has produced information describing its guidance on this procedure for patients, carers 
and those with a wider interest in healthcare. It explains the nature of the procedure and the 
decision made, and has been written with patient consent in mind. This information is available 
from www.nice.org.uk/IPG013publicinfoenglish and bilingually in English and Welsh from 
www.nice.org.uk/IPG013publicinfowelsh.
Sources of evidence
The evidence considered by the Interventional Procedures Advisory Committee is described in 
the following document.
Interventional Procedures Overview of Pancreatic Islet Cell Transplantation, March 2003. 
Available from; www.nice.org.uk/IP071overview
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Appendix 3; Local ethic committee submission
ROYAL FREE HOSPITAL AND 
MEDICAL SCHOOL ETHICS 
COMMITTEE
APPLICATION FORM word 97
EC R E F.................................(leave blank)
SHORT TITLE OF PROJECT 
(or your reference number)
Pancreatic Islet Transplantation
FULL TITLE
Clinical pancreatic islet transplantation in patients with insulin 
dependent diabetes.
CONTACT NAME & ADDRESS
(to be used in all correspondence relating to this application)
Dr Martin Press, FRCP,
Consultant Physician,
Department of Endocrinology,
Royal Free Hampstead NHS Trust.
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SECTION 1 Details of Applicants
1. Responsible Consultant(s)
Name Dr Martin Press Prof Stephen Powis
Department Endocrinology Nephrology
Name Mr Keith Rolles Miss Rozanne Lord
Department Surgery Nephrology
2. Name(s), qualification(s) and status of research worker(s) directly involved
Name Stephen Hughes Status Senior Research Scientist
Qualifications BSc, PhD Signature..............................................
Name Mark Lowdell Status Head of Cellular Therapeutics
Qualifications PhD Signature..................................................
3. Are other departments involved? YES
If yes, which: Radiology
Signatures o f Head(s) o f collaborating department(s) denoting approval
........................................................................Department.................................
........................................................................ Department.................................
4. Who is sponsoring the study:
See Trust/Medical School research project registration sheet.
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SECTION 2 Details of Project
5. Aims and objectives of project
To ameliorate or correct Type 1 diabetes by the intraportal transplantation of isolated 
donor pancreatic islets.
6. Scientific background of study (Approx 250 words)
Metabolic control of insulin-dependent (Type 1) diabetes, sufficiently good to prevent 
complications such as blindness, amputations and renal failure, is not possible with 
conventional management without an unacceptably high risk of hypoglycaemia. 
Transplantation of the whole pancreas results in near-normal metabolic control and has 
been shown to reverse diabetic retinopathy and nephropathy, but it necessitates major 
surgery and carries with it a high morbidity due to the pancreatic digestive enzymes.
Transplantation of isolated pancreatic islets obviates these disadvantages, requiring only 
the intraportal injection of the isolated islets. A major breakthrough was reported three 
years ago from the University of Edmonton by Dr James Shapiro (N Engl J Med 2000; 
343:230-8) who took advantage of a new immunosuppressive drug (rapamycin, 
sirolimus) to devise a steroid-free immunosuppressive regimen. Using this protocol, his 
group has now transplanted some 55 patients, and is reporting an 80% one year insulin 
independence rate (compared to 8% with ‘conventional’ immunosuppression).
At the Royal Free we have been developing the methodology of pancreatic digestion and 
islet purification and have now processed 32 pancreases. Our results are now good 
enough that we are in a position to do our first clinical transplant. Using this protocol, 
more than 200 successful transplants have now been performed world wide, and the 
technique is becoming an accepted clinical procedure.
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SECTION 2 (continued) Details of Project
7. Brief outline of project (Approx 250 words)
This application builds directly on a previously approved project (M218-2000) which 
has enabled us, as part of the UK Islet Transplant Consortium, to develop the 
methodology to separate pancreatic islets from donor pancreases obtained from brain 
dead cadaveric donors. Although this part of the programme was covered by an MREC 
protocol, considerable differences between the protocols of individual centres means that 
each centre is applying for its own LREC approval.
Donor pancreases will be retrieved under strict aseptic conditions under the supervision 
o f Miss Rozanne Lord and Mr Keith Rolles and their respective organ procurement 
teams. The pancreases will be brought back to the Cellular Therapeutics Laboratory 
where they will be digested with collagenase and the islets purified under the strictest 
sterile conditions as per the previously approved protocol. The pancreatic islets will 
then be transplanted into the portal vein in the Radiology Department either 
transjugularly or percutaneously according to standard clinical methodology under local 
anaesthesia.
Recipients will receive an immunosuppressive regimen identical to that used by Dr 
Shapiro. Induction therapy is with daclizumab, followed by maintenance 
immunosuppression with sirolimus and low dose tacrolimus. Anti-infectious agents will 
be used as appropriate according to standard management of immunosuppressed patients.
Patients may require more than one transplant in order to achieve the engraftment of 
sufficient islets to allow them to discontinue their insulin injections. Most patients in 
Edmonton have required two.
8. Study design (e.g. cohort, case control, epidemiological analysis)
If we and other centres are successful in replicating Dr Shapiro’s technique (and we 
have no reason to suspect that we will not be), this technique will cease to be clinical 
research and will take its place as a standard clinical procedure alongside the 
transplantation of other organs.
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SECTION 2 (continued) Details of Project
9. Size of the study. Will the study involve:
(a) Human Subjects ? Yes
i) How many patients will be recruited?
This is limited by the availability o f donor pancreases and by funding issues. The trust 
has generously agreed to prov ide funding designed to cover the first three patients, and 
Diabetes UK has agreed to cover the clinical costs o f the first 10 patients (in the whole 
country). We will be aiming to perform approximately 12 transplants per year thereafter, 
subject to funding issues being resolved.
ii) How many controls will be needed?
None
iii) What is the primary end point?
Normalisation o f metabolic control w ithout the need for exogenous insulin injections
iv) How was the size of the study determined?
Practical considerations (see (i) above)
v) What is the statistical power of the study?
Not appropriate
(b) Patient Records? No
i) How many records will be examined?
ii) How many control records will be examined?
iii) What is the primary end point?
iv) How was the size of the study determined?
v) W hat is the statistical power of the study?
10. Independent Review
Has the study been externally independently reviewed No
If vv.v state which body individual has undertaken the review..........................................
If no vou must obtain the signature o f a person who has reviewed the study and who can guarantee its 
potential usefulness, either on increasing scientific knowledge or enhancing therapeutic power.
NB The person must be wholly independent o f the study (i.e. not the head of department




SECTION 3 Recruitment of Subjects
11. How will the subjects in the study be:
i) selected? According to criteria agreed within the UK Islet Transplant Consortium. 
These give priority to patients with recurrent episodes o f severe hypoglycaemia, 
particularly if hypoglycaemic warning symptoms are deficient, and to patients who have 
diabetic complications which are progressing despite the best metabolic control 
achievable with conventional insulin injections.
ii) recruited? From diabetic out-patient clinics at the Royal Free.
iii) what inclusion criteria will be used? Patients aged 18-65 with C- 
peptide negative insulin dependent diabetes.
iv) what exclusion criteria will be used? Impaired renal or liver function; myocardial 
infarct within past 6 months; neoplasm within past 5 years; steroid use or other cause of 
insulin resistance; pregnancy or intended pregnancy; active hepatitis, HIV, tuberculosis 
or other chronic infection; evidence o f likely non-compliance with medications or 
management.
How will the control subjects be: N/A
i) selected?
ii) recruited?
iii) what inclusion criteria will be used?
iv) what exclusion criteria will be used?
12. Will there be payment to research subjects of any sort? No
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SECTION 4 Consent
13. Is written consent to be obtained? Yes
If yes, please attach a copy o f the consent form to be used
If no written consent is to be obtained, please justify
14. How long will the subject have to decide whether to take part in the study?
Likely to be many weeks in most cases.
15. Will the subject be give a written information sheet Yes
or letter?
If yes please attach a copy to this application form  
If no, please justify
16. Have any special arrangements been made for subjects
for whom English is not a first language? No
If yes, give details:
If no, please justify: A high degree o f understanding and co-operation is essential for the success 
o f this project. Patients must be able to follow and comply with complicated instructions.
17. Will any of the subjects be from one of the following vulnerable groups?
Children under 18 
People with learning difficulties 
Unconscious or seriously ill 
Psychiatric patients 
Elderly patients
Other vulnerable groups No
If yes. please justify
What special arrangements have been made to deal with the issue of 
consent for the subjects above?
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SECTION 5 Details of intervention
18. Substances to be given to the subjects (Special diets, drugs, isotopic tracers etc. State dose, 
and mode and frequency o f administration)
Daclizumab, 1 mg/kg iv every 14 days for 5 doses
Sirolimus, 0.2 mg/kg loading dose, then 0.1 mg/kg/day adjusted according to 
blood levels to give 12-15 ng/ml for the first 3 months and then 7-10 ng/ml. 
Tacrolimus, 1 mg bd, titrated to give trough levels of 3-6 ng/ml.
Co-Trimazole, 480 mg/day for 3-6 months
19. Does the study involve the use of a new medicinal product 
or medical device or an existing product outside the terms 
of its product licence? Yes
If yes has a pharmaceutical or other commercial company 
arranged this trial and obtained a Clinical Trial Certificate
or Clinical Trial Exemption? No
Or have you obtained approval of the licensing
authority by means of a DDX? Yes
DDX or CTX Number........................................................(Please attach a copy)
20. Will any ionising or radioactive substances or X-Rays be
administered? Yes
If yes please fill in Annex A
21. Please list those procedures in the study to which subjects will be exposed indicating
those which will be part of normal care and those that will be additional (e.g. taking more 
samples than would otherwise be necessary). Please also indicate where treatment is withheld as a 
result of taking part in the project.
Portal vein catheterisation, either percutaneous or transjugular is outside normal 
diabetic care. The procedure may need to be repeated more than once to obtain a 
sufficient mass of engrafted islets.
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SECTION 6 Risks and ethical problems
22. Are there any potential hazards? Yes
If yes, please give details, and give the likelihood o f occurrence. Also give details of
precautions taken to meet them, and arrangements to deal with adverse events.
Portal vein catheterisation is associated with a risk of haemorrhage or thrombosis, but 
the procedure is in routine use at this hospital and we would regard the risks as 
extremely small. Immunosuppression carries with it an increased risk of infections, and 
infection-related neoplasia, as with any other clinical transplant procedure. Sirolimus 
tends to cause mouth ulcers during the first weeks when the dose is high. Since it is still 
a relatively new drug, its long term risks remain unknown. Tacrolimus may cause 
nephrotoxicity.
23. Is this study likely to cause discomfort or distress? Yes
If yes, please justify and give details
The portal vein catheterisation, which is performed under local anaesthetic, may be 
associated with slight discomfort.
24. Are there any particular ethical problems or
considerations that you consider to be important
or difficult with the proposed study? No
If yes, please give details
25. Will information be given to the patient's General
Practitioner? Yes
Please note: permission should always be sought from 
research subjects before doing this
If yes, please enclose a copy o f  the information sheet fo r the GP 
If no, please justify
26. If the study is on hospital patients, will consent of all 
Consultants whose patients are involved in this
research be sought? Yes
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SECTION 7 Indemnity and Confidentiality
27. Is this NHS sponsored research to which
HSG (96) 48 applies? Yes
or
Is this research sponsored by the medical school 
for which indemnity is provided by an insurance
policy taken out by the medical school? No
or
Is this pharmaceutical company sponsored research, 
the company providing indemnity to the most recent
ABPI guidelines? No
If yes please enclose a copy o f  the indemnity form and state 
 The maximum indemnity per patient (ideally over
£2million). Maximum Indemnity £ ..................................
or
Is indemnity being provided in some other way No
If yes please specify
28. In the case of equipment or medical devices will
indemnity be provided by the manufacturer to the 
level specified in ABHI (Association of British
Health-Care Industries) guidelines. N/A
If no please justify
29. Will the study data be retrieved from computer? No
Will the study date be held on computer? Yes
If, yes, will the Data Protection Act (1998)
be followed? Yes
30. Will the study include Audio/video recording? No
If yes (1) has specific consent been obtained? Yes No
(2) what will happen to the recordings at the end o f the study?
31. Will medical records be examined by research
workers outside the employment of the NHS? No
If yes, please ensure that this is made clear to the 
patient on the information sheet.
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PLEASE ENSURE T H A T  YOU C O M P LE TE  TH E  C H E C K LIS T  AND  
ENCLOSE A L L  R ELEVA N T DO C U M EN TS
DECLARATION
The information in this form is accurate to the best o f my knowledge and belief and I take full 
responsibility for it.
I agree to supply interim reports on an annual basis and a final report, and to advise the ethics committee 
of any adverse or unexpected events that may occur during this project.
The research for which I am seeking ethical approval will be undertaken in no more than four LREC’s 
geographical boundaries (applications involving five or more centres should be sent to a multi-centre 
research ethics committee - see health service guidelines HAG(97)23).
Signature of Responsible Consultant................................................................................
Date...................................
FOR ETH IC S  C O M M IT T E E  USE
First Meeting.........................................
Applicant interviewed 
Approved without changes 
Approved after revision 
Rejected
Signature of Chairman.........................................  Date of Approval.
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